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Abstract 
LAUREN E. MCCULLOUGH: Modifying Effects of Oxidative Stress and DNA repair 
Variants on Physical Activity and Breast Cancer Risk 
(Under the direction of Marilie Gammon) 
 
Purpose. The mechanisms driving the inverse association between recreational 
physical activity (RPA) and breast cancer risk are unclear. Exercise both increases reactive 
oxygen species production, which may transform normal epithelium to a malignant 
phenotype, and enhances antioxidant capacity, which could protect against subsequent 
oxidative insult. Physical activity may also improve damage repair systems, particularly 
those that operate on oxidative damage. Given the paradoxical and complex effects of 
physical activity both oxidative stress and DNA repair pathways are of interest. 
Polymorphisms in these pathways may modify the association between RPA and breast 
cancer incidence. Methods. We estimated interactions between RPA and several 
polymorphisms in oxidative stress-related genes (CAT, COMT, GPX, GSTP1, GSTA1, 
GSTM1, GSTP1, MPO, and MnSOD) as well as DNA repair genes (ERCC1, MGMT, MLH1, 
MSH2, MSH3, OGG1, XPA, XPC, XPD, XPF, XPG, and XRCC1). Data were from the Long 
Island Breast Cancer Study Project, a population-based, case-control study with interview 
and biomarker data available on 1053 cases and 1102 controls. Results. Six variants in 
antioxidant and DNA repair pathway genes (CAT rs1001179, GSTP1-Ile105Val, XPC-
Ala499Val, XPF-Arg415Gln, XPG-Asp1104His and MLH1-lle219Val) interacted with 
postmenopausal RPA (p=0.043, 0.006, 0.048, 0.022, 0.012, and 0.010, respectively). Highly 
active women with genotypes related to reduced antioxidant capacity were at increased risk 
of breast cancer (CAT OR=1.61; 95% CI, 1.06-2.45) while risk reductions were observed 
among moderately active women with genotypes related to enhanced antioxidant capacity 
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(GSTP1 OR=0.56; 95% CI, 0.38-0.84). With respect to DNA repair we found risk reductions 
for highly active women with common genotypes for XPC (OR=0.57; 95% CI, 0.38-0.84) and 
XPF (OR=0.64; 95% CI, 0.46-0.89) compared to non-active women homozygous for the 
major alleles. Non-significant risk reductions were observed among active women with at 
least one variant allele for XPG and MLH1, respectively. Conclusions. Genes involved in 
antioxidant and DNA repair pathways may modify the RPA-breast cancer risk association. 
While the functional significance of many polymorphisms with respect to breast cancer 
remains largely unknown, the observed associations are biologically plausible and 
consistent across multiple indicators of physical activity reducing the likelihood that these 
findings are attributable to chance. Our results merit further investigation. 
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Chapter I: Background 
This dissertation aimed to examine effect modification of the physical activity-breast 
cancer association by single nucleotide polymorphisms (SNP) in two different pathways: (1) 
oxidative stress and (2) DNA repair. This investigation began by estimating the associations 
between genetic variants in catalase (CAT); mismatch repair (MMR) and breast cancer risk, 
using resources from the Long Island Breast Cancer Study Project (LIBCSP), a population-
based, case-control study with detailed data on recreational physical activity (RPA) and 
genetic markers. I subsequently examined how functional variants in candidate genes from 
the aforementioned pathways modified the effect of physical activity on breast cancer 
incidence. Secondary aims involved examining the effects of multiple genetic 
polymorphisms on breast cancer risk using SNP*SNP analyses,  gene*gene analyses and a 
pathway based approach, as well as evaluating associations between genetic 
polymorphisms and breast cancer risk in hormonally distinct case groups (e.g. hormone 
receptor positive and hormone receptor negative).    
Chapter one provides a detailed review of the relevant literature, to inform discussion 
of the study rationale and approach.  Specifically, this chapter summarizes the breast 
cancer literature (1.1), details the physical activity-breast cancer mechanisms described to 
date (1.2), and provides biologic rationale for two alternative pathways (e.g. oxidative stress 
[1.3] and DNA repair [1.4]) that may, in part, drive the observed inverse association between 
exercise and breast cancer risk.  
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1.1 Breast Cancer Biology and Epidemiology  
 Although much of what is understood about the etiology of breast cancer has 
evolved from risk factor epidemiology, many of the underlying mechanisms of the disease 
remain unknown. Many established breast cancer risk factors, such as reproductive 
characteristics, are not easily modifiable but known to play an important role in breast 
cancer development. A large proportion of breast cancer risk may, however, be attributed to 
factors which are amendable to intervention. The case for these modifiable or lifestyle risk 
factors are most clearly revealed by the large differences in breast cancer incidence 
between countries [1] and the monotonic increase in risk among immigrants across 
generations. Physical activity and obesity have emerged as two important, potentially 
modifiable, targets for breast cancer risk reduction and may account for a large proportion of 
breast cancer cases. Identifying pathways through which these factors operate could play 
an important role in advancing the knowledge of breast cancer etiology, and improving risk 
reduction strategies for breast cancer. The following section outlines the trends in breast 
cancer incidence, potential mechanisms, and risk factors for the disease.  
1.1.1 Trends in Breast Cancer Incidence  
Breast cancer is the leading cause of global cancer incidence and mortality among 
women. Among women in the United States (US), breast cancer is the primary cause of, 
non-melanoma, cancer related illness with an estimated 226,870 new cases and 39,510 
deaths attributable to breast cancer in 2012 [2]. Breast cancer differentially affects women 
by age and race (Figure A.1). From 2000-2004 94% of incident cases in the US occurred in 
women over the age of 40 and most women were of European decent [3]. While Caucasian 
women show a higher rate of breast cancer incidence after age 40, African American 
women experience the highest rates of premenopausal breast cancer. From 2000-2004 the 
annual incidence rate of breast cancer for all ages was 132.5 and 118.3 per 100,000 
person-years in Caucasian and African American women, respectively [3]. 
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1.1.2 Mechanisms of Breast Cancer Risk 
Prolonged exposure to circulating estrogens and progestins has long been 
suspected as a primary mechanism in breast cancer carcinogenesis. Increased endogenous 
hormone levels are proposed to elevate risk through enhanced cell proliferation which 
occurs at multiple points along the cancer continuum from initiation to tumor metastasis [4]. 
Increased cellular proliferation is likely to result in a greater number of deleterious mutations 
that, if un-repaired, could result in breast malignancy [5]. Estrogen may directly influence cell 
proliferation via induction of proteins involved in nucleic acid synthesis or through the 
activation of oncogenes. It can, similarly, indirectly impact proliferation by stimulating the 
secretion of prolactin or enhancing growth factor production [6]. Closely linked to estrogen 
are insulin and insulin-like growth factor (IGF). They have been proposed to work with 
estrogen to influence breast cancer risk by both increasing cell proliferation and preventing 
apoptosis [7]. Insulin is additionally known to reduce synthesis of sex-hormone-binding 
globulin (SHBG), a transporter of testosterone and estradiol, in the liver [7]. Reduced levels 
of SHBG result in increased availability of bioavailable estradiol. 
Another commonly proposed mechanism is reduced genomic integrity. There are a 
number of highly penetrant breast cancer susceptibility genes that have been implicated in 
familial breast cancer. Well established are breast cancer 1 (BRCA1) and breast cancer 2 
(BRCA2) which account for 15-20% of ancestral breast cancer clustering [8], and are 
commonly associated with early-onset breast cancer [9]. A 2003 pooled analysis reported 
an average 65% cumulative risk of breast cancer among BRCA1 carriers by age 70. The 
reported cumulative risk among BRCA2 carriers was 45% [10]. There are a number of other 
mutations considered to have middle penetrance. Ataxia telangiectasia mutated (ATM), 
CHK2 checkpoint homolog (CHEK2), tumor protein 53 (P53), phosphatase and tensin 
homolog (PTEN), and serine/threonine kinase 11 (STK11) have been classified as breast 
cancer associated genetic defects responsible for various aspects of genomic integrity [11]. 
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While mid to high penetrant genetic polymorphisms have been implicated in the etiology of 
heritable breast cancer, these variants are relatively uncommon in the population. Focus 
has shifted to finding common, low penetrance, polymorphisms which may contribute only a 
slight increase in risk. Alterations in these genes can serve as triggers for genomic 
instability, increased mutation, and could mediate, in part, the effects of physical activity and 
other breast cancer risk factors.  
1.1.3 Breast Cancer Risk Factor Epidemiology  
Reproductive Factors. Unlike many cancers breast cancer has a number of well-
established risk factors (Table A.1). As previously described, cumulative exposure to 
estrogens and progestins appears to play a large role in breast cancer carcinogenesis. 
Many of the established risk factors for breast cancer are therefore related to, or serve as 
proxies for, endogenous hormone levels [12]. Early age at menarche [12, 13], age at first 
birth [14], parity [14, 15], lactation history [16], and late age at menopause [12] are known to 
influence breast cancer incidence. These reproductive risk factors are hypothesized to 
primarily impact breast cancer risk by influencing the cumulative lifetime exposure of breast 
tissue to circulating estrogens and progestins [5]. For example, the inverse association 
between parity and breast cancer risk may be due to a reduction in the number of ovulatory 
cycles and thus decreased estradiol exposure, although other mechanisms (mammary cell 
differentiation and estrogen responsiveness) are likely to account for some portion of this 
association [17]. Findings in the LIBCSP [18] indicate that reproductive practices have an 
important role in breast cancer etiology. Investigators reported adjusted odds ratio (OR) and 
95% confidence intervals (95% CI) for several risk factors including: parity (OR=0.63 for 4+ 
children vs. none 95% CI: 0.48, 0.82), breastfeeding (OR=0.70 for 14 months vs. none, 95% 
CI: 0.53, 0.89), and age at first birth (OR=1.36 for 28+years vs. <22 years, 95% CI: 1.10, 
1.69). Age at menarche was not found to influence risk in this study population.  
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Exogenous Hormones. Oral contraceptives (OC) are the most commonly used 
contraceptive method for US women. Oral contraceptives generally contain 20 to 35 µg of 
ethinyl estradiol and are thus a frequent source of exposure to exogenous hormones in 
premenopausal women [19]. The most comprehensive assessment of the association 
between OC use and breast cancer risk is the 1996 Oxford pooled analysis of 54 
epidemiologic studies with 53,297 breast cancer cases and 100,239 controls. The analysis 
showed a slightly increased risk of breast cancer among current users (RR=1.24; 95% CI: 
1.15-1.33) compared to never users [20]. A risk reduction was observed after stopping OC 
use (Relative Risk [RR]=1.16 for 1-4 years after stopping and 1.07 for 5-9 years after 
stopping). No increased risk was found 10 or more years after discontinuation of OCs 
(RR=1.01; 95% CI: 0.96-1.05) [20]. A more recent 2002 study [21] reported no excess 
breast cancer risk among current or former OC users (OR=1.0; 95% CI: 0.8-1.3 and 
OR=0.9; 95% CI: 0.8-1.0, respectively). Differences in study results may be due to changes 
in OC formulations with newer contraceptives having lower-dose estrogen.  
Hormone replacement therapy (HRT) may be another source of exogenous 
hormones. It is frequently used among postmenopausal women to delay bone density loss 
and alleviate menopausal symptoms. A 2009 review of postmenopausal hormone therapy 
and breast cancer risk reported that while combined estrogen-progestin therapy (EPT) 
moderately increased the risk of breast cancer (20-40%), the evidence for unopposed 
estrogen showed no increase in risk [22]. This study did not account for relative duration of 
use. The Nurses’ Health Study found monotonic increases in breast cancer risk with current 
use of unopposed estrogen (p for trend <0.001) and a 42% increased risk among women 
with 20+ years of use compared to never users [23]. Exogenous hormone use was 
associated with breast cancer risk among Long Island study participants. The odds of breast 
cancer were elevated for OC use, HRT use, and long term HRT use [24]. The authors note 
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that the timing of exogenous hormone use is important in understanding risk, specifically 
among postmenopausal women.  
Environmental Factors. While a considerable number of risk factors have been 
linked to estrogen the etiology of breast cancer is multi-factorial and increased breast cancer 
risk could occur through many other pathways. It is well established that exposure to 
ionizing radiation leads to increased cancer risk. Women exposed to the atomic bomb in 
Nagasaki and Hiroshima Japan experienced as much as a 9-fold increase in breast cancer 
risk [25].  
Polycyclic aromatic hydrocarbon (PAH)-DNA adducts are among the most 
consistently reported environmental factors associated with breast cancer. Human PAH 
exposure primarily comes from byproducts of fuel burning, cigarette smoke, and the 
consumption of grilled and smoked foods [26]. LIBCSP investigators reported a 50% 
increased risk (95% CI: 1.04, 2.20) among women with highest PAH quantile compared to 
women in the lowest quantile [26].  
Cigarette Smoking. The association between cigarette smoking and breast cancer 
risk has been inconsistent, likely due to competing biologic mechanisms. Smoking is known 
to increase exposure to carcinogens. However, it has been suggested that smoking is 
related to appetite suppression, early initiation of menopause, and altered hormone 
metabolism which would therefore decrease overall exposure to estrogens [25]. The exact 
association between smoking and breast cancer remains to be elucidated, as active 
smoking has not consistently been found to be associated with breast cancer in the 
epidemiologic literature. Neither self-reported former or current smoking was associated with 
breast cancer risk among Long Island women [18]. However, LIBCSP data did indicate a 
positive association among women who resided with a smoking spouse for greater than 27 
years (OR=2.10; 95% CI: 1.47-3.02) [27]. 
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Alcohol Consumption. The consumption of alcohol has been associated with a 
modest increased risk of breast cancer [28]. It is suggested that the alcohol-breast cancer 
association may be directly related to alcohol metabolism and its effects on the levels of 
estrogen and estrogen receptors in breast cells [29]. Other mechanisms of the alcohol-
breast cancer relationship have been proposed. Mechanisms include an increase in reactive 
oxygen species (ROS), hydroxyl radicals, and DNA modification [28]. Reports from a 2006 
meta-analyses of high quality studies showed a 22% (95% CI: 1.09, 1.37) increased risk of 
breast cancer among women classified as drinkers, compared to abstainers [30]. Contrary to 
these results Long Island investigators found no association between ever alcohol use and 
never users [18].   
Diet. A number of dietary factors including: fat, fiber, and fruit and vegetable 
consumption have been evaluated in association with breast cancer risk. However, the role 
of diet in breast cancer etiology remains controversial [31] as the magnitude and direction of 
effect are known vary by study design [32]. Moreover, studies which observe an association 
between diet and breast cancer incidence show that dietary factors may only slightly modify 
risk. There are several rationales for null or weak associations in the diet-breast cancer 
literature. Lof and Widerpass (2009) suggest that: (1) measurement error may disguise 
existing associations, (2) dietary exposures may not be ascertained during the etiologically 
relevant time period, and (3) there may be differences in risk according to tumor 
characteristics or genetics [33]. Alternatively, there may also be no causal association 
between diet and breast cancer risk.  
Obesity. The relationship between obesity and breast cancer varies by menopausal 
status. Studies indicate that obesity decreases risk among premenopausal women while 
increasing risk among postmenopausal women [34]. Pichard and colleagues report a 
positive relationship between body mass index (BMI, the ratio of weight in kg squared to 
height in meters squared) and breast cancer with RRs ranging from 1.26 to 2.52 among 
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postmenopausal women [35]. The positive association between obesity and 
postmenopausal breast cancer is thought to occur through the aromatization of androgens 
in adipose tissue. These androgens are subsequently converted to estradiol, the most 
metabolically active form of estrogen, thereby increasing breast cancer risk [7, 36]. 
Compared to ovarian estrogen production among premenopausal women, adipose 
mediated estrogen production is highly unregulated [36]. In combination with reductions of 
SHBG (a frequently observed phenomena of obesity-related hyperinsulemia), unregulated 
estrogen production results a greater than 2-fold increase in free estradiol among 
postmenopausal women [36].  
Physical Activity. There has been an overwhelming amount of epidemiological 
literature describing the beneficial effects of exercise in breast cancer risk reduction [37-45]. 
Studies suggest that risk reduction is approximately 25% when the most physically active 
woman is compared to the least physically active woman, even among high risk populations 
[44, 46]. The most obvious mechanism through which physical activity may influence cancer 
risk is by reducing adipose tissue, and consequently the hormonal milieu that occurs with 
postmenopausal obesity (discussed above) [41]. However, physical activity has been shown 
to reduce the risk of premenopausal breast cancer and the inverse association with 
postmenopausal breast cancer risk persists even upon controlling for body weight [47, 48]. 
These observations indicate that in addition to an obesity-mediated pathway, physical 
activity is likely to influence breast cancer carcinogenesis through independent mechanisms.  
1.1.4 Conclusions 
 Breast cancer remains an important public health concern in both the US and 
abroad. There has been considerable research in identifying the epidemiologic risk factors 
associated with breast cancer, but the underlying mechanisms of the disease remain 
unknown. While many of the established risk factors have been linked to hormone 
pathways, they are primarily reproductive and unlikely to be intervened upon. There are a 
 
 9    
 
9
 
number of non-reproductive risk factors known to play a role in breast cancer development. 
While they may not be as predictive as those which are reproductive, they can ultimately be 
controlled, aiding in the reduction of breast malignancy development. Physical activity 
appears to play an important role in the reduction of both pre- and postmenopausal breast 
cancer risk. Given the widespread accessibility of physical activity, identifying mechanisms 
through which it acts, independent of obesity, has become increasingly important. 
This dissertation focused on pathways relevant to breast cancer and physical 
activity, specifically oxidative stress and DNA repair. In the following sections I describe the 
current state of knowledge of the inverse association observed between physical activity 
and breast cancer risk, summarize the mechanistic pathways which have been evaluated to 
date and present a conceptual model of the hypothesized mechanisms through which 
physical activity is proposed to act. Finally, I review two pathways (i.e. oxidative stress and 
DNA repair) that play a potential role in the etiology of breast cancer, as well as provide a 
rationale for examining these two pathways in the molecular epidemiology of physical 
activity.  
1.2 Recreational Physical Activity 
Physical activity has been associated with reduced incidence of a number of chronic 
diseases including heart disease [49, 50], diabetes [50, 51], stroke [50], osteoporosis [52] 
and cancer [50]. Increased activity has also been proposed to counter disability, and 
improve cognitive functioning. Interest in physical activity for the primary prevention of breast 
cancer has increased, as there are convincing epidemiologic data that show a beneficial 
effect of exercise on breast cancer risk reduction [53]. While most of the established risk 
factors for breast cancer such as family history and reproductive characteristics are not 
easily amenable to intervention, physical activity may be one of few risk factors for cancer 
that can be modified through lifestyle and behavior change. It is unclear, however, whether 
activity alone provides a protective effect or if it serves as a proxy for overall health status. 
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Elucidation of the underlying mechanism linking physical activity inversely to breast cancer 
risk would strengthen the biologically plausibility of the association. Mechanistic insight 
could additionally aid in identifying targets for intervention, inform the recommendations for 
lowering breast cancer risk, and provide new clues to cancer biology.  
1.2.1 Definitions and Measures of Physical Activity  
Physical activity is defined as bodily movement produced by skeletal muscles 
resulting in a quantifiable form of energy expenditure [54]. Physical activity can be broadly 
classified as either cardiorespiratory (aerobic activity) or resistance (anabolic activity), each 
distinct in their physiological effects. Aerobic activities profoundly impact the cardiovascular 
and respiratory systems while anabolic activities influence the neural and muscular systems 
[55]. All individuals are exposed to physical activity in several domains across the life span. 
The Centers for Disease Control and Prevention (CDC) defines regular physical activity 
among adults as at least 150 minutes a week of moderate-intensity aerobic activity or 75 
minutes a week of vigorous-intensity aerobic activity. These recommendations are based on 
the Healthy People 2010 physical activity objectives and the 2008 Physical Activity 
Guidelines for Americans. The CDC’s analysis from the Behavioral Risk Factor Surveillance 
System (BRFSS) indicated that 76% of the US population participated in some type of 
physical activity during month prior to interview [56]. With a nationwide prevalence of 
approximately 75% physical activity may conceivably be one of the most pervasive 
modifiable exposures associated with breast cancer risk.  
There are three dimensions to physical activity, each of which may be varied in their 
effects on carcinogenesis. Several investigators advocate that a complete assessment of an 
individual’s energy expenditure from physical activity would include information on all of 
these important dimensions [37, 40]. The first component is frequency, which reflects the 
number of times the activity is performed (e.g., times per month/week/year). The second 
dimension is duration, broadly defined as the length of each activity session (e.g., minutes 
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or hours per episode). The final element is the intensity or rate of energy expenditure 
required to execute the activity. Metabolic equivalents of energy expenditure (MET) are 
commonly used to assess intensity. One MET unit is defined as the energy expended sitting 
quietly. This is equal to 3.5 millimeters of oxygen per kilogram of body weight per minute 
[57]. According to the CDC and the American College of Sports Medicine, light, moderate, 
and vigorous activities are classified as <3 METs, 3-6 METs, and >6 METs, respectively 
[58]. A summary measure of the three components is MET-hours, obtained by multiplying all 
three dimensions of activity. MET-hours may reflect the activity dose of one session, day, 
week, or month and is useful when grouping participants or comparing activity levels across 
populations. The type of activity may also be important in quantifying physical activity as 
recreational activities tend to be higher intensity and shorter duration compared to activities 
related to occupation or daily living which are traditionally low intensity and longer in 
duration.  
Due to the heterogeneity of physical activity and little standardization in assessment 
methods, it is often difficult to obtain valid estimates of energy expenditure [55]. While 
physiological measures of physical activity (e.g. resting heart rate and aerobic capacity) 
perform particularly well and are commonly regarded as a gold standard, they are not 
frequently employed in epidemiologic studies because they fail to capture the etiologically 
relevant time period and are often too expensive for large population-based designs [59]. 
Questionnaire based assessments are common practice in observational epidemiology and 
may query participants all three dimensions of physical activity. While there are qualitative 
differences in physical activity assessment across studies, the physical activity-breast 
cancer literature overwhelmingly supports an inverse association.  
1.2.2 Epidemiology of Physical Activity and Breast Cancer  
The association between physical activity and breast cancer has been studied at 
length. The overall findings are detailed in several reviews [37-45]. Risk reductions reported 
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in these studies range from 20-40% among active women [40, 41, 43, 44]. Generally slightly 
stronger associations have been found in case-control compared with cohort studies [37, 
42], although the Nurse’s Health Study reported a slightly stronger association for lifetime 
activity in the prospective design (prospective OR=0.58, 95% CI: 0.37, 0.93 versus 
retrospective OR=0.80; 95% CI: 0.50, 1.29) [60]. While early reports show risk reductions for 
both occupational and recreational activity, a comprehensive 2008 review of physical activity 
parameters and breast cancer risk [42] showed the greatest risk reductions for RPA (20% 
risk reduction). Activity related to occupation, transportation, and daily living each resulted in 
approximately 14% reduced risk. The same review reported similar risk reductions from 
vigorous activities (average 26%) and moderate intensity activities (average 22%).  
Timing. Determining the time period during which physical activity most influences 
breast cancer risk is of paramount importance in making recommendations for lowering 
incidence. The strength of the physical activity-breast cancer association may vary across 
the life course, as is observed for other established risk factors. In a 2001 review Latikka 
and colleagues [45] assessed the effect of physical activity at various phases of life on 
breast cancer outcomes. The literature primarily focused on current activity, of which the 
vast majority of studies (~82%) reported inverse associations. Two of three studies showed 
adolescent activity or activity during college may protect against breast cancer while 
inconsistencies were observed for studies that examined both historical and current activity 
[45]. Dorn et al. examined the physical activity-breast cancer association at two, ten, and 
twenty years prior to interview as well as across the lifetime [61]. Although most of the 
estimates were imprecise, they reported risk reductions for all physical activity categories 
above the referent in each time period with strongest effects observed for women active at 
least 20 yr prior to interview and among postmenopausal women who were consistently 
active throughout their lifetime [61]. A recent prospective study found moderate-to-vigorous 
activity during the past 10 years to be associated with decreased postmenopausal breast 
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cancer risk (RR=0.84; 95%CI=0.76, 0.93). The associations for activities performed during 
other periods of life were near null (RR=1.03, 1.01, and 0.97 for 15-18, 19-29, and 35-39 
years of age, respectively), and lifetime activity was not assessed [62]. Although the optimal 
timing of physical activity for breast cancer protection remains to be resolved, it appears that 
activity performed through adulthood and the postmenopausal years provide the greatest 
risk reductions. This was particularly true in our own study population [63]. In the only other 
study known to use the same comprehensive physical activity assessment as the LIBCSP 
only lifetime activity was reported [64] and exercise was shown to be inversely associated 
with breast cancer risk.  
Dose Response. There is some evidence for a dose response relationship between 
increasing activity levels and decreasing breast cancer risk. Thune and colleagues [43] 
observed graded dose-response relationships in 57% of studies evaluated (N=28). The 
proportion is as high as 87% in some reviews [40]. Evidence of dose-response relationships 
are more frequently observed in case-control compared to cohort studies [42, 43]. One 
review reported that 47% of case-control studies and 39% of cohort studies found linear 
tends for decreasing risk with increasing activity [42]. Linear trend analysis performed by 
Monninkhof and colleagues indicated a 6% (95% CI: 3%, 8%) decrease in breast cancer risk 
for each additional hour of physical activity per week [38]. In the LIBCSP we found a non-
linear dose response association between exercise and breast cancer with the greatest risk 
reductions observed among women in the third quartile of RPA [63]. 
Effect Measure Modification. Many of the observed differences in the effect of 
physical activity can be, in part, ascribed to methodological differences in evaluating activity 
across studies. It is also likely that these differences can be attributed to the heterogeneity 
of effects among subgroups of women. It is important to consider the association between 
physical activity and breast cancer risk within strata of menopausal status, body mass index, 
family history, and other potential effect measure modifiers. These analyses not only help to 
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identify at-risk subgroups, but they may aid in further understanding the biology driving the 
physical activity-breast cancer association.  
The body of literature to date indicates that there are stronger and more consistent 
effects of physical activity among postmenopausal women compared to premenopausal 
women [61, 65-67], although CIs overlap in many studies. A 2004 review study [41] showed 
that among 26 studies examining the association between physical activity and 
premenopausal breast cancer risk 50% found no association. Thirteen studies reported risk 
reductions, with seven being statistically significant. Among the 27 studies conducted in 
postmenopausal women, 22 (81%) found risk reductions when comparing the most active 
women to women who were least active. Sixteen of these studies reported statistically 
significant risk reductions. More recent reviews observed similar trends among pre and 
postmenopausal women [38]. While it is clear that an effect of physical activity persists in 
both pre and postmenopausal strata, risk reductions are greater in magnitude for 
postmenopausal  women (40% average risk reduction) compared to premenopausal women  
(33% average risk reduction) [42].  
Both independent and review studies demonstrate a protective effect of physical 
activity in low and high BMI categories. However, the magnitude of effect within strata of 
BMI has been shown to vary. One study reports significant decreases in invasive breast 
cancer risk with increasing levels of long-term strenuous recreational physical activity among 
women with a BMI < 25 (P trend=.03) but not among women with BMI ≥ 25 [68]. 
Investigators of the E3N cohort reported no effect modification by BMI on the physical 
activity-breast cancer association [46] as did investigators of the MARIE study, even upon 
stratifying by menopausal status [69]. Some review studies have drawn similar conclusions 
[38, 59]. Friedenreich and colleagues observed a trend of decreasing breast cancer risk with 
decreasing BMI and increasing physical activity. Risk reductions were approximately 25% 
among women with normal BMI (22–25 kg/m2) and 20% among women with high BMI (≥25 
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kg/m2). There were near null effects of physical activity on breast cancer risk among women 
classified as obese (≥30 kg/m2), although few studies reported effects in this strata [42]. 
Data from the LIBCSP showed that among postmenopausal women who engaged in more 
than 9 hrs/wk of RPA (on average) risk reductions were 27% for normal BMI, 15% for 
overweight women, and near null (OR=0.99) for women with BMI ≥30 kg/m2 [63]. 
Few studies have assessed modification by family history, but the greatest risk reductions 
have been reported for women without a family history of breast cancer. Dallal et al. [68] 
reported significant decreases in breast cancer risk with increasing levels of strenuous 
recreational physical activity among women with no first-degree family history of breast 
cancer (P trend=.01). This trend was not observed among women with a family history of 
breast cancer (P trend=.72). Similar associations for family history have been observed in 
other studies [64, 70] and Friedenreich [42] reported an average risk reduction of 6% among 
women without a family history, compared to an average increased risk of 20% for women 
with a family history of breast malignancy. Contrary to these findings, Pijpe and colleagues 
[71] reported a reduced risk of breast cancer among BRCA1/2 mutation carriers engaging in 
sports participation (HR=0.59, 95%CI=0.36-0.95 among women with a medium versus low 
level of sport intensity and duration). Additionally, one study reported delayed onset of 
breast cancer among BRCA1 mutation carriers who were physically active [72]. 
Energy intake and energy expenditure together determine an individual’s overall 
energy balance which greatly affects adiposity and breast cancer risk. It is therefore 
important to determine if energy intake modifies the physical activity-breast cancer 
relationship. Studies which have been able to control for energy report no difference in the 
effects of physical activity for high vs. low consumers of total energy [42, 59]. An average 
risk reduction of 21% has been reported for both groups [42].  
Etiologic Heterogeneity. While hormone receptor status is not an effect modifier, 
but a marker of potential etiologic heterogeneity, studies have assessed the physical 
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activity-breast cancer association within strata of these breast cancer outcomes. 
Inconsistencies have been observed in the literature. Dallal and colleagues [68] report 
significant decreases in breast cancer risk with increasing levels of both moderate (P 
trend=0.003) and strenuous (P trend=0.003) RPA among women with estrogen receptor 
(ER) negative tumors. No associations were observed for ER+, ER+/progesterone receptor 
(PR)+, or ER+/PR- cancers. These results are contrary to similar analyses which report no 
difference in the physical activity-breast cancer association by receptor status [64], and still 
others showing stronger associations for ER+ tumors [73]. Friedenreich and colleges 
reported risk reductions of 29% and 14% for hormone receptor negative and positive 
tumors, respectively [42].  
1.2.3 Physical Activity Mechanisms 
The biologic pathways influencing the physical activity-breast cancer association are 
less understood than its epidemiology. While it is consistently observed that physical activity 
aids in the reduction of breast cancer risk, there has been little molecular evidence 
demonstrating the physical activity cancer prevention paradigm [44, 74, 75]. The lack of 
information on the molecular epidemiology of physical activity and the strong potential for 
confounding effects emphasize the need for mechanistic data to facilitate causal inference 
and identify new targets for intervention. There are several mechanisms that may mediate 
the association between physical activity and breast cancer risk. While reduction in 
hormonal pathways and obesity related mechanisms offer the most convincing explanation 
to date, other physiological effects of exercise may prove beneficial as well. Mechanisms 
commonly cited in the literature include: changes in body weight, sex steroid hormones, 
insulin, growth factors, inflammation, and immune functioning (Figure A.2) [74-78].  
Body Weight. The most commonly proposed mechanism for the physical activity 
breast cancer association is through a reduction in body weight. Increased body weight is an 
independent risk factor for postmenopausal breast cancer and its effects on endogenous 
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estrogens are well documented. Research has shown that visceral fat (fat accumulated over 
the central abdomen) is metabolically active and has numerous physiological corollaries 
thought to influence carcinogenesis [79]. Physical activity is known to preferentially reduce 
central obesity [59] and is likely one mechanism through which exercise may prevent cancer 
development. It is, however, difficult to disentangle physical activity dependent mechanisms 
from those associated with obesity, as the two are closely linked. 
Sex Steroid Hormones. Sex steroid hormones (particularly estrogens) are known to 
play an important role in pathogenesis of breast cancer. Physical activity has been shown to 
influence the amount circulating reproductive hormones in both pre- and postmenopausal 
women.   
The total number of menstrual cycles is a well-established risk factor for breast cancer. 
Among premenopausal women some epidemiologic studies have shown that excessive 
amounts of energy expenditure can cause temporary suppression of gonadal hormones, 
delayed menses, menstrual cycle irregularities, anovulation, and amenorrhea [80-83], 
primarily as a result of luteal phase inadequacy [39]. While these data suggest that exercise 
reduces cumulative exposure to sex steroid hormones thereby decreasing the risk of breast 
cancer [45, 80], more recent research indicates that beyond its effect on energy availability 
exercise has little disruptive effect on the hormonal milieu of premenopausal women [84]. 
Moreover, there is little evidence of a direct association between disturbances in menstrual 
characteristics and breast cancer incidence. 
Among premenopausal women the ovaries are the principal source of estrogens 
(primarily estradiol). Following menopause the ovaries produce very little estrogen. 
However, through the aromatization of androgens in fat tissue postmenopausal women may 
still be exposed to high endogenous estrogen levels [85]. The P450 enzyme aromatase is 
known to be involved in the biosynthesis of estrogens from androgenic precursors [77] and 
has been correlated with breast cancer [86]. In both pre and postmenopausal women 
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estradiol forms a reversible redox reaction with estrone which is subsequently metabolized 
along one of two pathways: 2-hydroxyestrone or 16α-hydroxyestrone [87]. Adipose 
mediated estrogen production is preferential to the bioactive 16α-hydroxyestrone pathway 
and is associated with decreased levels of the less bioactive 2-hydroxyestrone [88]. Among 
obese postmenopausal women the increased propensity for the 16α-hydroxyestrone 
pathway results in an even greater amount of circulating estrogen. In contrast, 
premenopausal women experience consistently high levels of estrogen from menarche, 
regardless of weight, so any additional exposure from the aromatization of androgens or 
16α-hydroxyestrone metabolizing pathway would not greatly impact overall estrogen levels.  
Bioavailability of sex steroids also increases after menopause as the levels of SHBG, 
the predominant carrier of estradiol, decreases [89]. This is of particular importance among 
women who are obese because circulating triglycerides from fat stores are able to dislodge 
estradiol from SHBG thereby increasing bioavailability of sex steroids [90]. Physical activity 
has been shown to reduce serum concentrations of both estrogens and androgens among 
postmenopausal women [83, 91-93], although there may be the possibility of a U-shaped 
relation between activity and hormone levels [92]. These changes are likely to occur through 
indirect effects of physical activity on obesity.  
Insulin. Insulin, a peptide hormone secreted by the beta cells of the pancreas, is 
primarily responsible for the regulation of blood glucose. Insulin is positively associated with 
breast cancer risk [94] and influenced by both central adiposity and physical activity [95]. 
Increases in visceral fat are associated with elevated levels of serum free fatty acids in the 
blood. These fatty acids are thought to cause a reduction in glucose uptake and an 
obligatory rise in insulin secretion in an effort to maintain glucose homeostasis [76, 77, 96, 
97].  Increased levels of insulin cause a cascade of deleterious events that include: (1) 
decreased production of insulin-like growth factor binding proteins (IGF-BPs), (2) amplified 
levels of IGF-1, and (3) reduced availability of SHBG [77, 98]. Increases in both insulin and 
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IGF-1 are proposed to inhibit apoptosis and stimulate the progression of neoplastic 
mammary cells from the G1 to S phase of the cell cycle [99]. Reduced SHBG increases the 
fraction of bioavailable estradiol and testosterone. These mechanisms, collectively, provide 
an opportunity for tumor development and progression.  
Insulin resistance occurs when insulin becomes less effective at lowering blood 
sugars. Physical activity may influence insulin resistance in multiple ways. Acute bouts of 
exercise are reported to increase glucose uptake by skeletal muscle resulting in improved 
insulin sensitivity [100, 101]. However, intervention studies show comparable improvements 
in insulin resistance for diet-induced or exercised-induced weight loss [101] suggesting that 
an overall reduction in adiposity, irrespective of the mechanism, increases insulin resistance. 
In addition to a reduction of insulin levels from physical activity, regular exercise has been 
proposed to influence cancer risk through its effects on IGF-1 [102]. The relation between 
physical activity and IGF-1 is not clear however; experimental studies have not shown an 
effect of exercise on circulating IGF-1 levels [103]. Similarly, animal models indicate that 
exercise training does not affect basal levels of IGF-1 [78]. The evidence is more consistent 
that physical activity increases levels of IGF-BP resulting in a decrease in overall IGF-1 
bioavailability and activity [99, 102]. Greater levels of physical activity could result in lower 
levels of endogenous sex hormones via any number of metabolic events including: reduced 
insulin resistance, reduced IGF-1, and increased production of SHBG. The overall effect is a 
lower risk of hormone-related cancers. These changes are also observed for reduced 
adiposity and may not be independently related to physical activity.  
Inflammation. Adipokines (a variety of cytokines) are biologically active polypeptides 
secreted from white adipose tissue. A number of adipokines are considered indicators of 
inflammation including: leptin, adiopenctin, tumor necrosis factor alpha (TNF-α), and 
interleukin-6 (IL-6) [104]. Inflammation is a complex biological response of vascular tissues 
to harmful stimuli (i.e. invading pathogens) and a necessary step in the initiation of wound 
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healing. Pro-inflammatory cytokines TNF-α and interleukin-1-beta (IL-1β) are produced at 
the infection site in response to leptin. These markers stimulate the release of IL-6 and 
collectively activate C-reactive protein (CRP) during acute phase response. Following 
clearance signal transduction of IL-1β and TNF- α are blocked by the release of IL-1 
receptor antagonist and soluble TNF- α receptors [99]. Chronic inflammation is a condition 
that results in an increase in the circulating levels of pro-inflammatory markers TNF-α, IL-6, 
and leptin (often highly expressed in adipose tissue) and a decrease in anti-inflammatory 
markers, such as adiponectin, which are inversely correlated with adiposity [105]. Chronic 
inflammation is not only a risk factor for obesity, but has been associated with several other 
conditions including metabolic syndrome [106], type 2 diabetes [107], and some cancers 
[108, 109]. Increases in cancer risk due to chronic inflammation may occur because of 
changes in the microenvironment, increased proliferative activity, and oxidative stress [110]. 
These factors are likely to work together to deregulate normal cell development thus 
increasing the propensity for malignancy.  
While obesity has clear mechanistic associations with inflammation it has been 
suggested that regular exercise may reduce inflammation independent of weight loss. 
Studies support an inverse association between chronic physical activity and inflammatory 
markers CRP, TNFα, and IL-6 [44, 111, 112]. One study reported that while there are small 
increases of pro-inflammatory markers, a surge of cytokine inhibitors are initiated following 
exercise [113]. In contrast to acute infection the cytokine response to exercise does not 
involve amplification of pro-inflammatory cytokines. Rather, it is initiated by IL-6 and followed 
by an increase in anti-inflammatory markers thereby decreasing the likelihood of low grade 
chronic inflammation. Although these observations are indicative of an independent effect of 
exercise on inflammation, not all intervention studies of exercise have shown reductions in 
these inflammatory markers [44]. 
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Immune Function. It is hypothesized that the immune system aids in cancer risk 
reduction by recognizing and eliminating abnormal cells [114]. It is also probable that the 
immune system modulates susceptibility to tumor formation by hindering cell growth or by 
counteracting the effects of tumor growth promoters [87]. Regular moderate physical activity 
may therefore reduce risk of cancer by stimulating components of the innate immune 
response. Studies indicate that in response to moderate physical activity a number of innate 
immune parameters (i.e. macrophages, monocytes, lymphocytes, neutrophils, eosinophils, 
killer cells, and acute-phase proteins) increase in function and/or quantity [78, 115, 116]. 
These effects are transient, with levels of immune parameters dropping below pre-exercise 
levels following activity [116]. The improved immune function that is hypothesized to occur 
with physical activity may vary by exercise type, intensity, or duration. An inverted ‘J’-shaped 
dose-response relationship between intensity of physical activity and immune function is 
frequently reported with the greatest benefit occurring among individuals who undertake 
regular moderate exercise [44, 87]. Depression of immune function may be induced by 
excessive exercise at high intensity levels [44]. While there appears to be evidence for the 
immune system contributing to the association between physical activity and breast cancer 
susceptibility, this relationship is largely untested and requires further investigation.  
Other Mechanisms. The physical activity-breast cancer mechanisms described 
above primarily involve targets of adiposity and weight loss. It is likely that many of these 
mechanisms work synergistically acting through a common obesity related pathway, but 
even early epidemiologic studies show that upon control for body weight an effect for 
physical activity persists [47, 48]. Similarly, animal models have shown that the negative 
energy balance induced by exercise does not, alone, explain the cancer preventive effects 
of physical activity [78]. These results suggest that while physical activity and weight 
reduction are strongly linked, each is likely to confer an independent benefit to reduce breast 
cancer risk. In addition to being targets of obesity, the proposed mechanisms are primarily 
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related to the promotion and progression of postmenopausal breast cancer. Physical activity 
may, however, influence risk at multiple points along the cancer continuum (Figure A.3). 
Exercise may influence the development of cancer by decreasing the rates of genetic and 
epigenetic alterations or by shifting the equilibrium of growth and death in cancer cells.  
There have been few attempts to disentangle the effect of exercise from those of 
energy balance. While obesity related pathways are biologically plausible and likely to 
influence the physical activity-breast cancer association, other pathways important in 
carcinogenesis should be considered. Some investigators propose that physical activity may 
work through mechanisms further upstream including pathways related to early stages of 
malignant transformation [74, 75]. Markers associated with oxidative stress and DNA repair 
have been shown to be pertinent to breast cancer, but they may also be modifiable by 
exercise [42, 74, 83]. To date there are no epidemiologic studies which have evaluated the 
biologic plausibility of these pathways. 
1.2.4 Conclusions 
It is well established that physical activity reduces the risk of breast cancer. While the 
epidemiologic literature shows decreases in risk from all types of physical activity, moderate 
recreational activity appears to have the strongest association with risk reduction. Similarly, 
activities done throughout the lifetime have been consistently associated with breast cancer 
risk reduction compared to activities performed around the time of diagnosis [42]. Several 
mechanisms have been proposed to mediate the association between physical activity and 
breast cancer risk. They include sex steroid hormones, insulin resistance, growth factors, 
inflammation, and immune function. While these mechanisms are biologically plausible and 
likely to contribute to the inverse association between physical activity and breast cancer 
risk, they are greatly influenced by body weight – a consistent risk factor for 
postmenopausal breast cancer. Other pathways, independent of obesity, should be 
considered in the physical activity-breast cancer paradigm. The remaining sections will 
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explore the role of oxidative stress and DNA repair in the physical activity-breast cancer 
association 
 
1.3 Oxidative Stress  
Reactive oxygen species may be generated through any number of endogenous or 
exogenous processes. The term ROS is commonly used to describe certain reactive oxygen 
metabolites containing unpaired electrons in their outer orbit [117, 118]. ROS includes free 
radical derivatives of molecular oxygen (e.g. superoxide radical O2●-, hydrogen peroxide 
H2O2, hydroxyl radical ●OH) which are continuously generated within a cell as a result of 
oxidative metabolism [119, 120]. ROS may be produced by other endogenous processes 
such as estrogen metabolism, peroxisomes activity, or inflammatory cell activation. ROS 
and ROS-generating compounds are ubiquitous in the environment commonly found in 
inhaled smoke, alcohol, and ingested goods [121, 122]. While modest levels of ROS are 
useful for cell signaling processes [123] excess ROS may result in DNA damage, lipid 
peroxidation, and protein modification [121, 124-126]. These changes are known as 
oxidative stress, a term used to refer to the global burden of harmful reactive biochemical 
species present in tissue as a consequence of the regular cellular oxidative metabolism of 
endogenous and exogenous compounds [127]. 
1.3.1 Endogenous Responses to Oxidative Stress 
 When endogenous or exogenous ROS production occurs in an environment with 
sufficient in vivo defense mechanisms to scavenge the ROS, there are seemingly few 
harmful effects. When there is excess ROS production or insufficient defense mechanisms, 
oxidative stress may ensue. There are several antioxidant defenses that can protect against 
increases in lipid peroxidation counteracting oxidative damage. Enzymes responsible for 
neutralizing ROS endogenously include catalase (CAT), manganese superoxide dismutase 
(MnSOD), glutathione peroxidase (GPx), as well as glutathione S-transferases (GST) [127]. 
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These enzymes form the first line of defense against superoxide and hydrogen peroxide. 
Secondary defenses include reduced GPx and GST [128, 129], which play a central role in 
the defense against free radicals, peroxides, as well as a wide array of xenobiotics and 
carcinogens [130]. If peroxide or other free radical derivatives of molecular oxygen are not 
neutralized by the above mechanisms, they may contribute to additional ROS generation by 
myeloperoxidase (MPO) [131]. MPO generates ROS endogenously performing as an 
antimicrobial enzyme, catalyzing a reaction between H2O2 and chloride to generate 
hypochlorous acid [132]. Hypochlorous acid further reacts with other biological molecules to 
generate secondary radicals [133]. Endothelial nitric oxide synthase is also responsible for 
the generation of reactive nitrogen species (RNS), catalyzing the production of the NO 
radical [134]. The levels of potentially cytotoxic reactive species within the body may 
therefore depend on the balance between endogenous pro- and anti-oxidants. 
1.3.2 Biologic Plausibility of the Oxidative Stress-Breast Cancer Association 
 Oxidative stress may play an important role in the risk of many chronic diseases 
including cardiovascular disease, aging, and human cancer [135-138]. The function of 
oxidative stress in carcinogenesis has been widely demonstrated in small human and 
animal studies, providing increasing evidence that it may be involved in the pathophysiology 
of breast cancer [127, 139-141]. Oxidative damage has been suggested to contribute to the 
formation of DNA adducts [142] and has been implicated in neoplastic transformation [143]. 
Oxidative damage has frequently been reported to be higher among women with breast 
cancer, compared to controls [127]. Similarly, studies have observed enhanced lipid 
peroxidation in breast tumor tissue compared to uninvolved adjacent tissue. Elevations in 
both enzymatic (SOD, CAT, GPx, GST) and nonenzymatic (GST) antioxidants in tumor cell 
lines have been observed in some [126, 144-146] but not all [126, 147] studies. 
 Although the exact mechanisms remain to be elucidated it is likely that oxidative 
damage to DNA results in genetic mutations or alterations in gene expression [148]. Genetic 
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variants that influence pro or anti-oxidant mechanisms may therefore play an important role 
in breast cancer carcinogenesis [127]. CAT is a heme enzyme that has a primary role in 
neutralizing ROS by converting H2O2 into H2O and O2 [127]. Mouse models have shown that 
acatalasemic mice (C3H strain), with approximately one tenth the CAT blood and tissue 
levels of normal mice, were more susceptible to spontaneous mammary carcinoma  after 
feeding on regular laboratory chow for 15 months [149]. While these studies are limited to 
the animal literature such associations could be assessed by evaluating the impact of 
catalase activity (using genotype as a proxy) on breast cancer risk. 
1.3.3 Epidemiology of Catalase and Breast Cancer Risk 
 Activity levels of the CAT enzyme is likely affected by functional polymorphisms in 
the gene. A common 262 C/T polymorphism (rs1001179) has been identified in the 
promoter region of the human CAT gene [150]. Endogenous variability associated with this 
SNP may play an important role in host response to oxidative stress. Studies have shown 
that the variant CAT allele (T) is associated with hypertension [151] and vitiligo [152], both 
conditions related to oxidative stress. The 262 C/T polymorphism has been shown to affect 
the transcriptional activity of the promoter [150] and is thought to result in reduced enzyme 
activity [153-155]. Using a sample of 420 controls Ahn and colleagues examined the 
functional effects of this variant on catalase enzyme activity. They found a dose-response 
reduction in activity by CAT genotypes, with geometric means of 115.4, 82.1, and 73.5 
units/mg hemoglobin for CC, CT, and TT genotypes, respectively. The reported % activity 
difference for CT genotype versus CC genotype was 28.8% (P = 0.002) and was 36.3% (P = 
0.02) for TT genotype versus CC genotypes [153]. These associations were also observed 
in a smaller, yet independent, study population [156].  
 There have been few reports of the association between the catalase-262 C/T 
polymorphism and breast cancer risk in the epidemiologic literature. Investigators from the 
LIBCSP found that women with the common CC genotype had a 17% reduction in risk of 
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breast cancer (95% CI: 0.69, 1.00) compared to women with at least one T allele (CT and 
TT genotypes) [156]. Follow-up studies reported approximately null associations between 
CAT genotypes and breast cancer risk [157, 158], although there were less participants in 
both studies (N=569 and N=505 for Quick et al., 2008 and Li et al., 2009, respectively). 
While no other CAT variants have been reported in the epidemiologic literature, other 
polymorphisms may be independently associated or act, in combination, with this functional 
variant to influence breast cancer incidence. 
1.3.4 Oxidative Stress and Physical Activity  
 Several risk factors associated with breast cancer (i.e. alcohol consumption, 
cigarette smoking, exposure to environmental tobacco smoke, and reduced estrogen 
metabolism) may exert their harmful effects via generation of ROS [144, 159-161] while 
others (i.e. consumption of fruits vegetables and antioxidants) are suggested to oppose 
ROS formation [127] therefore reducing the risk of breast malignancy. Several studies have 
examined the association between ROS related risk factors, genetic variants and breast 
cancer risk – hypothesizing that ROS generating risk factors act, in combination, with 
reduced antioxidant expression to increase the risk of breast cancer. Ahn and colleagues 
reported that current smokers with at risk GSTA1 polymorphisms (B/B genotypes) had a 
1.89-fold increase in risk (OR=1.89; 95% CI=1.09–3.25), compared with never smokers with 
the common A/A genotype [162]. Among ever users of HRT the increased risk of breast 
cancer was more pronounced among women with variant CT or TT CAT genotypes 
(OR=1.88; 95% CI=1.29-2.75) than among women with the CC genotype (OR=1.15; 95% 
CI=0.86-1.54) although CAT genotype alone was not associated with breast cancer risk 
[157]. Exposures known to oppose ROS generation have been shown to obliterate the 
increased risk associated with genotype. Among women with the at risk B/B GSTA1 
genotype, Ahn et al. observed an inverse trend between cruciferous vegetable consumption 
and breast cancer risk (P for trend = 0.05) [162]. Similarly, high fruit consumers with the 
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common CAT genotype (CC) have been shown to have the lowest risk of breast cancer 
(OR=0.59; 95%CI=0.38-0.89). Women who were low consumer/common genotype or high 
consumer/variant genotype had OR’s (95%CI’s) = 0.94 (0.65-1.37) and 1.06 (0.66-1.73), 
respectively [156]. These data indicate that genotypes related to reduced antioxidant 
expression may be associated with increased breast cancer through risk factors that 
increase ROS generation.  
Studies have shown that physical activity is a strong inducer of lipid peroxidation and 
free radicals [119, 163, 164]. While the dimensions of exercise-induced ROS production are 
unknown, there is some evidence that strenuous activity [165-167], endurance and 
resistance training [168] increase lipid peroxidation. Three mechanisms of exercise induced 
ROS production have been proposed [169]. One mechanism is via an electron ‘leak’ of the 
mitochondrial electron transport chain. During activity whole body oxygen consumption 
increases 10 to 20-fold and local muscle consumption 100 to 200-fold. While the majority of 
oxygen binds to hydrogen transforming it to water through the electron transport chain, an 
electron leak at the ubiquinone–cytochrome b level may result in the formation of superoxide 
radicals. Thus, as oxygen consumption increases during exercise there is a parallel increase 
in free radical production and lipid peroxidation. Another possible mechanism is ischaemia-
reperfusion. During exercise, blood flow is restricted in many organs and tissues (e.g. 
kidneys, splanchnic region) to increase blood supply to the working muscles. As a result, the 
regions with restricted blood flow may experience a hypoxic state which heightens as the 
intensity of exercise increases. At the cessation of exercise these regions undergo re-
oxygenation, which may lead to a burst of ROS production typical of ischemia-reperfusion. A 
third mechanism is auto-oxidation of catecholamines, whose levels are amplified many-fold 
during exercise leading to increased oxidative stress.  
Regular physical activity is also known to stimulate endogenous antioxidants as a 
physiological response to the oxidative stress [170, 171]. Up-regulation of antioxidant 
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enzymes may render cells more resistant to subsequent oxidative insult [172] thereby 
neutralizing the potentially mutagenic effects of lipid peroxidation [173]. Regular exercise 
has been shown to enhance antioxidant status at multiple levels in both animal models and 
clinic studies. Rodent studies showed increased levels of hepatic CAT [174-176] with 
exercise training. Amplified levels of hepatic SOD [175, 176] and cytosolic SOD activity [174] 
have also been documented. Clinical studies showed that among runners, there is a positive 
correlation between exercise training and GST [171], GPX, as well as CAT activity [177]. In 
addition to changes in antioxidant enzymes, exercise induced oxidative damage may also 
lead to increased cellular apoptosis providing yet another potential mechanism driving the 
inverse association between physical activity and breast cancer [178].  
1.3.5 Conclusions 
 ROS induced oxidative damage generates products that have the potential to react 
with DNA, which may lead to mutations in proto-oncogenes and tumor-suppressor genes. 
These changes (if unrepaired) could result in the transformation of normal epithelium to a 
malignant phenotype [139, 140] making it a potentially important contributor to the etiology 
of breast cancer. Levels of oxidative stress in the body are ultimately determined by 
variability in exposure to endogenous or exogenous factors that could increase ROS, as well 
as cellular response to ROS [127]. Catalase and other antioxidant enzymes are responsible 
for neutralizing free oxygen derivatives. Enzymatic levels have been shown to vary by 
malignancy status in breast tissue which lends support to the oxidative stress-breast cancer 
hypothesis. This hypothesis may be further tested by examining the association between 
inherited genetic variants in CAT and breast cancer risk, as studies have shown a dose-
response reduction in activity with increasing number of variant alleles.  
While the immediate systemic response to physical activity is an increase in ROS 
production, the lasting effect of regular endurance training is adaptation of antioxidant 
capacity. Increased antioxidant capacity may protect against the unfavorable effects of 
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oxygen free radicals and prevent oxidative damage. These changes seem to occur after 
moderate to exhaustive exercise, which parallels current knowledge of the inverse 
association between physical activity and breast cancer. It is therefore plausible that lipid 
peroxidation and subsequent increases in antioxidant capacity are important mechanisms 
for physical activity. This could be assessed by examining the extent to which antioxidant 
genotypes in multiple oxidative stress related genes modify the effect of physical activity on 
breast cancer risk.  
1.4 DNA Repair  
Models of causation are important to distinguish epidemiological risk factors and 
associations with disease. Cancer research dating back to the 1920s has shown that tumor 
initiation begins with DNA alterations resulting from inherent, spontaneous, or carcinogen 
induced genetic changes.  These changes may lead to DNA damage and mutations that, in 
the absence of apoptosis, may propagate through the genome leading to unregulated cell 
growth. One mechanism of DNA damage is through the generation of ROS [179] which may 
damage DNA both directly and indirectly by forming lipid peroxidation products. Several 
types of oxidative DNA damage have been identified [125], but the most common oxidative 
stress-induced DNA lesion is 8-oxodeoxyguanosine (8-oxo-dG) [122, 180]. These lesions 
are excised exclusively by 8-oxoguanine DNA glycosylase, the enzyme encoded by DNA 
repair gene 8-Oxoguanine glycosylase (OGG1) [180].  
DNA integrity may be compromised by both endogenous and exogenous processes, 
but damage may be prevented or repaired through any number of innate defenses including: 
neutralization by endogenous antioxidants, detoxification of reactive metabolites, apoptosis, 
cell cycle arrest, and DNA repair [181]. If these mechanisms are insufficient however, 
uncorrected oxidative damage may ensue, contributing to the formation of somatic 
mutations in tumor suppressor genes or proto-oncogenes [182]. Persistent mutations in 
critical genes may result in genomic instability and ultimately, carcinogenesis [183]. 
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Polymorphic sites in DNA repair pathway genes are therefore strong candidates for cancer 
susceptibility genes [184].  
DNA is primarily maintained by repair mechanisms, which recognize, excise, and 
replace damaged nucleotides. The mechanism of repair is contingent on both the structure 
of the damage and its location within the genome. There are at least four repair pathways 
(Table A.2) that operate on damaged DNA: double strand break (DSB) repair, base excision 
repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR) [181, 185].  
Oxidative DNA damage is repaired mainly through the BER pathway [181]. However, 
research suggests that oxidative stress may lead to inactivation of both NER [186] and MMR 
activity [187]. The following text will give an overview of the DNA repair pathways, 
summarize associations between DNA repair variants and breast cancer, provide biologic 
rationale for exploring the role of MMR in breast carcinogenesis, as well as review the 
evidence for the association between DNA repair and physical activity.  
1.4.1 DNA Repair Pathways  
Double Strand Break Repair. Double-strand breaks can be produced by exogenous 
agents, including ionizing radiation, chemotherapeutic agents, endogenously generated 
ROS and replication errors [188]. Double strand breaks are among the most dangerous type 
of DNA damage, as the unavailability of a damage-free template makes repair more difficult 
[181]. There are two main DSB repair pathways: homologous recombination (HR) and non-
homologous end joining (NHEJ) [189]. The HR pathway involves greater than 15 molecules 
including the breast and ovarian cancer genes BRCA1 and BRCA2, as well as x-ray repair 
cross-complementing protein (XRCC)1, XRCC2, and ATM. DNA-dependent protein kinase A 
is an essential component of the NHEJ pathway, although other molecules (e.g. Ligase IV) 
are important [188]. In HR the damaged ends are removed and strands extended using a 
homologous sequence to guide repair. NHEJ is not contingent upon homologies between 
the two recombining ends and repairs damage by directly ligating the broken ends – 
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potentially resulting in more error [190]. NHEJ additionally has two known sub-pathways: 
classic NHEJ (described above) and alternative NHEJ [191]. Little is known about the 
mechanisms and factors involved in alternative NHEJ. 
Base Excision Repair. BER is essential to repairing oxidative DNA damage and 
other small lesions such as those produced by methylating agents and nonbulky adducts 
[181]. Repair is initiated by DNA glycosylases, which recognize and remove damaged 
nucleotides by cleavage of the N-glycosylic bond between the base and its associated 
deoxyribose group, generating an apurinic/apyrimidinic (AP) site [192]. The AP site is further 
processed by AP endonuclease which converts the base lesion into a single strand break. 
The break is repaired via DNA synthesis and ligation which occurs along one of two 
pathways: short-patch BER (replacement of a single nucleotide) or long-patch BER 
(synthesis of multiple nucleotides) [193, 194]. Each pathway necessitates its own set of 
enzymes. The short-patch BER pathway requires four proteins: AP endonuclease (APE1), 
DNA polymerase β, and DNA ligase III/XRCC1 heterodimer. The long-patch BER pathway 
involves six: APE1, replication factor C, proliferating cell nuclear antigen, flap endonuclease 
1, DNA polymerases δ/ε, and the DNA ligase I [192, 194, 195].  
Nucelotide Excision Repair. The NER pathway repairs bulky lesions such as 
pyrimidine dimmers and other UV-induced photoproducts, oxidative damage, cross-links, 
and chemical adducts [181, 189, 196, 197]. This pathway is essential in removing UV-
induced DNA damage as evidenced by Xeroderma pigmentosum (XP), an autosomal 
recessive genetic disorder characterized by extreme sensitivity to sunlight that results from 
germline mutations of NER proteins [198, 199]. The NER pathway consists of, at minimum, 
four major steps: damage recognition, unwinding of DNA, removal of the damaged 
fragment, and synthesis of DNA (reviewed in [189]). Damage is recognized by a protein 
called XPC, which is bound to the protein HHRAD23B (R23). Together they form the XPC–
HHRAD23 heterodimeric subcomplex. Several other proteins bind to the complex, assisting 
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with base damage recognition (XPA and replication protein A), unwinding of DNA 
(transcription factor IIH (TFIIH)), and excision (XPG). Six subunits containing two DNA 
helicase activities (XPB and XPD) make up TFIIH and are responsible for unwinding DNA 
near the site of damage. Binding of the ERCC1–XPF heterodimeric subcomplex produces 
the final NER multiprotein. Excision occurs at junctions both 3’ and 5’ to the site of base 
damage by XPG and the ERCC1–XPF complex, respectively. The resulting oligonucleotide 
fragment is excised from the genome. DNA repair synthesis involved polymerases δ or ε, a 
number of replication proteins, and DNA ligase [189, 200].  
Mismatch Repair. The MMR genes repair incorrect pairings of nucleotide bases 
(base-base or insertion-deletion mismatches) which may occur as a result of genetic 
recombination, replicative errors in DNA polymerase, deamination of 5-methylcytosine to 
thymine, or environmental mutagens [201, 202]. MMR is essential for maintaining genomic 
stability as its proteins have been shown to encourage cytotoxicity [203], p53 
phosphorylation [204], cell-cycle arrest [205], and cell death [204, 206, 207] in DNA 
damaged cells. Loss of MMR function thwarts the correction of replicative errors leading to 
genomic instability. These changes can be detected by polymorphisms in microsatellites 
which are characterized by repeated regions of one to six nucleotide units scattered 
throughout the genome. Microsatellite instability (MSI) is a hallmark of MMR dysfunction in 
colorectal cancer and other malignancies (discussed below) and occurs during replication 
when the two strands of DNA become misaligned, resulting in small loops of unpaired DNA 
[208, 209]. Loss of MMR function may occur because of mutations in one of six genes 
associated with MMR: MLH1, MLH3, MSH2, MSH3, MSH6 and postmeiotic segregation 
increased 2 (PMS2). These genes make up the MutS and MutL homologue proteins 
involved in MMR (Figure A.4). MutS homologues include MSH2-MSH6 (MutSα) and MSH2-
MSH3 (MutSβ). It is suggested that MutSα is responsible for the repair of base:base 
mispairs and MutSβ is responsible for insertion/deletion mispairs [210]. The MutL 
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homologues include MLH1-PMS2 (MutLα) and MLH1-MLH3 (MutLβ). Once bound to the 
mismatch, MutS associates with its complementing MutL heterodimeric complex. The 
associated complex exchanges bound adenosine diphosphate (ADP) from adenosine 
triphosphate (ATP) resulting in a conformational change and the formation of a clamp that 
translocates along DNA. Proliferating cell nuclear antigen (PCNA), interacting with MSH3 
and/or MSH6, corrects the strand that retains the primer. The mismatch strand is 
subsequently degraded by a 3->5 exonuclease and re-synthesized by DNA polymerase γ 
and PCNA [201].  
1.4.2 Epidemiology of DNA Repair and Breast Cancer 
Approximately 130 human genes are involved in the four DNA repair pathways previously 
described, each playing an important role in the maintenance of genomic integrity [211]. 
Knowing that reduced DNA repair may lead to genetic instability and carcinogenesis, genes 
involved in these pathways may potentially serve as candidate cancer-susceptibility markers 
[181, 183]. In a 2000 review by Berwick and Vineis, investigators cite consistent 
associations (OR range 2.0-10.0) between DNA repair capacity and cancer occurrence 
[183]. Reductions in repair capacity are likely to be associated with functional polymorphic 
sites in DNA repair genes.  
A comprehensive review of all studies examining associations between DNA repair 
polymorphisms and risk of several types of cancers was conducted by Goode and 
colleagues [181]. By April 2002 investigators had identified 30 published studies of adult 
glioma, bladder cancer, breast cancer, esophageal cancer, lung cancer, prostate cancer, 
skin cancer (melanoma and nonmelanoma), squamous cell carcinoma of the head and 
neck, skin cancer, and stomach cancer and the following DNA repair variants: OGG1 and 
XRCC1 (BER genes); DNA excision repair protein (ERCC)1, xeroderma pigmentosum 
(XP)C, XPD, and XPF (NER genes); and BRCA2 and XRCC3 (DSB repair genes) [181]. At 
the time of the Goode 2002 review only XRCC1 and BRCA2 variants had been evaluated in 
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association with breast cancer incidence. A single study of the Arg194Trp polymorphism in 
XRCC3 showed a reduced risk of breast cancer among study participants with Trp (OR=0.7, 
95%CI: 0.4, 1.3 for at least one Trp allele vs. Arg/Arg) [212]. The Asn372His polymorphism 
of BRCA2 was associated with breast cancer risk in several studies. The combined odds of 
breast cancer among women with the His/His genotype was 1.3 (95% CI: 1.1, 1.6) times the 
odds of breast cancer among women with Asn/Asn genotype [181].  
 Since the Goode 2002 review, a number of studies have examined the effects of 
DNA repair polymorphisms in breast cancer incidence. There are mixed results for the 
function of DSB repair genes in the etiology of breast cancer [213], but the vast majority of 
the evidence is supportive of an association [214-216]. Among all DSB polymorphisms only 
one in XRCC3 is consistently associated with breast cancer susceptibility, although its effect 
is likely small [215]. Epidemiologic studies conducted among Caucasian women have not 
supported a role for genetic variations in the BER pathway and breast carcinogenesis [217, 
218]. However, current data suggest that associations may be positive and more stable 
when considering specific ethnic groups including Asian [217, 219] and Indian [220, 221] 
populations. Variants in NER pathway genes have been most readily studied in both 
individual epidemiologic investigations [216, 222-229] and meta analyses [230-232]. The 
literature, overall, is inconsistent which may reflect differences in study populations, low 
statistical power or other methodological issues. 
 There remains a dearth of literature examining polymorphisms in MMR and breast 
cancer outcomes with only five published studies to date [225, 228, 233-235]. Poplawski 
and colleagues examined two common polymorphisms of MSH2: an A  G transition at 127 
position producing an Asn  Ser substitution at codon 127 and a G  A transition at 1032 
position resulting in a Gly  Asp change at codon 322. Both polymorphisms are capable of 
changing the biological properties, structure, and function of the MSH2 protein [233]. Study 
results showed a strong, although imprecise, association between the G/G genotype of the 
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Gly322Asp polymorphism and breast cancer occurrence (OR=8.39; 95% CI: 1.44, 48.8) as 
well as an inverse association with the G/A genotype (OR=0.13; 95% CI: 0.02, 0.83) [233]. 
The associations with Asn127Ser were imprecise and not statistically significant. In a 
hospital-based sample of Korean women Lee and colleagues reported that the risk of breast 
cancer increased in a dose response manner with the number of G alleles in the MLH1 –93 
G>A polymorphism (OR=1.33; 95% CI=0.81-2.19; OR=2.24; 95% CI=1.21-4.17, 
respectively; p for trend = 0.01). This effect was observed only among postmenopausal 
women, and upon correcting for multiple comparisons the associations were no longer 
significant [225]. A 2008 case control study reported a decrease in breast cancer risk in 
carriers of the variant alleles in the IIe219Val polymorphism of MLH1 (OR=0.49 95% 
CI=0.29-0.85) [228]. While several other polymorphisms were examined (MSH3: Arg940Gln, 
Thr1036Ala and MSH6: Gly39Glu) no other statistically significant associations emerged 
among Caucasian women. The most recent study [234], conducted in a hospital setting 
among Portuguese women, estimated the effects of polymorphism in several MMR genes 
(MSH3, MSH4, MSH6, MLH1, MLH3, PMS1 and mutY homologue [MUTYH]). The 
Leu844Pro, polymorphism of MLH3 was found to be associated with breast cancer 
incidence. The OR’s (95% CI’s) for Leu/Leu and Pro/Pro genotypes were 0.65 (0.45-0.95) 
and 0.62 (0.41-0.94), respectively. The most recent study [235] found an inverse association 
between MSH3 rs6151838 and breast cancer (OR=0.73; adjusted p=0.048) as well as an 
inverse association between PMS1 rs5743030 and PR+ breast cancer (OR=0.61; adjusted 
p=0.047). Collectively, these data show that putative at risk alleles in MMR may be 
associated with breast cancer outcomes. However, these studies are plagued with small 
samples and less than optimal design schemes making additional studies warranted.  
1.4.3 Biologic Plausibility of the Mismatch Repair-Breast Cancer Association 
Available evidence indicates that that a considerable fraction of breast tumors show 
instability in sequence motifs of mono- and di-nucleotide repeats [236-240]. This 
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phenonema is known as MSI and has been shown to be closely associated with MMR 
deficiency [181, 241]. These deficiencies occur frequently in hereditary non-polyposis 
colorectal cancers (HNPCC) [242-245] as well as other MSI related cancers including some 
sporadic colorectal tumors, hematological malignancies, endometrial, prostatic, and gastric 
cancers [202, 246-248]. In comparison to HNPCC syndrome the role of MSI and MMR gene 
dysfunction in breast cancer development is less well established.  
MMR gene dysfunction is proposed to occur through two mechanisms: epigenetic 
gene silencing through hypermethylation and genetic mutations in MMR genes [249, 250]. 
These changes may lead to increased mutations of oncogenes, tumor suppressor genes, 
and loss of DNA damage-induced apoptosis, therefore facilitating carcinogenesis [251]. 
While several MMR genes are associated with cancer predisposition, MSH2 and MLH1 
genes are central to all mismatch recognition and alterations in them have been shown to be 
the most common mechanism inducing cancer-related MSI [252-254]. In a study of 32 
sporadic breast tumors Murata and colleagues identified MSI in approximately 47% of 
samples. Greater than 90% of MSI tumors showed reduced protein expression of MSH2 
(N=2) or MLH1 (N=5) and approximately 50% had genetic alterations is both genes [255]. 
While these findings indicate high correlations between MMR dysfunction and MSI in breast 
cancer, not all studies observed this relationship. The rates of MSI in sporadic breast cancer 
have been shown to vary greatly between studies [240, 255, 256]. Chintamani and 
colleagues report a range from 5-30% [202]. This variation is most likely due to differences 
in microsatellie markers used for analysis. It may alternatively indicate that progression 
differs, mechanistically, in primary breast cancer compared to HNPCC [202]. For example, 
the lack of a correlation between MMR loss and MSI in breast cancer may be due to 
involvement of MMR genes that do not induce MSI or potential interactions within population 
subgroups.  
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MMR gene expression also appears to be associated with clinicopathological 
parameters of breast cancer. There is accumulating evidence that reduced expression of 
MSH2 and MLH1 are related to tumor progression and invasion [202, 255, 257] although 
some studies report null effects  [257, 258]. Although modest, the evidence to date indicates 
that breast cancer is associated with MSI, MSI is primarily caused by variations in MMR 
genes, and polymorphisms in MMR genes are potentially important modulators of breast 
cancer progression.  
1.4.4 DNA Repair and Physical Activity  
While few meaningful effects of DNA repair variants on breast cancer outcomes have 
been reported in epidemiologic studies it is plausible that these polymorphisms may more 
profoundly influence carcinogenesis by modifying the effect of environmental exposures on 
cancer risk [183, 184]. The effects of smoking [228, 229, 259-262]; PAH-DNA adducts [222]; 
radiation exposure [263, 264]; and dietary factors [259, 260, 265, 266] have each been 
shown to be modified by SNPs in DNA repair genes. I identified no epidemiologic studies 
which examined associations between DNA repair variants and breast cancer with respect 
to physical activity.  
Physical activity has been shown, repeatedly, to increase the formation of reactive 
oxygen and nitrogen species [119, 163, 164], which may influence carcinogenesis. Regular 
exercise training may also result in improved damage repair systems [170, 171, 267, 268]. 
As early as 1999, Radak and colleagues showed that exercise decreased the degree of 
oxidative damage in lipids, proteins, and DNA (namely 8-oxo-dG) in the skeletal muscle of 
trained rats [269]. The investigators hypothesized that the observed reduction in oxidative 
damage could be attributed to the increased regulation of repair systems [267]. A 2002 
follow up investigation reported similar findings [270]. In addition to observing a reduction in 
the number of skeletal 8-oxo-dG lesions in exercised rodents, investigators confirmed 
increases in 8-oxo-dG repair which was measured by the nicking  of a 32P-labeled damaged 
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oligonucleotide. This study also found increased chymotrypsin-like activity of the 
proteasome complex, a repair enzyme important in the degradation of proteins modified by 
oxidative stress [270].  
Much like the animal literature, clinical studies show significantly reduced levels of 
basal 8-oxo-dG among physically active study participants compared to individuals 
classified as sedentary [268](Sato 2003). Sato and colleagues [268] reported significant 
reductions in the 8-oxo-dG levels of sedentary participants following 30 minutes of mild 
exercise. There was no change among active men. These data suggest that physical activity 
may reduce interim levels of 8-oxo-dG and that over time, sustained involvement in physical 
activity could result in systemic reductions of 8-oxo-dG. In addition to reductions of 8-oxo-
dG, data from clinical studies of trained cyclists [271] and marathon runners [272] showed 
that DNA excision repair enzymes NESP and RAD23A [271], as well as OGG1 [272] are up-
regulated with exercise training.  
The extent of physical activity-induced DNA repair may vary based on exposure 
frequency, endogenous activation, detoxification, antioxidant capacity or other defense 
mechanisms. Although reductions in oxidative induced DNA damage could be an artifact of 
any of the above pathways, the animal and clinical evidence to date suggests that exercise 
could result in up-regulation of DNA repair enzymes and may be an important part of the 
exercise induced adaptation process.  
1.4.5 Conclusions  
While it has been well established that select DNA repair mechanisms are relevant to 
breast cancer incidence, few studies have examined the association with MMR variants. 
Previously conducted breast cancer studies have reported significant associations with 
minor alleles in MMR SNPs, which may vary by menopausal status. But results are 
inconsistent, are conducted among different international populations with varying genetic 
profiles, and are based on small, select samples. Additional investigations are of interest as 
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MMR greatly contributes to the overall fidelity of replication and genomic integrity. Moreover, 
there is an increasing amount of evidence suggesting that both MMR dysfunction and MSI 
are correlated with clinical markers of breast cancer.   
Gene-environment interactions have been frequently examined in the breast cancer 
literature. Investigators have published several positive results for an interaction between 
DNA repair variants and cigarette smoking, radiation exposure, PAH-DNA adducts, dietary 
antioxidants, and fruit and vegetable consumption. While it has been recognized that 
physical activity may exert its effects via DNA repair, no study had considered a possible 
interaction with physical activity levels. Animal and clinical studies showed that DNA repair 
enzymes are up regulated with physical activity which is likely to result in diminished DNA 
damage. An epidemiologic model was tested by assessing the joint effects of low physical 
activity and reduced DNA repair capacity on breast cancer incidence.  
1.5 Summary and Specific Aims 
Breast cancer is the leading cause of global cancer incidence and mortality among 
women. Among US women it is the primary cause of, non-melanoma, cancer-related illness 
and is second to lung cancer in mortality. With almost half of women engaging in some type 
of physical activity, it is conceivably one of the most prevalent environmental exposures 
associated with breast cancer risk. Physical activity has been suggested to reduce the risk 
of breast cancer by at least 25%; however the inverse association seen with physical activity 
could be due to a healthy person effect and serve as a proxy for other healthy behaviors that 
are associated with breast cancer risk (e.g. low BMI and healthy diet). Identifying women 
who are particularly susceptible to the beneficial effects of physical activity based on genetic 
characteristics could aid in validating the biologic plausibility of this association. Moreover, it 
could facilitate the ability to elucidate the mechanism through which physical activity exerts 
its effects, and ultimately allow us to better tailor our public health messages.  
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Physical activity may intervene along multiple paths in the stages of carcinogenesis. 
It is likely to operate in obesity-related pathways (e.g. insulin resistance and hormonal 
pathways) that are related to both promotion and progression and as well as through 
pathways like oxidative stress and DNA repair that are more closely linked to initiation. 
There is a dearth of literature on how physical activity is modified by genetic variability in 
these latter pathways. Physical activity, a known inducer of ROS, may influence breast 
cancer risk by up-regulating antioxidant enzymes and overall antioxidant capacity. It could 
also impact breast carcinogenesis by improving damage-repair systems, particularly those 
that operate on ROS induced single-strand breaks including (e.g. BER, NER and MMR). 
While these mechanisms are not mutually exclusive, they may work to diminish DNA 
damage lowering the likelihood of cancer initiating events. Polymorphic sites in oxidative 
stress and DNA repair pathways were therefore strong candidates for cancer susceptibility 
genes and may modify the effects of exercise on breast cancer.  
This dissertation research evaluated associations between novel polymorphisms in 
oxidative stress (CAT), and DNA repair (MLH1, MSH2, and MSH3) and breast cancer. 
Importantly, this research was the first to assess interactions between RPA, oxidative stress 
and DNA repair polymorphisms with respect to breast cancer risk. In addition to the SNPs 
evaluated for main effects, selected oxidative stress and DNA repair polymorphisms of 
interest for gene-physical activity interactions were those previously genotyped in the 
LIBCSP: CAT (-262C>T), COMT (Val158Met and rs737865), GPX (Pro198Leu), GSTA1 
(rs3957396), GSTM1 (gene deletion), GSTP1 (Ile105Val), GSTT1 (gene deletion), MnSOD 
(Val16Ala), MPO (463G>A), ERCC1 (C8092A), MGMT (Leu84Phe, Ile143Val, Lys178Arg), 
OGG1 (Ser326Cys), XPA (4G>A), XPC (Ala499Val, Lys939Gln), XPD (Asp312Asn, 
Lys751Gln), XPF (Arg415Gln), XPG (Asp1104His), and XRCC1 (Arg194Trp, Gln399Arg). 
The study aims were defined by the biologic pathway under investigation: 
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AIM 1. Oxidative Stress 
AIM 1A: to determine the main effect of select SNPs in CAT on breast cancer risk. 
AIM 1B: to explore the potential interactions between SNPs in CAT and breast 
cancer risk (SNP-SNP interactions).  
AIM 1C: to evaluate interactions between polymorphisms in oxidative stress genes 
(CAT, COMT, GPX, GSTA1, GSTM1, GSTP1, GSTT1, MnSOD and MPO) and self-
reported recreational physical activity on breast cancer risk (gene-environment 
interactions) 
AIM 2. DNA Repair 
AIM 2A: to determine the main effect of select SNPs in three candidate genes 
(MLH1, MSH2, and MSH3) of the mismatch repair (MMR) pathway on breast cancer 
risk. 
AIM 2B: to explore potential interactions between genes in the MMR pathway 
(MLH1, MSH2, and MSH3) and breast cancer risk (gene-gene interactions).  
AIM 2C: to evaluate interactions between polymorphisms in DNA repair genes 
(ERCC1, MGMT, MLH1, MSH2, MSH3, OGG1, XPA, XPC, XPD, XPF, XPG and 
XRCC1) and self-reported recreational physical activity on breast cancer risk (gene-
environment interactions) 
 
These aims were accomplished through the analysis of extant data from the LIBCSP; 
a population-based case-control study developed to investigate the association between 
environmental factors and breast cancer risk in Long Island, NY. This dissertation employed 
pre-existing physical activity and biomarker data, as well as newly genotyped SNP data to 
examine the aforementioned aims.  
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Chapter II: Materials and Methods 
2.1 Study Rationale, Research Aims and Hypotheses 
Breast cancer is the most common malignancy and the second-leading cause of 
cancer-related death among women in the United States. Physical activity is known to 
reduce the risk of breast cancer, particularly among post-menopausal women, and may be a 
modifiable protective factor important for intervention. The mechanisms driving the observed 
inverse association remain unresolved. While much attention has been given to obesity-
related pathways in the attempt to understand the molecular effects of physical activity on 
breast cancer risk, strong evidence is lacking. It is well documented that exercise may work 
through obesity driven pathways but independent and review studies alike suggest that 
these mechanisms may not fully account for observed association with breast cancer risk. 
The numerous physiologic consequences of physical activity necessitate a more complete 
understanding of the mechanisms driving the inverse association. Given exercise is a known 
inducer of ROS and lipid peroxidation, polymorphisms in oxidative stress or DNA repair may 
modify the exercise-breast association contributing to disease risk.  
To my knowledge this dissertation was the first investigation to explore the potential 
modifying effects of DNA repair and oxidative stress variants on physical activity. While 
these pathways have been well examined in their association with breast cancer risk, and 
modifying effects assessed among a number of other environmental modulators, their 
impact on physical activity had not previously been evaluated in the epidemiologic literature.  
The aims of this ancillary study were therefore two-fold. I first estimated effects of several 
novel SNPs in oxidative stress and DNA repair pathways using the resources of a large 
population-based case-control study: the Long Island Breast Cancer Study Project. This 
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research could increase understanding of breast cancer etiology with respect to oxidative 
stress and DNA repair pathways. I subsequently examined whether the effect of physical 
activity on breast cancer risk was modified by individual variability in the genetic variants of 
these pathways. Understanding the association between physical activity and breast cancer 
has important public health implications due to the high incidence of breast cancer and the 
relative ease of access to physical activity in the US general population. Interactions 
between physical activity, oxidative stress and DNA repair polymorphisms may help 
elucidate underlying mechanisms linking exercise to breast cancer.  Further, it could aid in 
identifying subgroups of women who are particularly susceptible to the beneficial effects of 
physical activity, based on genetic characteristics, both strengthening the biological 
plausibility of this relationship and informing public health recommendations for lowering 
breast cancer risk.  
The specific aims of this project were outlined in section 1.5 and are as follows:  
AIM 1A: to determine the main effect of select SNPs in CAT on breast cancer risk 
Hypothesis: genotypes related to reduce antioxidant capacity will be positively associated 
with breast cancer 
AIM 1B: to explore the potential interactions between SNPs in CAT and breast cancer risk  
Hypothesis: joint effects of risk genotypes will be greater than multiplicative. 
AIM 1C: to evaluate interactions between polymorphisms in oxidative stress genes and self-
reported recreational physical activity on breast cancer  
Hypothesis: genotypes related to reduce antioxidant capacity will antagonistically reverse 
the beneficial effects of high physical activity.  
 
AIM 2A: to determine the main effect of select SNPs in three candidate genes (MLH1, 
MSH2, and MSH3) of the mismatch repair (MMR) pathway on breast cancer risk 
 
 44    
 
44
 
Hypothesis: genotypes related to reduce DNA repair capacity will be positively associated 
with breast cancer 
AIM 2B: to explore potential interactions between genes in the MMR pathway (MLH1, 
MSH2, and MSH3) and breast cancer risk  
Hypothesis: joint effects among risk genotypes will be greater than multiplicative  
AIM 2C: to evaluate interactions between polymorphisms in DNA repair genes and self-
reported recreational physical activity on breast cancer risk  
Hypothesis: genotypes related to related to reduced DNA repair capacity will act 
synergistically with low levels of physical activity to increase the risk of breast cancer greater 
than would be expected by their individual effects  
 
These aims were accomplished through the analysis of extant data from the LIBCSP; 
a large a population-based case-control study rich in measures of lifetime physical activity 
and biomarker data [18]. This dissertation employed the pre-existing physical activity 
measures well as newly genotyped MMR and CAT data obtained from the banked DNA of 
approximately 1,053 breast cancer cases and 1,102 controls. The following sections detail 
the LIBCSP study population and parent study design, provides a description of the 
laboratory assays, covariates, and statistical analyses for this analysis, and reviews the 
perceived advantages and limitations of this research.  
 
2.2 Long Island Breast Cancer Study Project 
2.2.1 Eligibility  
The LIBCSP is a federally-funded population based study conducted among adult 
English-speaking female residents of Nassau and Suffolk counties, Long Island, New York. 
The LIBCSP case-control study was federally mandated and generally supported by Long 
Island activists, as well as New York State government. Eligible cases for the study were 
 
 45    
 
45
 
English-speaking women of all ages and races newly diagnosed with first primary in situ or 
invasive breast cancer between August 1, 1996, and July 31, 1997, and were residents of 
either Nassau or Suffolk counties at the time of diagnosis. Eligible controls for the study 
were English-speaking female residents of Nassau and Suffolk counties at the time of 
identification, without a personal history of breast cancer. Controls were frequency matched 
to the expected age distribution of case subjects by 5-year age group.  
2.2.2 Case Identification 
As a part of the data collection procedures for the parent study, newly diagnosed 
cases were identified through a ‘super-rapid’ identification network with a goal to ascertain 
potentially eligible cases prior to commencing chemotherapy. This network consisted of 28 
hospitals on Long Island, as well as three large tertiary care hospitals in New York City. 
Pathology departments of most hospitals were contacted on a weekly basis (two to three 
times per week), although institutions with a large proportion of diagnosed cases were 
contacted daily. Study personnel contacted physicians of potentially eligible case women to 
confirm diagnosis, date of diagnosis, and to seek permission to contact the patient for 
potential participation in the study. Prior to case identification investigators contacted over 
400 primary care physicians, internists, surgeons, and oncologists who could potentially be 
involved in the diagnosis or treatment of Long Island breast cancer cases. Physicians were 
mailed information regarding the study and asked for a documented approval and 
cooperation. No physician indicated refusal to participate. A total of 2,271 women were 
initially identified as potential eligible cases. Approximately 73% (2,030) were determined to 
be eligible according to the study’s criteria and physician consent was obtained for 90.5% 
(1,837). Physician refusal was most often due to poor health status because of age-related 
co-morbidity. For cases, the average length of time between date of diagnosis and interview 
was 96 days.  
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2.2.3 Control Identification  
Potentially eligible control women under the age of 65 were identified by Waksberg’s 
method of random digit dialing (RDD) [273]. RDD selection began July 1, 1996, and 
continued in eight waves over the subsequent twelve months. For women 65 and older 
investigators used the Health Care Finance Administration (HCFA) rosters for control 
recruitment. HCFA selection occurred twice during the 12-month ascertainment period and 
coincided with the 12 months of case identification. The response rate to the RDD telephone 
screener in Long Island was 77.9%. However, when applied to participants under age 65 the 
response rate is approximately 57.9% of all control respondents. The average length of time 
between control identification and interview date was 167 days.  
2.2.4 Subject Recruitment and Participation 
Eligible case and control women were first contacted by mail which included a letter 
detailing the study as well as a descriptive brochure. The letter was followed up with contact 
from a trained recruiter who telephoned the subject to answer questions and arrange for a 
study interview. The main questionnaire was completed by 1,508 (82.1%) of eligible case 
women (n=235 with in situ breast cancer) and 1,556 (62.7%) of eligible control women 
(Figure A.5). Motives for non-response to the interview among cases and controls included 
subject refusal (n = 218 (12.4%) and 573 (21.6%), respectively); too ill, cognitively impaired, 
or deceased (n = 76 (4.1%) and n = 193 (7.8%)), and non-locatable, moved out of area, or 
other (n = 26 (1.4%) and n = 195 (7.9%)). Study participants ranged from age 24 to 98 
years. Response to interview varied by age with 88.9% of cases and 76.1% of controls 
under age 65 years participating versus 71.6% of cases and 43.3% and controls over 65 
years of age. 
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2.2.5 Study Interview 
Prior to conducting any component of the interview, written signed informed consent 
was obtained from participants. The interview consisted of (1) the interviewer-administered 
main questionnaire (2) a self-administered food frequency questionnaire and (3) collection of 
a biologic sample (blood) and completion of a specimen check-list. All interviews were 
conducted by a certified phlebotomist or nurse who underwent a week long, standardized, 
training course in interview administration. Interviews took place in the participant’s home.   
Main Questionnaire. Data were collected through an interviewer-administered 
questionnaire which took an average of 101 minutes to complete. Respondents were asked 
about their demographic characteristics, residential history in Nassau and Suffolk counties, 
occupational history, medical history, family history of cancer, menstrual history, use of 
exogenous hormones, reproductive history, body size changes by decade of life, active and 
passive cigarette smoking, and use of alcohol by decade of life.  
For quality control, a random 20% of all respondents were re-contacted via phone to 
insure that the interview occurred, verify the length of the interview, and to briefly re-
interview the participants. Completed questionnaires were shipped to Westat, Inc., 
Bethesda, MD, for data verification, coding, and data entry, as well as initial range and logic 
checks. 
Assessment of Recreational Physical Activity. As part of the main LIBCSP 
questionnaire administration, interviewers asked subjects about their participation in 
recreational physical activity. The recreational physical activity instrument used for the 
parent study was a modification of that developed by Bernstein and colleagues [274]. A 
recreational physical activity (RPA) screener was used to query participant’s regular 
involvement in physical activity or exercise during any period throughout the life-course. 
Participants were asked: “Have you ever participated in any physical activities or exercises 
on a regular basis – that is, for at least 1 hour per week for 3 months or more in any year?” 
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These activities included participation as a member of a sports team; participation in 
individual sports, such as swimming, gymnastics, running, jogging, or walking for exercise; 
gym workouts and trainings; as well as participation in dance or exercise classes.  
Biologic Sample Collection. After completing an additional informed consent form, 
participants were asked to donate blood sample. Additionally, women were asked to 
complete a self-administered specimen checklist which queried participants about foods, 
drugs, and behaviors they may have engaged in the few days prior to the sample donation. 
For 73.1% (n=1,102) of case and 73.3% (n=1,141) of control respondents who had 
completed the main interview, a nonfasting 40 mL blood sample was obtained (Table A.3). 
The blood samples were collected in 5 EDTA-treated lavender-top tubes and shipped at 
room temperature, overnight, to Dr. Regina Santella's laboratory at Columbia University for 
processing. For most subjects, processing and aliquoting of the biologic samples occurred 
within 24 h of collection. Aliquots of plasma, red blood cells, mononuclear cells, and 
granulocytes from 40ml of blood were stored at −80 degrees centigrade with bar-code 
labels, which were preprinted with the subjects’ randomly selected study identification 
number. Based on previous analysis of DNA in LIBCSP, I anticipated approximately 1053 
cases and 1102 controls with blood available for genotyping [224]. The final sample size 
was primarily dependent on sufficient DNA to complete the assays and the number of failed 
samples within each SNP.  Donation of biologic samples varied with age, with a lower 
proportion of older control women donating blood. However, case-control status was not a 
predictor of blood donation among interview respondents.   
2.2.6 Medical Record Retrieval and Abstraction 
Cases were asked to sign medical record release forms to assess clinical 
characteristics of the primary breast cancer diagnosis (e.g., stage of disease [in situ vs. 
invasive], hormone receptor status). Signed medical record release forms were obtained for 
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1,473 case respondents. Records were successfully located and abstracted for 1,402 
participants (Table A.3). 
2.2.7 Population Characteristics 
Age at reference was approximately normally distributed across the study population 
with the greatest percentage of women falling within the 45-54 age range for both cases and 
controls. The majority of the women were white: 93.8% and 91.8% of cases and controls, 
respectively. The sample population was well educated with roughly 87% of all cases and 
90% of all controls completing high school. In both groups greater than 95% of the women 
were currently or previously married and approximately 65% of cases and 68% of controls 
had an income greater than $35,000 per year.  
Many well established risk factors for breast cancer were confirmed to affect risk 
among women of all ages on Long Island [18]. These include age adjusted parity (OR=0.63 
for 4+ children vs. none, 95%CI=0.48, 0.82), breastfeeding (OR=0.70 for 14 months vs. 
none, 95% CI=0.53, 0.89), age at first birth (OR=1.36 for 28+years vs. <22 years, 95% 
CI=1.10, 1.69), and family history of breast cancer in mother or sister (OR=1.66 vs. none, 
95% CI=1.36, 2.02).  
2.2.8 Conclusions 
 LIBCSP is a large population based case-control study. Unique to the LIBCSP data 
is the wide range of ages (20-98 years) for both breast cancer cases and controls. Overall, 
the study had good response rates for both groups and was able to obtain DNA for most of 
its participants facilitating laboratory assays. Other population-based case-control studies 
rich in biomarker data could be used for the analysis but none have reliable measures of 
lifetime physical activity in relation to breast cancer risk. Moreover, the investigators of the 
LIBCSP obtained a wealth of additional questionnaire data beyond the initial scope of the 
parent study, enhancing the ability to assess and control for potential modifiers and 
confounders.  
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2.3 Genotyping 
Biomarker studies have often been proposed to assess the role of physical activity in 
the etiology of cancer [59, 74, 83]. To better understand the physical activity-breast cancer 
association one would ideally want to: (1) measure some biomarker of physical activity 
exposure in association with breast cancer outcomes; (2) use biomarkers of altered function 
to estimate the extent to which normal cellular processes have been impacted by physical 
activity; and (3) determine what biomarkers of susceptibility modify the causal pathway from 
exposure to disease [275]. A general lack of biomarkers of exposure impedes the ability to 
establish a true causal association between physical activity and chronic disease outcomes 
[74]. Studies using biomarkers of altered function, primarily conducted in experimental and 
clinical settings, have shown that correlates of DNA repair are up-regulated with exercise. 
Similarly, some antioxidant enzymes are increased with regular physical activity. These 
studies are however, infeasible in large population-based designs typical of many modern 
epidemiologic studies. At best biomarkers of susceptibility can be employed in molecular 
epidemiology studies of physical activity to better comprehend the “black box” from 
exposure to disease [275]. Correctly specifying what biomarkers influence or modify the 
effect of physical activity on breast cancer outcomes could aid in strengthening the 
argument for a causal association.  
The following sections detail the genetic approach considered for analyses, including 
strengths and limitations of each approach, the methods used for selecting SNPs, as well as 
the genotyping procedures employed in the LIBCSP.  
 
2.3.1 Genetic Approach  
To study associations between inter-individual variation of MMR, oxidative stress 
variants and breast cancer, I examined polymorphisms in three MMR genes (MLH1, MSH2, 
MSH3) and one oxidative stress gene (CAT) using a candidate gene approach. There were 
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two approaches considered for these analyses: (1) the candidate gene approach which 
directly estimate the effects of genetic variants hypothesized to play a role in a disease and 
(2) genome-wide scanning which scans markers across the genomes of thousands of 
individuals to identify genetic variation associated with a particular disease. Each approach 
has specific advantages and disadvantages. 
Genome Wide Association Studies. Genome-wide scanning has been successful, 
enabling the discovery of new associations that have been replicated in multiple studies. 
Interestingly, many of the loci identified to date were not listed as candidate genes for their 
respective disease [276]. This approach is therefore useful for identifying candidate genes 
that were previously unknown or that occur in unexplored regions of DNA. Genome-wide 
scanning methods are based primarily on statistical associations between a single SNP and 
a phenotypic group, ignoring prior knowledge about disease pathobiology [277, 278].  The 
disease-associated SNPs found in genome-wide association studies (GWAS) are therefore 
unlikely to be the functional variants, instead serving as proxies for the true causal variant 
contributing to disease. The modeling framework employed in most GWAS tests only one 
SNP at a time in association with the phenotype under investigation. It thus requires novel 
bostatistical methods to control for multiple comparisons and new analytic approaches that 
account for heterogeneity across populations, gene-gene, and gene-environment 
interactions [277].  
Candidate Gene Approach. It is commonly hypothesized that a large component of 
the genetic variation observed in disease phenotype is due to functional mutations in 
putative genes. These putative genes are also known as candidate genes and may either 
directly or indirectly regulate the developmental processes of investigated traits [278]. The 
candidate gene approach has been commonly applied in gene-disease research primarily 
by evaluating the effects of the causative genetic variants, or those in linkage disequilibrium 
(LD) with the functional variants, using association studies. In candidate-gene studies genes 
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are selected a priori based on their etiological role in disease and are conducted in 
population-based samples [279]. This approach to uncovering the genetic architecture of 
complex traits capitalizes on both the biological understanding of the phenotype, as well as 
the increased statistical efficiency of association analysis [279]. 
In spite of this, candidate-gene studies have a number of limitations. While 
association studies are well powered to detect genes of small effect, they often result in 
spurious positive associations that fail to be replicated when followed up in subsequent 
analyses [278]. There are, however, many reasons for the lack of reproducibility seen with 
some candidate genes studies. Tabor and colleagues (2002) suggest that discrepant 
findings may be due to variations in study design, heterogeneity across populations, and 
phenotype definition. The candidate gene approach is also criticized because of its highly 
subjective method of choosing specific candidates from a number of potential causative 
genes. These selections are based heavily on existing knowledge of the known or presumed 
biology of the phenotype under investigation which is most often finite or unknown creating, 
in some applications, an information bottleneck [278].  
Both GWAS and the candidate gene approach have strengths and limitations. Given 
the aim of this dissertation was to explore interactions between variants, physical activity 
and breast cancer risk, the optimal approach for this work was a candidate gene model.  A 
candidate-gene study is better able to assess gene-environment interactions and is rooted 
in biology of both the disease phenotype and effect measure modifier. It was therefore a 
useful first step in exploring biological mechanisms between genetic determinants and 
complex disease, a primary goal of this dissertation.  
2.3.2 SNP Selection and Tests of Hardy Weinberg Equilibrium 
In an effort to maximize the likelihood of finding a biologically important association 
and reduce the chance of detecting false positives, I prioritized the selection of both genes 
and variants in oxidative stress and DNA repair pathways. The MLH1, MSH2, MSH3 and 
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CAT genes were chosen for this dissertation because they play a critical role in the DNA 
mismatch repair process and against lipid peroxidation, respectively. While I did not attempt 
to capture all genetic variability within these genes, targeted SNP selection was informed by 
functional data, association studies in the breast cancer literature, and patterns of LD within 
each gene. The additional SNPs selected for the gene*physical activity interaction were 
based primarily on probable functional application as no prior studies had assessed 
interactions with physical activity. The genes and respective SNPs for gene-environment 
interactions are detailed in Table A.4.   
SNP Function. Identifying functional SNPs is important because these SNPs are 
likely to play an essential role in gene expression and therefore cell phenotype [280]. 
Functional SNPs may additionally help to define a biological mechanism through which 
genotype is causally associated with disease. A single base pair change affecting polyphen 
prediction, transcription factor binding prediction, miRNA binding, 3D conformation, or 
splicing regulation were defined as potentially functional SNPs. Similarly, base pair changes 
that were nonsynonymous or resulted in a stop codon were also classified as potentially 
functional. These polymorphisms were identified through the breast cancer literature and the 
SNPinfo web server (SNP function prediction).  
SNPs Identified in the Breast Cancer Literature. A total of 6 SNPs in the genes of 
interest had been evaluated in the breast cancer literature. Four of these SNPs (rs1001179, 
rs1799977, rs1800734, and rs4987188) were associated with breast cancer risk in at least 
one study. The CAT SNP (rs1001179) was previously genotyped as part of the LIBCSP. 
Both rs1799977 and rs1800734 are located in MLH1. The former SNP was selected for 
genotyping because: (1) it is known to have functional properties and (2) the latter has only 
been associated in Korean populations. While rs4987188 is known to have functional 
properties, its MAF is 3% and was therefore excluded from this analysis.  
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Tag SNPs. Tag SNPs are polymorphisms that are highly correlated with other SNPs 
in a gene [281] which, upon genotyping, can be used to infer characteristics of un-typed 
SNPs. This method is based on the degree of LD between the tag and un-typed SNPs 
which is specified a priori. A tagSNP approach maximizes the ability to capture genetic 
variation across a genomic region while reducing costs. Two programs were used to identify 
tagSNPs: the Tagger SNP selection program in Haploview version 4.2 [282, 283] and the 
SNPinfo web server from the National Institute of Environmental Health Service [284]. For 
both programs tagSNPs were selected using data from phase II of the International HapMap 
Project database [285]. Given the racial homogeneity of the LIBCSP population with DNA 
available for the proposed analyses (93.4% White and 6.6% Non-White [224]), the CEU 
population (30 Utah trios with ancestry from northern and western Europe) was used as the 
reference panel for SNP selection.  
Both programs use pairwise tagging methods to select a maximally informative set of 
common SNPs incorporating LD information based on the r2 statistic [286]. The r2 statistic is 
used to assess the degree of correlation between SNPs. It is a measure of how well the 
identity of one allele at a polymorphic locus predicts the identity of the allele at another 
polymorphic locus. An r2=1.0 indicates that the examined loci are in “perfect LD”. Other 
measures of linkage disequilibrium (i.e. D’) are often used, but fail to obligate identical minor 
allele frequencies (MAF) among SNPs when D’=1 [286]. The tagging algorithm begins by 
calculating the r2 between all pairs of SNPs in the gene region (including 1000 base pairs up 
and down stream) above a pre-specified MAF threshold. The single SNP that is correlated 
with the greatest number of other SNPs at a specified r2 is identified and grouped with its 
correlated SNPs into a bin. The best tag SNP in each bin is then selected based on all 
pairwise r2. This process is repeated using the remaining un-binned SNPs until only SNPs 
not in high LD with other SNPs remain. These are placed into their own singleton bin. This 
combined group of tag SNPs represents the minimum set of informative SNPs for the gene. 
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For the present study an r2 of 0.80 and MAF of 0.05 or greater were imposed on SNP 
selection procedures. The tagging procedures described above were used to select SNPs 
for CAT, MLH1, MSH2, and MSH3. Due to limited resources TagSNP selection was 
prioritized based on a combination of factors including: location within the gene, bin size, 
and MAF. A total of 9 SNPs were identified for genotyping in the four genes under study 
(Table A.5). Figures A.6-A.9 show the LD plots for each gene in the CEU population. 
Haplotypes. While the tagSNP approach is useful for examining the independent 
effect of common genetic variants on breast cancer risk, it fails to account for contributions 
among rare variants as well as the physical location of a potential causal allele relative to 
another causal allele. A broad multilocus haplotype approach examines variation across the 
gene by identifying a set of closely linked genetic markers present on one chromosome 
which tend to be inherited together [287]. Haplotype analyses may have greater power to 
detect susceptibility alleles compared to multiple single SNP analyses when the true causal 
allele is unknown or when disease is influenced by multiple causal alleles occurring in cis 
[288-291]. Assessment of haplotypes may be obligatory when two or more SNPs are in high 
LD (r2 ≥ 0.7) with one another. The SNP selection approach used in this project was 
designed to select the minimally sufficient number of tagSNPs to characterize each gene in 
the CEU HapMap population using an a priori r2 value of 0.8. Using plink v1.06, I calculated 
pairwise LD between all genotyped SNPs and found none to be in high LD (Table A.6). The 
most highly correlated SNPs (MSH2: rs3732182 and rs4583514) had an r2 value of 0.634. 
Hardy-Weinberg Equilibrium. Tests of Hardy-Weinberg equilibrium (HWE) were 
conducted for candidate gene SNPs to ensure assumptions of independent inheritance were 
upheld in the LIBCSP. Departures from HWE were assessed among Caucasian controls, as 
this demographic group best represented the source population [292]. Deviations from HWE 
may indicate genotyping error, selection bias, population stratification, new mutations, or a 
violation of the HWE population assumptions in controls, while among cases it may denote 
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an association between the putative at risk allele and disease [293]. For a biallelic locus in a 
randomly mating population, where the frequency of alleles are represented by ‘p’ (major 
allele) and ‘q’ (minor allele), there is a mathematical relationship between the frequency of 
alleles at a genetic locus and the genotypes resulting from those alleles: p2 + 2pq + q2 = 1 
[292]. This equation was used to determine the expected genotypic frequencies under the 
conditions of HWE and subsequently compared to the observed frequencies using a one 
degree of freedom Pearson’s chi-square test. All SNPs for MMR related genes were in HWE 
(Table A.7). Two CAT SNPs (rs4756146 and rs2284365) were observed to deviate 
significantly from HWE (Table A.8), although the respective MAFs were comparable to the 
CEU HapMap population.  
2.3.3 Genotyping Procedures and Quality Control  
LIBCSP genotyping was conducted by Dr. Regina Santella’s laboratory at Columbia 
University, New York, NY. All DNA samples were available on 96 well master plates. 
Controls for genotype at each locus and two no-DNA controls were included on each plate. 
Plates have a 10% duplication rate with laboratory personnel blinded to both duplication and 
case control status. Genotyping was performed using Taqman (Applied Biosystems, Foster 
City, CA) assays. Briefly, TaqMan probes are hydrolysis probes designed to anneal within a 
DNA region amplified by a specific set of primers. They consist of a fluorophore and a 
quencher covalently attached to the 5’ and 3’-end of the oligonucleotide, respectively. As the 
Taq polymerase extends the primer and synthesizes the lagging strand, the 5' to 3' nuclease 
activity of Taq polymerase degrades the dual-labeled probe that has annealed to the 
template. This releases the fluorophore, thereby relieving the quenching effect and allowing 
for the transmission of fluorescence signals from the flurophore. The resulting fluorescence 
signal allows one to quantify the amount of polymerase chain reaction (PCR) product 
formed during PCR [294]. The fluorescence profiles are subsequently quantified using 
Sequence Detection Software (Applied Biosystems). The rs numbers for the SNPs of 
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interest were given to Applied Biosystems for the preparation of the specific kits. Taqman, 
samples were run on an ABI 7900 Real Time PCR system.  
2.4 Variable Construction and Covariates 
The following section describes the selection and coding of covariates including the 
primary exposure, effect modifiers, and all potential confounders. SNP selection and 
genotyping for MLH1, MSH2, MSH3, and CAT were detailed in section 2.3. Similarly, section 
2.2 described the data collection process for the RPA measurement. Confounders were 
selected a priori using directed acyclic graphs (DAG) [295] on the basis of subject matter 
knowledge. Final selection of confounders was based on modeling strategies discussed in 
section 2.5. 
2.4.1 Exposure Variable Construction  
 Genotype information comes from two sources: the parent study’s previously 
assayed DNA samples and new laboratory analyses using isolated DNA to genotype CAT, 
MLH1, MSH2, and MSH3 SNPs. The details of ascertainment and analyses for these 
exposures have been described previously (Section 2.2). There are several model forms 
that may potentially be used to estimate genotype effects. The allelic identity at a particular 
locus on both copies of a chromosome determines the genotype. Since the SNPs selected 
for this analysis are biallelic, there are only three possible genotypes for each SNP: (1) 
homozygous for the common allele; (2) heterozygous; or (3) homozygous for the minor 
allele. A general model assumes no relationship between the three genotypes. In the 
dominant genetic model a single variant allele is sufficient to affect disease risk; the 
heterozygotes and minor allele homozygotes are therefore collectively considered the 
‘exposed’ group. In a recessive genetic model two variant alleles are needed to affect 
disease risk; the heterozygotes and major allele homozygotes are together considered the 
‘referent’ group. Under the additive genetic model, the effects of genotype are linear; the 
change in disease risk is thus proportional to the number of variant alleles in the genotype 
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[296]. All SNP associations were be initially estimated using the general model. The general 
model is known to have less power than the true, correctly specified mode of inheritance 
because it requires two degrees of freedom compared to the one degree of freedom 
required for other genetic models [297]. When the true model form is unknown however, the 
general model is more powerful than choosing any incorrectly specified model form. For this 
dissertation the mode of inheritance for most SNPs was not known; the general model was 
therefore most appropriate to estimate genotype effects. However, for most loci, a more 
flexible modeling approach was necessary.  
 For each analysis the SNPs were modeled categorically using indicator variables. 
Two indicator variables were created, one for the heterozygote genotype and another for the 
minor allele homozygote genotype. Estimated ORs contrasted the effect of heterozygote vs. 
major allele homozygote (referent group) and minor allele homozygote vs. major allele 
homozygote. In most instances data were too sparse among the minor allele homozygote 
genotype to specify the mode of inheritance (i.e. dominant, recessive, or additive). I was 
therefore forced to use a dominant model, particularly for assessing interactions with 
physical activity.  
2.4.2 Effect Modifier Variable Construction 
Biologic mechanisms that lead to the development of breast cancer are likely to have 
multiple interacting component causes. It was therefore important that, in addition to 
estimating main effects of candidate genes, I evaluated statistical interaction with non-
genetic breast cancer risk factors. In doing this I was able to estimate the extent to which 
genotype associations may influence these risk factors. One of the central aspects of this 
project was to uncover mechanisms through which RPA exerts its protective effects on 
breast cancer outcomes. Using a candidate gene approach based on biologic plausibility I 
selected one oxidative stress gene (CAT) and three MMR genes (MLH1, MSH2 and MSH3) 
to investigate. These genes were evaluated in addition to functional oxidative stress and 
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DNA repair genes already ascertained in the LIBCSP. Section 2.2.5 provided an overview of 
the physical activity data collection. Respondents were asked about all recreational physical 
activities in which they had engaged for at least one hour per week and at least three 
months or more in any year over their entire lifetime. Those participants who replied never 
having participated in RPA were classified as having no RPA. For those women who 
answered yes, a detailed lifetime history of physical activity was created using recall cues 
such as life events calendars and residential history. For each participant the investigators 
obtained the name of the activity, the ages the activity was started and stopped (if 
applicable), the number of hours per week and months per year the activity was usually 
performed. The total years of participation in the activity was also recorded. When activities 
were terminated and begun again at a later time each episode was coded separately, 
allowing for an evaluation of activity patterns at various ages. For participants who listed an 
activity without providing the number of months per year of participation, 12 months per year 
was imputed if the activity was deemed non-seasonal. If the activity was characterized as 
being seasonal the reported menopause specific mean months per year was imputed. The 
complete assessment provided a detailed self-reported lifetime history of each participant’s 
RPA. These data were ultimately converted into hours per week and weeks per year of 
participation and the values summed across all activities for each year of a woman’s life, 
providing a lifetime duration-frequency variable for RPA from menarche (left truncated) to 
reference date.  
Similarly, for women classified as ever having participated in recreational physical 
activity, metabolic equivalents of energy expenditure (MET) scores were assigned to each 
reported activity according to a published database [57]. In scenarios where the activity 
reported was not in the published database, efforts were made to find activities in the 
database similar to that which was reported and use the corresponding MET score. These 
scores were multiplied by the number of hours per week the participant reported engaging in 
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the activity and were summed across all activities to create a lifetime intensity-duration-
frequency variable for RPA from menarche to reference date.  
A total of 149 subjects (4.9%) were missing the lifetime duration-frequency RPA 
variable. This includes 70 (4.6%) cases and 79 (5.1% controls). One hundred ninety two 
participants were missing MET scores including 90 (6.0%) cases and 102 (6.6%) controls. A 
sensitivity analysis was conducted imputing the highest, lowest, and mean reported activity 
level for postmenopausal women missing RPA from first live birth to menopause [298]. 
Results from the logistic models of the three datasets generated by the different imputations 
were not materially different from the complete case analysis. These individuals were 
therefore excluded from analyses.  
Variable construction for the RPA was assessed in detail for a previous analysis [63]. 
For this project I explored several constructions for the physical activity variable including 
categorization based on control quartiles, parametric specifications (e.g., logit, linear), and 
flexible modeling (e.g, quadratic, higher order polynomials, or splines) (Figures A.10-A.15). 
RPA distributions based on control quartiles appeared to best described the shape of the 
data using the fewest number of parameters. In order to maintain reasonable cell sizes for 
gene*environment interactions on an additive scale, however, the RPA variable was 
modeled categorically using indicators for high (greater than or equal to control median), low 
(less than control median), and no (based on the RPA screener) physical activity. In all 
analyses the lowest RPA group (no activity) served as the referent.  
  In addition to the physical activity data the baseline questionnaire queried women on 
a number of other exposures including reproductive, medical and environmental histories; 
self-reported weight and height by decade of life; cigarette and alcohol use; use of 
exogenous hormones; energy intake; demographic characteristics; and, among cases, 
tumor receptor status. While other exposures have been shown to modify the effect of 
oxidative stress or DNA repair variants within this study population [156, 162, 224, 259, 299] 
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these analyses were considered beyond the scope of the project, as the primary aim of this 
dissertation was to assess the interactions with RPA.  
2.4.3 Confounders  
I expected minimal confounding of the association between breast cancer and CAT, 
MLH1, MSH2, and MSH3. Based on the DAG in Figure A.16, a minimally sufficient 
adjustment set for both oxidative stress and DNA repair variants included race, family history 
of breast cancer, and religion. The LIBCSP population for the proposed study is primarily 
Caucasian (93.4%) making race unlikely to play an important role in these analyses. Both 
family history of breast cancer and religion (specifically Judaism) may represent proxies for 
increased frequency of high penetrant, low prevalence breast cancer susceptibility genes 
(primarily BRCA1). Adjustment for these variables may be important as 19.2% of cases and 
13.0% of controls report a family history of breast cancer among a first degree relative, and 
17.2% of case and 15.4% of controls self-identified as Jewish in this study population [26]. 
Given these data I expected minimal confounding of the main genotype effect. I also 
anticipated little confounding of the gene-environment interaction, as a potential confounder 
must affect both components of the interaction on the multiplicative scale. If there were 
evidence for interaction on the additive scale however, some covariates could confound the 
association between physical activity and breast cancer risk within strata of genotype. There 
were no such instances in these analyses as interaction was only observed in multiplicative 
models (See Chapters 3 and 4).  
 2.5 Data Analysis 
The primary objective of this dissertation was to elucidate the mechanism through 
which physical activity may act on breast cancer risk. This was accomplished by assessing 
potential interactions within two closely linked pathways: oxidative stress (AIM 1) and DNA 
repair (AIM 2). There are three principal analyses for each pathway: (A) estimation of the 
association between selected SNPs and breast cancer risk (main effects), (B) evaluation of 
 
 62    
 
62
 
2-way interactions between genes/SNPs within a pathway and breast cancer outcomes 
(gene-gene or SNP-SNP interactions), and (C) evaluation of interactions between functional 
variants and self-reported lifetime physical activity on breast cancer risk (gene-environment 
interactions). All statistical analyses were conducted using SAS version 9.1.2 (SAS Institute, 
Cary, NC). 
2.5.1 Descriptive Statistics  
The distribution of participant characteristics (SNPs, potential confounders and effect 
modifiers) were calculated as counts and frequencies for categorical variables and reported 
separately for cases and controls in the total study population (Tables A.9-A.10) as well as 
among white women only (Tables A.11-A.12).  
2.5.2 Main Effect of SNPs 
Unconditional logistic regression models were used to estimate ORs and 95% CIs for 
the main effect of each candidate SNP genotype on breast cancer risk, with adjustments 
made for the frequency matching factor – age at reference date [300] (Table A.13-A.14). 
These estimates were also calculated among white women only to verify that results did not 
change materially by including women of other racial demographics in the model (Table 
A.15-A.16).    
The binary logistic model function used to estimate OR’s was: Logit [D=1|X=x] = α + 
β1X1 + β2X2, where 
α = model intercept 
X1 = presence or absence of heterozygote genotype 
X2 = presence or absence of minor allele homozygote genotype  
β1 = regression coefficient corresponding to heterozygote genotype 
β2 = regression coefficient corresponding to minor allele homozygote genotype 
D = case (1) or control (0) status 
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Covariates, selected based on DAG analyses, were considered confounders if they 
were associated with exposure in the source population, associated with disease among 
women who were unexposed and resulted in at least a 10% change in estimate when added 
to the model, compared to a model without the covariate [301]. None of the identified 
covariates met these criteria (Tables A.17-A.18).  In addition to estimating the main effects I 
assessed potential heterogeneity of effects across strata of menopausal status, family 
history, and religion (Tables A.19-A.20). Race was also explored as a potential effect 
modifier, but given the low proportion of African American and ‘other’ women in the LIBCSP 
our analysis was limited in assessing potential modification by these variables. This 
dissertation also explored the possibility that both MMR and CAT SNP effects varied by 
tumor receptor status (Tables A.21-A.22) using broad categories or hormone receptor (HR) 
positive (any ER or PR+) and HR negative (ER-/PR-) to serve as proxies for the less 
aggressive luminal subtypes and more aggressive triple negative/ human epidermal growth 
factor receptor 2+ (HER2+) subtypes [302].  
2.5.3 Interactions  
A statistical interaction occurs when there is departure from additivity of effects on 
one chosen outcome scale [303]. Evidence for a biological interaction between two 
exposures may be inferred from measures of statistical interaction calculated from 
regression models. While multiplicative interactions are likely more reflective of a multistage 
disease like breast cancer, additive interactions on the risk scale may better reveal 
biological interactions [303].  
Gene-Gene/SNP-SNP Interactions. Interaction between MMR genes, CAT SNPs, 
and breast cancer development was evaluated using a likelihood ratio test (LRT): the 
difference of two -2LogL values of logistic models calculated with and without the interaction 
terms for SNP1 and SNP2 (Tables A.23-A.24). I subsequently explored pathway effects by 
collapsing the number of ‘at risk’ alleles in the CAT gene (Table A.25) and variant alleles 
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within the MMR pathway (Table A.26) to calculate adjusted ORs for breast cancer (Tables 
A.27-A.26). Low-, intermediate-, and high-risk categories for each pathway were defined 
based on similar point estimates of breast cancer risk for each number of putative high-risk 
or variant alleles (Tables A.27-A.28). Similar analyses had been conducted among variants 
in the NER pathway using both LIBCSP [222] and Carolina Breast Cancer Study [229] study 
data.   
Gene-Environment Interaction. To assess potential interaction between functional 
polymorphisms in oxidative stress and DNA repair genes, RPA and breast cancer risk I 
examined both multiplicative and additive interactions. Multiplicative interactions were 
assessed by including a multiplicative interaction term in the regression model and 
calculating departures from the multiplicative null using the LRT (Tables A.29-A.32). The 
LRT compares the -2 log likelihood (-2LL) of two models, one of which is nested within the 
other, to determine if the addition of the interaction term improves model fit.  
The basic logistic regression model allowing for interaction is: logit [D=1|X=x] = α + 
β1X1 + β2X2 + β3(X1)(X2) 
where α = model intercept 
X1 = exposure 
X2 = effect modifier 
β1 = regression coefficient corresponding to the exposure 
β2 = regression coefficient corresponding to the outcome 
β3 = regression coefficient corresponding to the excess effect of joint exposure 
Departures from the additive null were evaluated by the interaction contrast ratio 
(ICR) [303] using indicator terms for participants with the genotype only, exposure only, and 
both the genotype and exposure of interest (Tables A.33-A.36). The magnitude of additive 
interaction effect between SNPs and physical activity was determined by estimating the 
adjusted interaction contrast ratio (ICR) using the formula: ICR OR exposed, variant – OR exposed – 
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OR
 variant + 1 and its respective confidence interval obtained by ICR ± 1.96 standard 
error(ICR) [304]. ICRs less than zero indicated less than additive effects, ICRs of zero 
suggested no interaction on the additive scale, and ICRs greater than zero implied 
superadditivity [303]. While it would have been interesting to explore gene-environment 
interactions using the total variant approach discussed above, limited power in the LIBCSP 
hindered assessment of interactions using this method.    
2.5.4 Sample Size and Power 
The total sample with data available for genotyping included 1053 cases and 1102 
controls. For these analyses, the estimated study power varied based on the genetic model 
selected, frequency of the at-risk genotype (10% to 50%), the expected ORs for the 
association between the genotypes and risk of breast cancer, and if women are categorized 
by menopausal status. Power calculations were based on the generally accepted standard 
two sided α=0.05 and were calculated using POWER version 3.0 software available through 
the National Cancer Institute and described in Garcia-Closas [305].  
The study had more than adequate power to detect even modest associations for 
main gene effects (using an additive, dominant, or recessive model). Based on previous 
analyses I expected the genetic effect to range between 1.2 and 2.0. Power was estimated 
as ≥ 80% for ORs ≥ 1.5 for all women combined and for postmenopausal women alone 
assuming a two-sided α=0.05, 1% disease prevalence, and at-risk genotype prevalence of 
at least 10%. Figure A.17 shows the expected study power for varying frequencies of the 
at-risk genotype among pre and postmenopausal women combined. To examine OR effect 
modification [305, 306] of most gene*gene or gene*physical activity combinations 80% 
power was expected to detect substantial interactions of OR > 4.5 and OR > 5 multiplicative 
(Figure A.18) and additive models (Figure A.19), respectively. These calculations assumed 
a 2-level genetic model, 3-level physical activity categorization, and an at risk genotype 
prevalence of at least 25%. Power declined with decreasing at-risk genotype prevalence 
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and increasing numbers of physical activity categories.   
2.6 Strengths and Limitations 
2.6.1 Study Design 
One major advantage of using the Long Island data set was its large population-
based design. This provided sufficient statistical power to examine gene-gene and gene-
environment interactions. Moreover, LIBCSP is unique among epidemiologic studies of 
breast cancer given that there was no upper or lower age limit for subject eligibility, making it 
one of few studies that can provide extensive data on the epidemiology of breast cancer 
among women 65 years of age and over. Similar to other population based case-control 
studies LIBCSP experienced lower participation rates among controls compared to cases 
(62.7% vs. 82.1%, respectively), which may indicate the presence of participation bias. 
These differences are primarily attributed to poor response among elderly control women ≥ 
65 years where a 43.3% response rate was achieved in comparison to the 71.2% response 
rate among case women. These differences were less evident among women under 65 
years with an 88.9% and 76.1% response rate among cases and controls, respectively [18].  
Despite the population-based nature of the sample, a limitation of the study is its 
relatively homogenous population, specifically with regard to race. The racial homogeneity 
of the study population restricts the ability to evaluate modification by breast cancer 
subtypes (e.g. Luminal A, Luminal B, HER2, and Basal-like) which are known to vary by 
both menopausal status and race [307]. The overwhelming majority of the women included 
in the parent LIBCSP study were classified as estrogen receptor positive, progesterone 
receptor positive, and HER-2/neu negative (Dr. Marilie Gammon, personal communication, 
2009) which are indicative of the luminal A subtype [307]. Given the narrow range of breast 
cancer subtypes I was limited in my ability to detect differences by tumor status. Similarly, 
because of the differences in the ethnic distribution of this study population compared to the 
US population as a whole, study results may not be readily applicable to all women of the 
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US. While this limits external validity, the internal validity of the study will be enhanced and 
will apply to women with the highest risk of developing breast cancer, namely white, 
postmenopausal women. Importantly, this study may provide some clues about the 
underlying biologic mechanisms of physical activity which are unlikely to vary by race 
despite potential racial variation in the frequency of specific alleles and prevalence of 
exposure.  
2.6.2 Exposure Assessment 
The proposed ancillary project is efficient because the exposure data and biologic 
specimens have been obtained through the parent study. The detailed exposure information 
from LIBCSP will enable us to explore several different measures of physical activity (e.g. 
hours/wk and MET hrs/wk) as well as several time periods throughout the reproductive 
lifespan and potential interaction with MLH1, MSH2, MSH3, and CAT to influence breast 
cancer risk. The physical activity assessment is unique in that it is one of few population 
based studies to inquire about recreational physical activity by decade from menses to 
reference date.  
 Physical Activity. A perceived weakness of large scale studies of physical activity is 
the inability to accurately assess activity in the distant past. By design, a case-control study 
such as this must often rely on self-reported data to ascertain relevant exposure and 
covariate information. Errors in reporting or differential reporting by cases and controls have 
the potential to bias the study results. Ideally, etiologic studies of physical activity would 
assess exercise-related biomarkers of biologically effective dose [74]. These markers would 
represent the amount of an external exposure that has both entered the body and interacted 
with molecular targets. The use of these biomarkers is thought to increase the validity of 
exposure assessment, however in the realm of physical activity there are currently no such 
markers.  
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 Activity levels in the LIBCSP were assessed via an interviewer administered 
questionnaire, which could be hampered by measurement error. To reduce these errors, 
Long Island interviewers were educated and trained to collect data in a systematic manner 
[18]. Nevertheless, differential recall of physical activity among cases and controls could 
potentially bias results. In these analyses such errors are potentially superfluous because I 
was interested in estimating the effect of gene*environment interactions whereby there is no 
differential reporting of physical activity based on genotype [308]. It is often a concern that 
physical activity questionnaires lack content validity and reliability specifically when 
employed in case control studies. These errors could potentially reduce the ability of a study 
to identify important relationships. More objective measures such as accelerometers and 
pedometers could be used, but they are not feasible in large population-based studies and 
would fail to capture the etiologically relevant time period for breast cancer outcomes.  
 While the physical activity measurement in this study has not been validated, it is 
reassuring to note that the instrument has been useful in revealing important relationships 
between exercise and breast cancer risk in several epidemiologic studies [274, 309]. 
Similarly, the results obtained in the Long Island study data [63] for the main effect of 
physical activity among post-menopausal women (30% reduction in risk) is consistent with 
the 25% risk reduction reported in other independent and review studies [44, 46].  
Genetic Variants. Common sources of error for all biomarker studies are issues 
related to specimen collection, processing, and storage. A number of steps were taken to 
minimize these errors in LIBCSP. Samples from matched sets were assayed together in the 
same batch to ensure that effect estimates did not vary because of inter-assay variability. 
For quality control purposes 10% duplicates of the samples were distributed throughout 
DNA samples and laboratory personnel were blinded to case control status. Additionally, 
computerized algorithms in SAS were used to cross-check genetic data for inconsistencies.  
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Small sample size is an inherent limitation of most molecular epidemiology studies 
chiefly because of the infrequency of some minor alleles. The LIBCSP was well powered to 
investigate 2-way interactions (gene*environment and gene*gene among genes or physical 
activity. Higher order interactions were not assessed in this study.  
Finally, bias may arise if cases and controls differentially donated blood samples or if 
physical activity status was a predictor of blood donation. Among respondents who 
completed the interview there was no case-control differential between case and control 
participants who donated a blood sample.  
2.6.3 Data Analysis 
Multiple comparisons is a consideration in the proposed study, as there are no a 
priori evidence indicating an association exists between specific oxidative stress/DNA repair 
variants, physical activity, and breast cancer. There are a number of approaches to correct 
for these errors. The first approach would be to make no correction for multiple testing. This 
approach would obligate that the SNPs assessed are not highly correlated. While MMR and 
CAT SNPs selected for main effects analysis (N=9) are not highly correlated (highest 
pairwise R2 = 0.634), functional SNPs, chosen a priori for the gene-environment analyses 
(N=29) will likely be related. Further, the additional gene-environment component of the 
proposed study increases the number of comparisons to be performed (as some GxE 
interactions will be evaluated using multiple genetic models) making some correction for 
multiple comparisons warranted. Permutation methods can become computationally 
demanding with many SNPs and may not be applicable when covariates are included in the 
model. Similarly, more sophisticated approaches (e.g. Bayesian or Monte Carlo methods) 
involve many assumptions, are computationally intensive [287, 310] and may provide no 
added benefit over more direct approaches. To correct for multiple testing I proposed to 
employ the Bonferroni correction, or step down procedure [311], but given the biologically 
based hypothesis I made no correction for multiple comparisons.  
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2.6.4 Data Interpretation 
Identifying susceptibility or resistance alleles in gene-environment studies may help 
to uncover biologic pathways that are most relevant for environmental exposures known to 
impact disease susceptibility. While the term “gene-environment” often implies a specific 
biologic relationship between the genes and the environment I recognize that in 
epidemiologic studies these interactions are statistical, and do not indicate a specific 
disease mechanism. However, in using interactions as a best effort to uncover underlying 
biology some specific methods can be employed: (1) it is important to assess interactions on 
both multiplicative and additive scales given multistage diseases like cancer which are likely 
to have factors acting in both the same and different stages along the cancer continuum (2) 
to reduce the likelihood of spurious findings it is suggested that gene products and 
exposures be in the same biologic pathway. Further, selecting variants that alter gene 
function are likely more useful than screening large numbers of SNPs [312] (3) assessment 
of gene*environment interactions required multiple level stratification, invariably creating 
small cells. Caution was therefore employed in data interpretation.  
2.7 Summary 
The LIBCSP is a large population-based case-control investigation with a 
comprehensive, life-course assessment of recreational physical activity and is rich in genetic 
data. Moreover, the LIBCSP has extensive data on a number of breast cancer risk factors, 
confounders, and effect modifiers including information regarding breast tumor 
characteristics. The proposed research aimed to (1) evaluate associations between variants 
in CAT, the MMR pathway and breast cancer using multivariable logistic regression, 
adjusting for potential confounders (2) examine interactions between SNPs and/or genes in 
CAT and MMR, respectively, and (3) assess interactions between recreational physical 
activity, oxidative stress and DNA repair polymorphisms in BER, NER and MMR pathways 
with respect to breast cancer risk using multiplicative and additive models. No previous 
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epidemiologic research had evaluated potential interactions between physical activity and 
genetic variants on risk of breast cancer. 
This research may have widespread implications for breast cancer. Although there is 
evidence that some breast cancers exhibit MSI few studies have sought to explore the 
effects of MMR variants on breast cancer risk. These associations are important to 
understanding the etiology of breast cancer because MMR is involved in the overall 
maintenance of genomic stability. This dissertation would be the first to systematically 
evaluate these associations in a large population-base sample. Similarly, some studies 
show that the C/T polymorphism (rs1001179) in the promoter region of the CAT gene is 
associated with increased breast cancer risk, however few other polymorphisms have been 
evaluated. Both the animal and in vitro literature suggests that the generation of lipid 
peroxidation products play a large role in breast cancer susceptibility. Uncovering other risk 
variants in this gene may help to better understand the role of CAT in the maintenance of 
oxidative balance. 
Most observational studies show an inverse association between physical activity 
and breast cancer risk. Although the exact frequency, duration, and intensity are not well 
established there is adequate evidence that lifetime physical activity is an important 
modifiable factor for breast cancer. The importance of uncovering the underlying 
mechanisms of physical activity is frequently cited in the physical activity-breast cancer 
literature. However, little research has been conducted outside the obesity related pathways 
despite the strong biologic plausibility of both antioxidant and DNA repair pathways. 
Identifying women who are particularly susceptible to the beneficial effects of physical 
activity based on genetic characteristics could aid in validating the biologic plausibility of this 
association, helping to better identify new targets for intervention and inform public health 
recommendations for lowering breast cancer risk. 
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Chapter III: Polymorphisms in Oxidative Stress Genes, Recreational Physical Activity 
and Breast Cancer Risk 
3.1 Introduction 
Oxidative stress is hypothesized to play an important role in breast carcinogenesis 
[127, 139-141] and is caused by the imbalance of reactive oxygen species (ROS) production 
and antioxidant defenses which neutralize these molecules [172]. ROS may be generated 
through any number of endogenous or exogenous mechanisms. While modest levels of 
ROS are useful for cell signaling processes [123] excess production may result in DNA 
damage, lipid peroxidation, and protein modification [121, 125, 126].  When endogenous or 
exogenous ROS production occurs in an environment with sufficient in vivo defense 
mechanisms to scavenge the ROS, there are seemingly few harmful effects. When there is 
excess ROS production and/or insufficient defense mechanisms, oxidative stress may 
ensue. There are several antioxidant defenses that can protect against oxidative damage 
including catalase (CAT), manganese superoxide dismutase (MnSOD), glutathione 
peroxidase (GPX), glutathione S-transferases (GSTs), myeloperoxidase (MPO) and 
catechol- O-methyltransferase (COMT) [127].  CAT plays an important role in neutralizing 
ROS by converting H2O2 into H2O and O2 [127]. Activity levels of the CAT enzyme are likely 
affected by a functional polymorphism (rs1001179) in the promoter region of the gene [156]. 
While this polymorphism has been associated with decreased enzyme activity [153-156], its 
association with breast cancer risk is unclear [156-158]. Other polymorphisms in CAT may 
be important in understanding the underlying association with breast cancer incidence and 
should be considered. 
While physical inactivity is a well-established risk factor for breast cancer [42], the 
mechanisms driving the association are not well described [44, 74, 75]. Given the biological 
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adaptation of enhanced antioxidant enzymatic capacity that occurs with regular exercise and 
its contribution to ROS, the oxidative stress pathway may be of interest. Physical activity 
may therefore interact with antioxidant-related genetic polymorphisms to influence breast 
carcinogenesis. No previous epidemiologic investigations have explored this possibility. We 
hypothesized that genotypes related to reduced antioxidant expression may have an 
antagonistic effect on the benefits of physical activity. In this report, we aimed to: (1) 
examine the independent main effects of three variants in CAT (rs4756146, rs2284365, and 
rs480575) on breast cancer risk; (2) examine two-way interactions between SNPs in CAT 
and breast cancer risk; and (3) examine potential interaction between recreational physical 
activity (RPA) and several oxidative stress related genes (CAT, COMT, GPX, GSTA1, 
GSTM1, GSTP1, GSTT1, MnSOD, and MPO) with respect to breast cancer incidence. 
Secondary aims were to evaluate associations between CAT polymorphisms and breast 
cancer with cases categorized according to tumor hormone receptor status.  These aims 
were accomplished through the use of existing biomarker and questionnaire data from the 
LIBCSP.  
3.2 Materials and Methods  
3.2.1 Study population 
Study participants were from the LIBCSP, a population-based case-control study 
conducted among English-speaking female residents of Nassau and Suffolk counties, Long 
Island, New York. Details of the study methods have been described previously [18]. Briefly, 
LIBCSP cases were women aged 20-98 years diagnosed with a first primary in-situ or 
invasive breast cancer between August 1, 1996 and July 31, 1997. Case women were 
identified through daily or weekly contact with local hospital pathology departments. 
Population-based controls were women without a personal history of breast cancer 
randomly selected using random digit dialing for those under age 65 and the Health Care 
Finance Administration rosters for women ages 65 and older. Controls were frequency 
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matched to the expected age distribution of case women by 5-year age groups. All data 
were collected through a two-hour, interviewer-administered, structured questionnaire. 
Interview response among eligible cases and controls were 82.1% (n=1508) and 62.8% 
(n=1556), respectively. Respondents were more likely to be older (median age = 57 years in 
cases and 56 years in controls), postmenopausal (n = 1003 cases and 989 controls), and 
white (93.4% white, which reflects the underlying distribution of the source population). 
Of those who completed an interview, 73.1% of cases and 73.3% of controls donated 
a blood sample. Among women who donated blood, genotyping was unavailable for 4.4% of 
cases and 3.4% of controls primarily due to insufficient DNA. Our final sample therefore 
includes 1053 cases and 1102 controls. Written informed consent was obtained from all 
participants. This study was approved by the Institutional Review Board of the collaborating 
institutions. 
3.2.2 SNP Selection and Genotyping 
We selected three SNPs in CAT for genotyping (rs4756146, rs2284365, and 
rs480575). A tagging strategy was employed to maximize our ability to capture genetic 
variation across the gene (gene and 1000bp upstream and downstream). Tag SNPs were 
selected using the SNPinfo web server from the National Institute of Environmental Health 
Science [284] based on data from phase I and II of the International HapMap Project 
database [285]. Given the racial homogeneity of the LIBCSP population with DNA available 
for the proposed analyses [224]; the CEU population (30 Utah trios with ancestry from 
northern and western Europe) was used as the reference panel for SNP selection. We 
imposed a minor allele frequency (MAF) cutoff value of 10% and r2 threshold minimum of 
0.80 on SNP selection procedures. From the 11 tag SNPs identified to capture the CAT 
region, three were singleton or double bins, two had MAF < 10%, and one was previously 
genotyped in LIBCSP. Of the remaining 5 tag SNPs we selected three based on location, 
bin size, and linkage disequilibrium with functional variants.  
 
 75    
 
75
 
In addition to the newly genotyped CAT variants, we selected 10 functional 
polymorphisms from 9 genes in the oxidative stress pathway to assess gene*environment 
(G*E) interactions with RPA: (rs1001179), COMT (rs4680 and rs737865), GPX (rs1050450), 
GSTA1 (rs3957356), GSTM1 (gene deletion), GSTP1 (rs1695), GSTT1 (gene deletion), 
MnSOD (rs4880), and MPO (rs2333227). A single base pair change affecting polyphen 
prediction (GPX), transcription factor binding prediction (CAT, COMT rs737865, MNSOD, 
and GSTA1), miRNA binding (GPX), 3D conformation (COMT rs4680), or splicing regulation 
(GPX, COMT rs4680, MPO, and GSTP1) were defined as potentially functional SNPs. 
Similarly, base pair changes that were nonsynonymous (GPX, COMT rs4680, MPO, and 
GSTP1) or resulted in a stop codon were also classified as potentially functional. These 
polymorphisms were identified through the breast cancer literature and the SNPinfo web 
server [284]. The main effects of these associations with breast cancer risk have been 
previously reported in the LIBCSP study population [156, 162, 299, 313-316]. However, 
interactions with physical activity have not been considered. Previously published SNP-
specific effects among postmenopausal women for the genes of interest are provided in 
Table A.37 to offer a full pathway context for our findings on the effect of RPA and ROS-
related polymorphisms.    
A non-fasting 40 mL blood sample was obtained from participants at time of interview 
and shipped at room temperature, overnight, for processing. Genomic DNA was extracted 
from mononuclear cells in whole blood separated by Ficoll (Sigma Chemical Co., St. Louis, 
Missouri). Pelleted cells were frozen at −80o C until DNA isolation by standard phenol, and 
chloroform isoamyl alcohol extraction and RNase treatment were performed [18]. 
Genotyping of newly selected CAT SNPs was accomplished using Taqman assays (Applied 
Biosystems, Foster City, CA) in 384-well plates. For the remaining SNPs genotyping was 
performed by BioServe Biotechnologies (Laurel, MD) using Sequenom’s high-throughput 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, as described 
 
 76    
 
76
 
previously [299]. Controls for genotype and two non-template controls were included on 
each plate. Samples that were outside the variables defined by the controls were identified 
as non-informative and retested. For quality control, 10% of samples were distributed 
throughout the DNA samples as blinded duplicates. Laboratory personnel were blinded to 
case-control status, and all genotyping results were reviewed manually. 
3.2.3 Recreational Physical Activity and Covariate Assessment  
Exposure information was obtained from two sources: the interviewer-administered 
structured questionnaire and laboratory analyses using blood samples to obtain genotypes 
for CAT and oxidative stress genes. As part of the structured questionnaire participants 
were asked about their involvement in RPA using a modified instrument developed by 
Bernstein and colleagues [274]. Women were asked about all activities in which they had 
engaged for at least one hour per week and three months or more in any year over the life-
course. Women who reported never having participated in activity were classified as having 
no RPA. Among ever RPA participators information on the activity name, the ages the 
activity was started and stopped, and the number of hours per week and months per year 
the activity was performed was obtained. Activity data for ever participators were summed 
across all activities for each year of a woman’s life, providing a lifetime composite score of 
exercise duration from menarche (left truncated) to reference date. We previously reported 
the main effects of RPA during four etiologically relevant time periods (adolescent, 
reproductive, postmenopausal, and lifetime RPA) [63]. For the present analyses we 
assessed the interaction between polymorphisms in oxidative stress genes and two time 
periods for which the effects for breast cancer were strongest: postmenopausal and lifetime 
RPA. Given our previous analysis showed no substantial differences by intensity [63], we 
report RPA using average hours only.    
During the interviewer-administered structured questionnaire, participants were 
additionally queried about their demographic characteristics; reproductive, medical and 
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environmental histories; cigarette smoking and alcohol use; use of exogenous hormones; 
energy intake; and select anthropometric measurements. Among eligible cases, clinical data 
on the characteristics of their breast cancer diagnosis, including hormone receptor (HR) 
status, were obtained from medical records. 
3.2.4 Statistical Methods  
We first conducted tests for Hardy-Weinberg equilibrium (HWE) using observed 
genotype frequencies among Caucasian controls and X2 test with 1 degree of freedom 
[292]. Unconditional logistic regression [300] was used to estimate odds ratios (ORs) and 
95% confidence intervals (CIs) for the independent effects of CAT SNPs, their interactions, 
and the joint effect of oxidative stress variants and RPA. All CAT SNPs were initially 
evaluated using a general genetic model, but due to sparse data among women with the 
homozygous variant genotype, a dominant model (at least one variant allele vs. no variant 
alleles) was used for analyses of main effects and subsequent interactions.  
We identified potential confounders based on the known epidemiology of breast 
cancer and analysis of causal diagrams [295]. For CAT variants, potential confounders were 
first degree family history of breast cancer (yes/no), race (categorical), and religion 
(categorical). As reported in our recently published manuscript [63] that examines effects for 
RPA on breast cancer incidence, we considered the following potential confounders: 
education (categorical), family history of breast cancer (yes/no), history of benign breast 
disease (yes/no), income (categorical), lactation history (ever/never), use of oral 
contraceptives (ever/never), parity (categorical), and smoking history (never, current, 
former).  Confounders were included in the final model if their inclusion changed the 
exposure estimate by greater than 10% [301]. None of the above covariates met our 
criterion (which is consistent with the lack of confounding noted in our previous examination 
of the main effect of physical activity on breast cancer risk [63]. Additionally adjustment for 
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body mass did not alter our estimate by greater than 10%. Final models were therefore 
adjusted only for 5-year age group.  
The main effect of CAT variants on breast cancer risk was assessed among all 
women and within strata of menopausal status when the Breslow-Day p for homogeneity 
was <0.10 [317]. The effect of each CAT variant was evaluated by HR status stratifying 
cases into two groups using information on estrogen receptor (ER) and progesterone 
receptor (PR) status [302]: women with tumors that showed any hormone responsiveness 
(ER+/PR+, ER+/PR-, and ER-/PR+) and women who showed none (ER-/PR-).  
We evaluated potential G*E interactions (both additive and multiplicative) by using 
indicator terms for those with the genotype only, exposure only, and both the genotype and 
exposure of interest. For genotype we assessed interactions using a dominant genetic 
model and for RPA we classified participants into three categories with cut points based on 
the median value among controls: no RPA, low RPA (< control median), and high RPA (≥ 
control median). Departures from the multiplicative null were assessed using the likelihood 
ratio test, comparing a model with and without the interaction terms [317]. Departures from 
the additive null were estimated by the interaction contrast ratio (ICR). The magnitude of the 
additive interaction effect was estimated based on the following formula: ICR= OR11–
OR01–OR10+1 and its respective confidence interval obtained by ICR ±1.96 SE (ICR) [304]. 
If the relative risk, as approximated by the OR, for both genotype and exposure differed 
significantly from the relative risk of either factor alone added together minus 1, we 
concluded that there was evidence of additive interaction [303]. All analyses were conducted 
using SAS 9.1 (Cary, NC).  
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3.3 Results  
3.3.1 Hardy Weinberg Equilibrium  
Among Caucasian controls, the MAF for CAT SNPs rs4756146 C-, rs2284365 C- 
and rs480575 G-alleles were 14%, 25% and 31%, respectively. Allele frequencies were 
comparable to those of the CEU HapMap population (8%, 20%, and 30%), although control 
genotype distributions for rs4756146 (p=0.02) and rs2284365 (p=0.01) deviated significantly 
from HWE. Call rates were >95% for CAT SNPs and we observed good agreement in the 
randomly selected duplicates included for quality control (N discordant for rs4756146 [N=3, 
8.6%] and rs2284365 [N=0, 0%]) suggesting that deviation from HWE was not due to 
genotyping error.  
3.3.2 Main SNP Effects 
The genotype frequencies and age-adjusted associations with breast cancer risk for 
CAT polymorphisms are reported in Table 3.1. We observed no substantial associations 
between the CAT SNPs rs4756146, rs2284365 or rs480575 and breast cancer risk when 
genes were examined individually. However, the Breslow-day test for homogeneity revealed 
modification by menopausal status for rs4756146 (p=0.0419): strongest effects were 
observed among postmenopausal women; those with CT or CC genotypes had decreased 
risk of breast cancer compared to women with TT genotypes (OR=0.77; 95% CI, 0.59-0.99) 
(Table 3.2). We observed a non-significant increase in risk of breast cancer among 
premenopausal women carrying at least one variant allele (OR=1.27; 95% CI, 0.88-1.85). 
We also found some suggestion of difference in the effect of rs4756146 by HR status. There 
was an 11% risk reduction among pre and postmenopausal HR positive cases combined 
(OR=0.89; 95% CI, 0.69-1.15) and a 34% risk reduction among HR negative cases 
(OR=0.66; 95% CI, 0.40-1.08) compared to all controls. There was no modification by family 
history or religion for any SNP, and no heterogeneity by menopausal status or across tumor 
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types for CAT rs2284365 and CAT rs480575 (Table A.20). Our results did not vary upon 
restriction to Caucasian women.  
3.3.3 SNP-SNP Interactions  
We assessed all potential multiplicative interactions between the three newly 
genotyped CAT polymorphisms described above and a functional CAT polymorphism 
(rs1001179) previously reported by Ahn and colleagues [156]. Of the six possible 2-way 
combinations, we found only one potential interaction between rs480575 and rs2284365 
(Table A.38), although this interaction did not reach statistical significance (a priori α=0.05). 
We observed a significantly decreased risk of breast cancer among women who carried at 
least one variant allele for CAT rs480575 and were homozygous for common alleles for CAT 
rs2284365 (OR=0.69; 95% CI, 0.49-0.96).  
3.3.4 Gene-Environment (GxE) Interactions  
The OR (95% CI) for breast cancer risk by genotype and RPA are shown in Table 
3.3 along with previously reported postmenopausal age-adjusted main effects for RPA and 
genetic variants. While we observed similar GxE results for lifetime RPA among all women, 
the effects were stronger once restricted to postmenopausal participants. This is likely due 
to the strength of the main effect as we previously found stronger inverse associations for 
postmenopausal RPA than lifetime RPA [63]. Models are therefore presented among 
postmenopausal women, using reduced variables for RPA (none, < control median, ≥ 
control median) and a dominant genetic model.  
The association between postmenopausal breast cancer risk and carrying at least 
one variant CAT allele (rs1001179; CT and TT genotypes) was increased among women 
who had engaged in > 9.23 hrs/wk of RPA from menopause to reference date (OR=1.61; 
95% CI, 1.06-2.45; p for multiplicative interaction = 0.043). There was a modest risk 
reduction (OR=0.89; 95% CI, 0.59-1.34) among women who were heterozygous or 
homozygous for the variant allele and moderately active (0.01-9.23 hrs/wk). Despite the 
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significant interaction the estimate in the no activity group was 1.36 (95% CI, 0.83-1.21). We 
observed a significant 44% risk reduction (OR=0.56; 95% CI, 0.38-0.84) among 
postmenopausal women who engaged in low to moderate RPA with at least one G allele 
(AG and GG combined) in GSTP1 Ile105Val, compared with those with the AA genotype (p 
for multiplicative interaction = 0.006). Among highly active women there was little effect of 
genotype on breast cancer risk (OR=1.08; 95% CI, 0.71-1.64). There was some suggestion 
of an inverse association between the TC and CC genotypes of CAT SNP rs4756146 and 
postmenopausal breast cancer risk among non-active women (OR=0.57; 95% CI, 0.33-
0.98), however, we observed no significant interaction on the multiplicative scale for this or 
any of the remaining SNP-RPA combinations. Stratum specific effects of genotype were also 
assessed using splines for RPA. These analyses revealed similar results as our categorical 
classification of RPA (Figures A.20-A.21). Additionally, our models did not support the 
presence of an additive interaction between any of the 13 polymorphisms and RPA (Table 
A.36). 
3.4 Discussion 
In this population-based study, women with at least one variant allele in CAT 
rs4756146 had a 23% reduced risk of postmenopausal breast cancer compared to women 
with the common TT genotype. The association was not observed among premenopausal 
women, or when both pre- and postmenopausal women were considered together. 
Examination of potential interactions between CAT SNPs revealed a significantly decreased 
risk of breast cancer among women who carried at least one variant allele for rs480575 and 
were homozygous for common alleles for rs2284365, although a test of formal interaction 
was not significant. When we examined joint effects of polymorphisms in oxidative stress 
genes and RPA from menopause to reference date in relation to postmenopausal breast 
cancer risk, we found some evidence for modification of genotype effect by activity level. A 
non-statistically significant positive association was observed among women with more than 
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one variant CAT allele (rs1001179). This association was stronger and statistically 
significant among participants who were highly active. The inverse association between 
GSTP1 Ile105Val and breast cancer was more pronounced among women who were 
moderately active. These findings could indicate that lower neutralization of ROS may 
augment breast cancer risk among a background of high RPA, whereas higher enzymatic 
activity may result in enhanced risk reduction among women who are moderately physically 
active. However, given the lack of evidence across other oxidative stress markers these 
results require additional confirmation.  
There are multiple reports of the association between the functional catalase-262 
C/T polymorphism and breast cancer incidence in the epidemiologic literature [156-158], but 
no study to date has assessed the individual or combined effects of CAT tag SNPs 
(rs4756146, rs2284365, rs480575) and breast cancer risk. We found that the association 
among women carrying at least one variant allele in CAT SNP rs4756146 varied by 
menopausal status. While the exact mechanisms needs to be further investigated, it is 
possible that postmenopausal women (with a lower estrogen milieu) may more greatly 
benefit from ROS removal. Given the important role of CAT in neutralizing ROS [127], 
polymorphisms resulting in reduced enzyme activity may alter an individual’s ability to 
counter lipid peroxidation and DNA oxidation thereby influencing cancer risk. However, in 
light of the marginally significant odds ratios and little evidence for association among the 
remaining polymorphisms, these results may be due to chance.  
Many [156, 157, 162, 299], but not all [315], studies which examined the association 
between ROS related exposures, genotype and breast cancer risk have shown that both 
ROS-generating (e.g., cigarette smoking and exogenous hormones) and ROS-opposing 
factors (e.g., consumption of fruits and vegetables) may interact with endogenous sources 
of pro- and antioxidants to modify the effects of oxidative stress related genetic 
polymorphisms on breast cancer risk. Given the more complex physiological effects of 
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physical activity any interactions with SNPs in the oxidative stress pathway may be 
challenging to disentangle. 
Physical activity is a known inducer of ROS [119, 163, 164] and has been associated 
with lipid peroxidation among trained athletes [165-167]. The seemingly paradoxical inverse 
association between physical activity and breast cancer risk may be explained, in part, by 
the long-term effects of regular exercise. Some studies suggest that while exercise-induced 
ROS production may be an immediate systemic response to physical activity, the lasting 
effect of regular exercise training is adaptation of antioxidant capacity [170, 171]. Regular 
activity has been shown to enhance antioxidant status at multiple levels in both animal 
models and clinic studies [173, 318-321] and may render cells more resistant to subsequent 
oxidative insult [172] thereby neutralizing the potentially mutagenic effects of lipid 
peroxidation [173]. Changes in antioxidant status are proposed to occur even with moderate 
activity, which parallels our knowledge of the association between physical activity and 
breast cancer.  
We previously reported a non-linear dose response association between RPA and 
breast cancer risk among post-menopausal women in the LIBCSP [63]. While a significant 
30% risk reduction was observed among women in the third quartile of activity (OR=0.70; 
95% CI, 0.52-0.95) women in the highest quartile experienced a modest 16% risk reduction 
(OR=0.84, 95% CI, 0.63-1.13). Our finding is contrary to many previous epidemiologic 
studies, which report an inverse dose-response association between physical activity and 
breast cancer risk [42]; however, the high levels of activity reported by women in the 
LIBCSP permitted us to consider a wider range of effects than prior investigations. One 
possible explanation for inconsistent findings among highly active women may be the 
presence of modification by biologically relevant genotypes. While the effect estimates for 
RPA in quartiles 3 and 4 were not substantially different one could posit that ROS induction 
among women with very high activity levels could be amplified by reduced antioxidant 
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capacity in relevant genes such as CAT. Moreover, moderate levels of RPA may enhance 
risk reduction among women who are carriers of alleles known to be related to higher 
endogenous enzymatic activity such as the GSTP1 Ile105Val variant [322-324].  Although 
there is a strong biologic rational for the role of exercise in oxidative stress, the lack of 
modification across other genes may suggest that the observed results are due to chance 
and should be interpreted with caution. 
The effects observed in this study may be due to biases arising from sample 
selection, errors in recall, or misclassification of genotype. In the LIBCSP, blood donation 
varied by both age and race [18]. While genotype is likely associated with race, given the 
small number of non-white women (6.6% non-white) included in our study, racial variations 
in blood donation is likely negligible. Moreover, analyses restricted to Caucasian women 
resulted in little change to observed estimates. Inaccurate recall of exposure variables can 
similarly lead to biased results and is common in case-control studies. However, it is unlikely 
that misclassification of RPA is differential with respect to genotype. We therefore expect 
that recall differences by disease status would not substantially bias our interaction 
parameter estimates. Distributions of two CAT variants deviated significantly from HWE, 
which may inflate Type I error [325]. We anticipate that factors other than genotyping error 
(e.g. natural selection or nonrandom mating) may be responsible for the departure from 
HWE given the comparable allele frequency to the CEU HapMap population, the use of the 
high-throughput genotyping methods, as well as the high call and concordance rates. This 
study benefits from the relatively large sample size, which increased power to detect modest 
associations, perform subgroup analyses, and evaluate joint effects of genotype and RPA. 
However, even very large studies assessing main effects of genetic variants can quickly 
become underpowered when examining gene-environment interactions. Although the racial 
homogeneity of the LIBCSP population enhances internal validity, it is likely to reduce the 
generalizability of our study results. Despite potential racial variation in genotype frequency 
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and exposure prevalence, we believe that this study may provide clues about the underlying 
biologic mechanisms of oxidative stress and RPA which are unlikely to vary by race. 
In summary, variant alleles in rs4756146 appear to be associated with reduced 
breast cancer risk among postmenopausal women. The statistical interaction, on a 
multiplicative scale, between CAT, postmenopausal RPA and breast cancer may support 
our biologically plausible hypothesis that ROS generating risk factors act in combination with 
reduced antioxidant expression to increase the risk of breast cancer. Similarly, the observed 
interaction between GSTP1 and RPA could suggest that ROS are best neutralized in 
environments where there is amplified antioxidant capacity either via endogenous or 
exogenous mechanisms. This study is, to our knowledge, the first to assess the interaction 
between oxidative stress genotypes and exercise. Our findings may support the link 
between physical activity, genetic polymorphisms in genes related to antioxidant capacity 
and breast cancer risk, but given the probability of chance findings, these hypotheses 
should be explored in other studies with adequate power and equally detailed exposure 
assessment. Although genotype is non-modifiable, it is encouraging to note that women who 
were moderately physically active had enhanced risk reduction when they were carriers of 
alleles related to higher enzymatic activity. 
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TABLE 3.1 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Association between 
Catalase Variants and Breast Cancer Risk. The Long Island Breast Cancer Study Project (1996-
1997).  
  
 
Cases  
(N=1053)  
Controls  
(N=1102)  OR (95% CI) 
a
 
Gene  (rs) Genotype 
 
N 
 
% 
 
N 
 
% 
   
            CAT 
(rs4756146) TT  774  77.87%  809  75.82%  1.00 Reference 
 
TC 
 
201 
 
20.22% 
 
229 
 
21.46% 
 
0.93 (0.75, 1.16) 
 
CC 
 
19 
 
1.91% 
 
29 
 
2.72% 
 
0.68 (0.37, 1.22) 
 
TC and CC 
 
220 
 
22.13% 
 
258 
 
24.18% 
 
0.90 (0.74, 1.11) 
CAT 
(rs2284365) TT  589  59.43%  610  57.22%  1.00 Reference 
 
TC 
 
344 
 
34.71% 
 
371 
 
34.80% 
 
0.98 (0.81, 1.18) 
 
CC 
 
58 
 
5.85% 
 
85 
 
7.97% 
 
0.72 (0.50, 1.03) 
 
TC and CC 
 
402 
 
40.56% 
 
456 
 
42.77% 
 
0.93 (0.78, 1.11) 
CAT (rs480575) AA 
 
517 
 
52.54% 
 
504 
 
48.60% 
 
1.00 Reference 
 
AG 
 
378 
 
38.41% 
 
422 
 
40.69% 
 
0.89 (0.74, 1.08) 
 
GG 
 
89 
 
9.04% 
 
111 
 
10.70% 
 
0.78 (0.58, 1.06) 
 
AG and 
GG  467  47.45%  533  51.39%  0.87 (0.73, 1.04) 
a Odds ratio (OR) and 95% confidence interval (CI) 
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TABLE 3.2 Age Adjusted Odds Ratios and 95% Confidence Intervals for the 
Association between Catalase SNP rs4756146 and Breast Cancer Risk by 
Menopausal Status. The Long Island Breast Cancer Study Project (1996-1997).  
Gene (rs) Cases Controls 
 
   
    OR (95% CI) a 
CAT (rs4756146) Pre-Menopausal 
    
 
TT 241 282 1.00 Reference 
 
CT 70 68 1.32 (0.89, 1.94) 
 
CC 6 6 0.88 (0.27, 2.85) 
 
CT and CC 76 74 1.27 (0.88, 1.85) 
CAT (rs4756146) Post-Menopausal 
  
 
TT 514 491 1.00 Reference 
 
CT 127 152 0.81 (0.62, 1.06) 
 
CC 12 23 0.51 (0.25, 1.04) 
  CT and CC 139 175 0.77 (0.59, 0.99) 
a Odds ratio (OR) and 95% confidence interval (CI) 
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TABLE 3.3 Age Adjusted Odds Ratios and 95% Confidence Intervals for Multiplicative Effects of 
Oxidative Stress SNPs and Postmenopausal Recreational Physical Activity on Postmenopausal 
Breast Cancer Risk. The Long Island Breast Cancer Study Project (1996-1997). 
 
Homozygous for 
major allele 
At least one copy of minor 
allele  
Gene (SNP) major/minor allele 
Postmenopausal RPA 
(average hrs/wk) a 
Ca/Co b Ref Ca/Co OR (95% CI) c p for interaction 
CAT (rs4756146) T/C 
  
 
<0.01 133/104 1.00 33/44 0.57 (0.33, 0.98) 0.126 
0.01-9.23 169/140 1.00 48/51 0.78 (0.49, 1.24) 
 
>9.23 137/163 1.00 36/45 1.05 (0.63, 1.76) 
 CAT (rs2284365) T/C 
  
 
<0.01 104/80 1.00 64/69 0.70 (0.44, 1.13) 0.331 
0.01-9.23 126/109 1.00 92/81 0.97 (0.65, 1.44) 
 
>9.23 104/117 1.00 64/89 0.87 (0.57, 1.35) 
 CAT (rs480575) A/G 
  
 
<0.01 90/71 1.00 77/76 0.76 (0.48, 1.22) 0.692 
0.01-9.23 107/85 1.00 104/98 0.83 (0.55, 1.24) 
 
>9.23 93/99 1.00 79/100 0.91 (0.60, 1.39) 
 CAT (rs1001179) C/T d 
 <0.01 103/95 1.00 70/53 1.36 (0.83, 2.21) 0.043 
0.01-9.23 149/126 1.00 75/71 0.89 (0.59, 1.34) 
 >9.23 100/143 1.00 82/69 1.61 (1.06, 2.45) 
 COMT (rs4680) G/A e 
 <0.01 46/37 1.00 128/116 0.81 (0.47, 1.40)  0.446 
0.01-9.23 64/54 1.00 162/142 0.99 (0.64, 1.53) 
 >9.23 56/52 1.00 130/160 0.78 (0.49, 1.23) 
 COMT (rs737865) T/C f 
 <0.01 89/77 1.00 80/76 0.97 (0.60, 1.56) 0.439 
0.01-9.23 109/87 1.00 118/107 0.88 (0.59, 1.30) 
 >9.23 77/98 1.00 102/114 1.11 (0.74, 1.68) 
 GPX (rs1050450) C/T g 
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<0.01 97/82 1.00 93/70 1.46 (0.92, 2.34) 0.349 
0.01-9.23 107/97 1.00 120/96 1.08 (0.73, 1.61) 
 >9.23 79/103 1.00 103/109 1.18 (0.78, 1.79) 
 GSTA1 (rs3957356) G/A h 
 <0.01 49/48 1.00 124/104 1.11 (0.67, 1.84) 0.295 
0.01-9.23 76/68 1.00 151/126 1.07 (0.71, 1.63) 
 >9.23 59/61 1.00 124/152 0.84 (0.54, 1.30) 
 GSTP1 (rs1695) A/G i 
 <0.01 84/80 1.00 90/68 1.22 (0.77, 1.95) 0.006 
0.01-9.23 123/80 1.00 97/109 0.56 (0.38, 0.84) 
 >9.23 76/92 1.00 103/120 1.08 (0.71, 1.64) 
 GSTM1 (Null vs. Present) j 
 <0.01 72/73 1.00 86/65 1.40 (0.86, 2.28) 0.387 
0.01-9.23 105/99 1.00 111/78 1.38 (0.92, 2.08) 
 >9.23 93/108 1.00 82/88 1.12 (0.73, 1.71) 
 GSTT1 (Null vs. Present) k 
 <0.01 124/109 1.00 34/31 0.92 (0.51, 1.64) 0.526 
0.01-9.23 175/136 1.00 42/42 0.78 (0.48, 1.28) 
 >9.23 139/153 1.00 36/47 0.96 (0.58, 1.60) 
 MnSOD (rs4880) T/C l 
 <0.01 46/39 1.00 128/110 0.87 (0.51, 1.48) 0.195 
0.01-9.23 59/57 1.00 164/138 1.17 (0.76, 1.81) 
 >9.23 57/51 1.00 125/161 0.74 (0.47, 1.16) 
 MPO (rs2333227) G/A m 
 <0.01 105/95 1.00 69/57 1.16 (0.72, 1.87) 0.119 
0.01-9.23 144/112 1.00 82/84 0.76 (0.51, 1.14) 
 >9.23 109/136 1.00 74/76 1.16 (0.76, 1.76)   
a Postmenopausal RPA ≤ 9.23 hrs/wk (OR=0.99; 95% CI, 0.77-1.26) RPA > 9.23 hrs/wk (OR=0.77; 95% CI, 0.60-0.99) 
b
 Cases (Ca) and controls (Co) 
c Odds ratio (OR) and 95% confidence interval (CI) 
d
 Ahn et al. Am J Epidemiol. (2005) Postmenopausal OR=1.15; 95% CI, 0.92-1.43 
Note: Previous report used recessive model  
e
 Gaudet et al. Breast Cancer Res Treat. (2006) Postmenopausal OR=0.90; 95% CI, 0.70-1.14 
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f
 Gaudet et al. Breast Cancer Res Treat. (2006) Postmenopausal OR=0.91; 95% CI, 0.73-1.13 
g
 Ahn et al. Cancer Epidemiol Biomarkers Prev. (2005) Postmenopausal OR=1.13; 95% CI, 0.91-1.41 
h
 Ahn et al. Carcinogenesis. (2006) Postmenopausal OR=1.04; 95% CI, 0.83-1.31 
i
 Steck et al. J Nutr. (2007) Postmenopausal OR=0.93; 95% CI, 0.74-1.15 
j
 Steck et al. J Nutr. (2007) Postmenopausal OR=1.21; 95% CI, 0.97-1.52 
k
 Steck et al. J Nutr. (2007) Postmenopausal OR=0.92; 95% CI, 0.70-1.21 
l
 Gaudet et al. Cancer Causes Control. (2005) Postmenopausal OR=0.99; 95% CI, 0.81-1.21 
m
 Ahn et al. Cancer Res. (2004) Postmenopausal OR=0.91; 95% CI, 0.73-1.14 
Note: Previous report adjusted for age, family history and parity 
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Chapter IV: Polymorphisms in DNA Repair Genes, Recreational physical Activity and 
Breast Cancer Risk 
4.1 Introduction 
Damage to DNA may occur through a variety of endogenous or exogenous 
processes including oxidative damage through the generation of reactive oxygen species 
(ROS) [179]. If these compounds are not neutralized by endogenous antioxidants they have 
the capacity to react with biomolecules causing damage. The integrity of DNA is primarily 
maintained by four repair pathways that operate on impaired DNA: base excision repair 
(BER), double strand break (DSB) repair, nucleotide excision repair (NER) and mismatch 
repair (MMR) [181]. Of these, MMR is the least studied in breast carcinogenesis. MMR 
improves replication fidelity by correcting DNA polymerase-mediated replication errors [181, 
326]. MMR gene dysfunction is proposed to occur through one of two mechanisms: 
epigenetic gene silencing or genetic mutations in one of six genes associated with MMR 
[210, 249, 250]. These changes may lead to increased mutations of oncogenes, tumor 
suppressor genes, and loss of DNA damage-induced apoptosis, therefore facilitating 
carcinogenesis [251].  
Microsatellite instability (MSI), characterized as simple sequence repeats in DNA, is 
closely associated with MMR deficiency [181, 241] and is reported to be present in some 
breast tumors [236-240, 327]. Moreover, there is accumulating evidence that reduced tumor 
expression of MSH2 and MLH1 are related to breast tumor progression and invasion [202, 
255, 257]. While these data suggest a potential role for MMR in breast cancer susceptibility 
[239] there are few epidemiologic studies examining associations between germline 
polymorphisms in MMR and breast cancer incidence [225, 228, 233-235]. These data are 
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mixed and previous investigations have been limited by small samples or less than optimal 
designs making additional studies warranted. 
Polymorphisms in MMR or other DNA repair genes may interact with environmental 
exposures to influence carcinogenesis [183], even if the main effect of repair variants on 
breast cancer risk is small or null. Physical activity (PA) is known to be associated with 
breast cancer risk, particularly among postmenopausal women, but the complex 
physiological effects of exercise make the mechanisms driving the inverse association 
difficult to disentangle. While PA is an important contributor to ROS production, regular 
exercise may improve damage repair systems [170, 171, 267, 268], particularly those that 
operate on single-strand breaks induced by oxidation (i.e. BER, NER and MMR). Animal 
and clinical studies have shown that several DNA repair enzymes are up-regulated with long 
term exercise [269-272, 328]. These changes likely result in increased resistance to 
oxidative damage, diminished DNA impairment and a lower probability of initiating events. 
This could be tested through epidemiologic analyses assessing the joint effects of low PA 
and reduced DNA repair capacity on breast cancer incidence, but to date no study has 
considered this approach despite the biologic plausibility.  
We hypothesized that MMR variants related to reduced repair capacity may be 
associated with increased breast cancer risk. We also anticipate that genotypes associated 
with reduced DNA repair act synergistically with low levels of PA to increase the risk of 
breast cancer greater than would be expected by their individual effects. In this report, we 
aimed to: (1) examine the main effect of variants in MMR on breast cancer risk; (2) examine 
two-way interactions between SNPs in the MMR pathway and breast cancer incidence; and 
(3) examine the joint effects of recreational physical activity (RPA) and variants in DNA 
repair genes from the BER, NER and MMR pathways on breast cancer risk. Secondary aims 
were to evaluate associations between CAT polymorphisms and breast cancer with cases 
categorized according to tumor hormone receptor status, as well as to examine the 
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combined effect of MMR SNPs on breast cancer incidence using a pathway-based 
approach.   
4.2 Materials and Methods  
Resources for this project were drawn from the Long Island Breast Cancer Study 
Project (LIBCSP), a population-based investigation conducted on Long Island, New York. 
Details of the case-control study have been previously described [18]. This study was 
approved by the Institutional Review Board of the collaborating institutions. 
4.2.1 Study population  
LIBCSP case women were English speaking residents of Nassau and Suffolk 
counties in New York (NY) aged 20-98 years and newly diagnosed with a first primary in-situ 
or invasive breast cancer between August 1, 1996 and July 31, 1997. Population-based 
controls, without a personal history of breast cancer, were randomly selected from the same 
two counties using random digit dialing for women under age 65 and rosters from the Health 
Care Finance Administration for women ages 65 and older. Controls were frequency 
matched to the expected age distribution of case women by 5-year age groups. Distributions 
by race were similar for cases and controls (94% white, 4% black, and 2% other), and are 
consistent with the resident populations for these NY counties [18].  
Exposure and covariate data were obtained through an interviewer-administered 
structured questionnaire. Interviews were completed for 82.1% (n=1508) of eligible cases 
and 62.8% (n=1556) of controls. Among the women who completed an interview, blood 
samples were donated by 73.1% and 73.3% of cases and controls, respectively. Women 
who donated a blood sample differed somewhat from non-blood donors on key 
characteristics including age and race; blood donors more likely to be younger in age and 
white [18]. Genotyping was unavailable for 4.4% of cases and 3.4% of controls primarily due 
to insufficient DNA quantity. Thus, the final sample includes 1053 case and 1102 control 
women.  
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4.2.2 Single Nucleotide Polymorphism (SNP) Selection and Genotyping  
We selected five tag SNPs (MSH3: rs1650663; MLH1: rs2286940; MSH2: 
rs2303428, rs3732182 and rs4583514) and one functional variant (MLH1: rs1799977, a 
single non-synonymous base pair change affecting splicing regulation) from three genes in 
the MMR pathway for genotyping. A tagging strategy was employed to maximize our ability 
to capture genetic variation across the each gene. The National Institute of Environmental 
Health Service SNPinfo database [284] was used to select Tag SNPs based on data from 
phase I and II of the International HapMap Project [285]. The CEU population (30 Utah trios 
with ancestry from northern and western Europe) was selected as the reference panel given 
the racial homogeneity of the LIBCSP population with DNA available for analyses (93.4% 
White and 6.6% Non-White) [224]. SNP selection procedures were based on a minor allele 
frequency (MAF) cutoff value of 5% and r2 threshold minimum of 0.80 as well as a 
combination of factors including SNP location, MAF and bin size. In addition to the 
aforementioned MMR SNPs, we selected 14 presumed functional variants from 9 genes in 
BER and NER pathways to assess interactions with RPA: ERCC1 (rs3212986), MGMT 
(rs12917, rs2308321 and rs2308327), OGG1 (rs1052113), XPA (rs1800975), XPC 
(rs2228000 and rs2228001), XPD (rs1799793 and rs13181), XPF (rs1800067), XPG  
(rs17655), XRCC1 (rs1799782 and rs25487).  
A non-fasting 40 mL blood sample was obtained from participants at time of interview 
and shipped at room temperature, overnight, for processing. Genomic DNA was extracted 
from mononuclear cells in whole blood separated by Ficoll (Sigma Chemical Co., St. Louis, 
Missouri). Pelleted cells were frozen at −80o centigrade until DNA isolation by standard 
phenol, and chloroform/isoamyl alcohol extraction and RNase treatment [18]. Genotyping of 
newly selected CAT SNPs was accomplished using Taqman assays (Applied Biosystems, 
Foster City, CA) with 384-well plates. For the remaining SNPs genotyping was performed 
using several high-throughput genotyping methods, which have varied over the course of 
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the study. The fluorescence polarization (FP) method, as described by Chen and 
colleague’s [329], was used to genotype ERCC1, MGMT, OGG1, XPC, XPD (rs13181) and 
XRCC1. XPA and XPD (rs1799793) were genotyped using Taqman assays described 
above. Genotyping for XPF and XPG was accomplished using Sequenom’s high-throughput 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, previously 
reported by Ahn and colleagues [299]. Controls for genotype and two non-template controls 
were included on each plate. Samples that were outside the variables defined by the 
controls were identified as non-informative and retested. Ten percent of samples were 
distributed throughout the DNA samples for quality control and laboratory personnel blinded 
to case-control status.  
4.2.3 RPA and Covariate Assessment  
Other data for this project comes from the interviewer-administered LIBCSP 
questionnaire and, for cases, medical record abstraction. The comprehensive questionnaire 
lasted approximately 101 minutes, and was completed on average within 3 months of 
diagnosis for cases, and 6 months of study identification for controls. Study participants 
were asked about their demographic characteristics; reproductive, medical and 
environmental histories; cigarette smoking and alcohol use; use of exogenous hormones; 
energy intake; participation in PA, and select anthropometric measurements. RPA was 
assessed using a modified instrument developed by Bernstein and colleagues [274]. 
Women were screened for RPA participation by replying to the question: “Have you ever 
participated in any activities or exercises on a regular basis – that is, for at least 1 hour per 
week for 3 months or more in any year?” Women answering negatively were classified as 
having no RPA while subjects answering positively were further queried about their 
involvement. For these women the activity name, the ages the activity was started and 
stopped, and the number of hours per week and months per year the activity was performed 
were obtained. Activity data was summed across all activities for each year of a woman’s 
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life, providing a composite score of exercise duration from menarche (left truncated) to 
reference date. In this analysis we assessed the interaction between variants in DNA repair 
genes and two PA variables for which the effects for breast cancer were strongest in the 
LIBCSP population [63]: average hours per week of postmenopausal and lifetime RPA. Our 
findings showed little or no heterogeneity by RPA-intensity [63]. 
Among case women, clinical data (including hormone receptor [HR] status of the first 
primary breast cancer) were obtained from abstracting medical records.  
4.2.4 Statistical Methods 
All analyses were conducted using SAS 9.1 (Cary, NC). Evaluation of Hardy-
Weinberg equilibrium (HWE) was conducted using observed genotype frequencies among 
White controls and X2 test with 1 degree of freedom [292]. Odds ratios (ORs) and 
corresponding 95% CIs for the independent effects of MMR SNPs, their interactions, and 
the joint effect of DNA repair variants and RPA were estimated by unconditional logistic 
regression [300]. SNPs effects were assessed using a dominant genetic model because of 
the low prevalence of the homozygous recessive genotype among MMR SNPs.  
Main effects of MMR variants on breast cancer risk were assessed among all women 
combined, and within strata of menopausal status (pre vs. post) when the Breslow-Day p for 
homogeneity was <0.10 [317]. Effects were also evaluated by breast cancer subtype 
according to HR status, by stratifying cases into two HR groups using information on 
estrogen receptor (ER) and progesterone receptor (PR) status. Women who were ER or PR 
positive were classified as HR+ (which is consistent with considering luminal A and B 
intrinsic subtypes as a single group), while women with tumors that were negative for both 
ER and PR receptors were classified as HR- [302].  
Two-way interactions between MMR genes and breast cancer risk were assessed 
using a likelihood ratio test (LRT): the difference of the -2LogL values of logistic models 
calculated with and without the interaction terms for SNP1 and SNP2 [303]. For our MMR 
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pathway-based analysis we combined MMR genotypes, and calculated age-adjusted ORs 
for breast cancer stratifying on the number of ‘variant’ genotypes: 0-3, 4-7, ≥8 using 
methods previously described by Mohrenweiser [330].  
Additive and multiplicative gene by environment interactions were assessed using 
indicator terms for women with the genotype only, exposure only, and both the genotype 
and exposure of interest. A dominant genetic model was used for all SNPs. Among 
physically active women, participants were classified into categories based on the median 
average hours per week among controls creating three levels of RPA: no, low (< control 
medium), and high (≥ control median) RPA. Departures from the multiplicative null were 
assessed using the LRT, comparing a model with and without the interaction terms [317]. 
Departures from the additive null were estimated by the interaction contrast ratio (ICR) 
based on the formula: ICR= OR11–OR01–OR10+1 [303].  
Covariates considered as potential confounders for MMR variants were first degree 
family history of breast cancer (yes/no), race (categorical), and religion (categorical). For 
RPA, potential covariates included education (categorical), family history of breast cancer 
(yes/no), history of benign breast disease (yes/no), income (categorical), lactation history 
(ever/never), use of oral contraceptives (ever/never), parity (categorical), and smoking 
history (never, current, former) and were included in the final model if their inclusion 
changed the exposure estimate by > 10% [301]. None of these altered the estimate by 
greater than 10%. Final models were adjusted only for 5-year age group.  
4.3 Results  
4.3.1 Hardy Weinberg Equilibrium 
Genotype frequencies for polymorphisms in MSH3 (rs1650663) MLH1 (rs1799977, 
rs2286940) and MSH2 (rs2303428, rs3732182, rs4583514) are reported in Table 1. All 
genotypes were consistent with HWE. 
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4.3.2 Main SNP Effects   
There was no evidence of a main effect for any of the individual MMR minor alleles 
on breast cancer risk (Table 4.1), and these findings did not change materially with 
menopausal status (Table A.19). When we restricted these analyses to Whites only, results 
were similar to those observed among the entire study population. For some variants (MLH1 
rs1799977, MLH1 rs2286940, and MSH2 rs2303428) there was suggestion of heterogeneity 
by HR status (Table A.21). We observed moderate risk reductions for the minor alleles of 
rs1799977, rs2286940, and rs2303428 among HR negative cases (OR; 95% CI = 0.77; 
0.52-1.12, 0.69; 0.46-1.01 and 0.71; 0.39-1.27, respectively) and approximately null or 
slightly increased risk among HR positive cases (OR; 95% CI = 1.11; 0.89-1.37, 0.99; 0.78-
1.24 and 1.15; 0.86-1.54, respectively). There was no evidence of tumor heterogeneity by 
HR status for the remaining MMR polymorphisms (Table A.21).  
4.3.3 Gene-Gene (GxG) Interactions 
We evaluated all potential 2-way multiplicative interactions among MMR genes and 
found one significant effect between MLH1 (rs1799977) and MSH2 (rs2303428) (p for 
multiplicative interaction = 0.045). The modest decrease in breast cancer risk among minor 
allele carriers of the MLH1 (OR=0.81; 95% CI, 0.58-1.14) or MSH2 (OR=0.94; 95% CI, 0.77-
1.14) was antagonistically reversed among women who carried at least one minor allele in 
both genes (OR=1.25; 95% CI, 0.88-1.76) compared with women who were homozygous 
dominant for both MLH1 and MSH2, although the effect was not statistically significant 
(Table A.39).  
We found little or no association with breast cancer upon combining genotypes 
across the MMR pathway (Table A.25).  
4.3.4 Gene-Environment (GxE) Interactions 
The main effects of RPA [63] and DNA repair [122, 222, 224, 259, 260, 331] genes 
on breast cancer risk have been published previously in the LIBCSP study population [63],  
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although no study had previously reported DNA repair SNP-RPA interactions. In the 
LIBCSP, the effect estimate of moderate postmenopausal RPA (<9.24 hrs/wk) was near null 
(OR=0.99; 95% CI: 0.77-1.26), while high postmenopausal RPA (≥ 9.24 hrs/wk) was 
associated with reduced risk of postmenopausal breast cancer (OR=0.77; 95% CI: 0.60-
0.99) [63]. When we restricted these analyses to women with data available for genotyping 
we found similar, but more pronounced, effects for moderate and high postmenopausal 
RPA. SNP-specific main effects for the genes of interest showed no significant association 
with breast cancer risk. These data are summarized in Table 4.2 to facilitate understanding 
of SNP-RPA interactions shown in Table 4.3 and reported below.  
Our models did not support the presence of additive interactions between RPA and 
DNA repair genotypes (Tables A.33-A.34).  However, when we considered multiplicative 
interactions, significant results (p ≤ 0.05) were observed for lifetime RPA among all women 
and women carrying variants in MGMT, OGG1, XPC, XPF, and XPG (Table 4.4).  The 
interaction between MLH1 and lifetime RPA was near significant (p=0.051). Effect estimates 
were stronger and more consistent once we restricted our models to postmenopausal 
participants only. As shown in Table 4.3, we found statistically significant multiplicative 
interactions between postmenopausal RPA and several DNA repair gene polymorphisms 
including: XPC Ala499Val (rs2228000, p=0.048), XPF Arg415Gln (rs1800067, p=0.012), 
XPG Asp1104His (rs17655, p=0.022) and MLH1 lle219Val (rs1799977, p=0.010). 
Postmenopausal women homozygous for the major alleles of XPC Ala499Val or XPF 
Arg415Gln who engaged in greater than 9.23 hrs/wk of RPA from menopause to reference 
date experienced statistically significant reductions in breast cancer risk (OR=0.57; 95% CI, 
0.38-0.84 and OR=0.64; 95% CI, 0.46-0.89, respectively) compared to women homozygous 
for the major alleles who were inactive (<0.01 hrs/wk). Postmenopausal women with minor 
alleles in XPG Asp1104His and MLH1 lle219Val who were inactive during the 
postmenopausal years were at greatest risk of breast cancer risk (OR=1.42; 95% CI, 0.90-
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2.25 and OR=1.63; 95% CI, 1.04-2.56, respectively) compared to inactive women who 
carried no minor alleles. Although involvement in RPA attenuated the increased risk 
associated with minor allele carriers, the effects were not statistically significant.  
4.4 Discussion  
In the current study, we found no association between MMR variants and breast 
cancer risk. There was evidence of a significant gene-gene interaction on the multiplicative 
scale for MLH1 (rs1799977) and MSH2 (rs2303428); women who harbored minor alleles in 
both genes were at greater risk of breast cancer than women who carried no minor alleles or 
minor alleles in only one gene. Given both genes are necessary components for the MMR 
complex our finding of interaction on the multiplicative scale is biologically plausible [210].  
When we assessed the combined effects of MMR genes by counting the number of minor 
alleles, we found no indication of association with breast cancer risk.  
Our study also provides some evidence for modification of DNA repair genotype 
effect by postmenopausal activity level. Highly active women homozygous for the major 
allele in XPC Ala499Val and XPF Arg415Gln experienced significant breast cancer risk 
reductions compared to inactive women with the same genotype. In addition, we observed 
increased breast cancer risk among inactive women with minor alleles in XPG Asp1104His 
and MLH1 lle219Val compared to inactive women who were homozygous for the major 
allele. Our findings suggest that low RPA may augment breast cancer risk among women 
with variant alleles in DNA repair genes and that high levels of RPA could be particularly 
beneficial to women who are homozygous for the major allele. 
While there are several studies that assess the association between MMR variants 
and cancer risk, particularly for colorectal cancer, few investigations have been reported for 
breast cancer. Previous breast cancer studies [225, 228, 233-235] have reported significant 
associations with minor alleles in MMR SNPs, which may vary by menopausal status. But 
results are inconsistent, conducted among different international populations with varying 
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genetic profiles, and based on small, select samples. In our larger population-based study 
conducted among primarily white women on Long Island, NY, we found little evidence for 
associations between MMR polymorphisms and breast cancer, even when we considered 
menopausal status. These findings warrant additional investigation in larger studies with 
diverse populations as our data were suggestive of differences by HR status.  
Although previous studies indicate modest effects of DNA repair variants on breast 
cancer outcomes, it is possible that associations between some DNA repair variants and 
cancer risk may be apparent only in the presence of DNA damaging/repairing agents. 
Several investigations of breast cancer, including our own, have been suggestive of 
interactions between DNA repair polymorphisms and cigarette smoking, alcohol drinking, 
radiation exposure, body mass, intake of fruits, vegetables and antioxidant micronutrients [5, 
122, 228, 229, 259-264, 266]. Data from animal and clinical studies show that DNA repair 
can be up-regulated with long term exercise, but to our knowledge our report is the first 
epidemiologic study to consider interactions between PA, DNA repair and breast cancer risk 
among women.  
PA has consistently been shown to increase the formation of reactive oxygen and 
nitrogen species [119, 163, 164], which may influence carcinogenesis. Regular exercise 
training can also result in improvement of damage repair systems [170, 171, 267, 268]. A 
2002 study by Radak and colleagues [270] showed that regular exercise decreased the 
accumulation oxidative stress-induced 8-oxodeoxyguanosine (8-oxo-dG) lesions in the 
skeletal muscle of exercised rats. These lesions are excised exclusively by 8-oxoguanine 
DNA glycosylase, the enzyme encoded by OGG1 [180]. Similarly, investigators found that 8-
oxo-dG repair, measured by the nicking of a 32P-labeled damaged oligonucleotide, 
increased in the muscle of exercising animals as did the chymotrypsin-like activity of the 
proteasome complex, a repair enzyme important in the degradation of proteins modified by 
oxidative stress [270]. Clinical studies have shown that trained cyclists [271] and marathon 
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runners [272] exhibit up-regulation of DNA excision repair enzymes NESP and RAD23A 
[271], as well as OGG1 [272].  
We hypothesized that up-regulation of DNA repair enzymes might be an important 
part of the exercise induced adaptation process and that these changes could reduce the 
likelihood of initiating events in breast carcinogenesis. Our study results lend support to this 
hypothesis, as we found significant multiplicative interactions between variants in several 
DNA repair genes and both lifetime and postmenopausal RPA. The current data suggest 
that women who are homozygous for the major allele and engage in high postmenopausal 
RPA may be at reduced risk of postmenopausal breast cancer compared to their inactive 
counterparts. Moreover, women who are inactive and harbor minor DNA repair alleles may 
be at greater risk of breast cancer. While these findings support our hypothesis and are 
biologically plausible, the functional significance of many DNA repair gene polymorphisms 
remains largely unknown [216, 229]. Determining functional status of variants is challenging 
because of differences in study population characteristics, variations in assay used between 
studies, and limited ability to detect changes in DNA repair capacity based on single SNP 
analysis [332]. Both replication and additional mechanistic data are necessary to fully 
understand the PA, DNA repair, breast cancer association.   
Our study has several limitations. In the LIBCSP, blood donation varied by both age 
and race [18]. While genotype is likely associated with race, given the small number of non-
white women included in the study racial variations in blood donation is likely negligible. 
Moreover, when we restricted our analyses to White women, we observed little change in 
effect estimates. While our ability to generalize findings to non-white racial groups is limited, 
we believe that this study may provide clues about the underlying biologic mechanisms of 
DNA repair and RPA, which likely do not vary by race. Inaccurate recall of exposure 
variables may have biased our study results. However, neither cases nor controls were 
aware of their genotype at the time of the interview. Although exposure information on RPA 
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may be differentially recalled by cases and controls, this misclassification would not likely be 
differential by genotype. Finally, even with a sample size of 2000+ women, we were limited 
in our ability to detect modest GxE associations. Our results will therefore need to be 
confirmed in larger studies with similarly detailed assessment of RPA but expanded genetic 
data to capture additional variability in the MMR pathway. Multiple comparisons is a 
consideration in this study, as there were no a priori evidence that an association exists 
between PA, DNA repair variants and breast cancer. Given we selected genes based on 
their biologic relevance to breast cancer and PA, we were primarily interested in estimating 
effect estimates and corresponding 95% confidence intervals without adjusting for multiple 
comparisons. However, this approach could result in chance findings. The population-based 
study design, hypothesis-driven DNA repair SNP selection and testing, and detailed 
exposure assessment, are strengths of this study.  
In conclusion, we found little evidence to indicate that any of the six MMR 
polymorphisms investigated were associated with breast cancer risk. We did find evidence 
of an interaction between two SNPs in MLH1 (rs1799977) and MSH2 (rs2303428) and 
breast cancer risk. These genes are central to all mismatch recognition and alterations in 
them have been shown to be the most common mechanism inducing cancer-related MSI 
[252-254]. They may therefore play an important role in breast carcinogenesis. We 
previously reported significant inverse associations between RPA performed after 
menopause and postmenopausal breast cancer risk [63], and, in this report we find that this 
protection may be partially dependent upon DNA repair status, particularly XPC 499 C-
allele, XPF 415 G-allele, XPG 1104 C-allele, and MLH1 219 G-allele status. Our findings 
provide clues toward understanding the underlying role of DNA repair in the PA-breast 
cancer association. For example, our results suggest that exercise could result in up-
regulation of certain DNA repair enzymes lowering cancer risk. While the functional 
significance of many DNA repair polymorphisms with respect to breast cancer remains 
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largely unknown, the observed associations are consistent across multiple indicators of 
physical activity and repair pathways reducing the likelihood that these findings are 
attributable to chance. Our results therefore merit further investigation.    
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TABLE 4.1 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Association between 
Mismatch Repair Genes and Breast Cancer Risk. The Long Island Breast Cancer Study Project (1996-
1997).  
 
Cases  
(N=1053)  
Controls  
(N=1102) OR 95% CI 
Gene (rs) Genotype N 
 
% 
 
N 
 
% 
  
MSH3 (rs1650663) TT 497 
 
49.35% 
 
530 
 
49.58% 1.00 Reference 
 
CT 412 
 
40.91% 
 
429 
 
40.13% 1.02 (0.85, 1.22) 
 
CC 98 
 
9.73% 
 
110 
 
10.29% 0.98 (0.72, 1.32) 
 
CT and CC 510 
 
50.64% 
 
539 
 
50.42% 1.01 (0.85, 1.20) 
MLH1 (rs1799977) AA 503 
 
49.75% 
 
542 
 
50.56% 1.00 Reference 
 
AG 410 
 
40.55% 
 
443 
 
41.32% 0.98 (0.81, 1.17) 
 
GG 98 
 
9.69% 
 
87 
 
8.12% 1.17 (0.85, 1.60) 
 
AG and GG 508 
 
50.24% 
 
530 
 
49.44% 1.01 (0.85, 1.20) 
MLH1 (rs2286940) CC 340 
 
33.83% 
 
342 
 
31.84% 1.00 Reference 
 
CT 467 
 
46.47% 
 
541 
 
50.37% 0.85 (0.70, 1.04) 
 
TT 198 
 
19.70% 
 
191 
 
17.87% 1.01 (0.79, 1.30) 
 
CT and TT 665 
 
66.17% 
 
732 
 
68.24% 0.89 (0.74, 1.08) 
MSH2 (rs2303428) TT 828 
 
83.98% 
 
886 
 
84.14% 1.00 Reference 
 
CT 150 
 
15.21% 
 
155 
 
14.72% 1.07 (0.83, 1.36) 
 
CC 8 
 
0.81% 
 
12 
 
1.14% 0.66 (0.27, 1.66) 
 
CT and CC 158 
 
16.02% 
 
167 
 
15.86% 1.04 (0.81, 1.32) 
MSH2 (rs3732182) GG 542 
 
54.36% 
 
574 
 
53.75% 1.00 Reference 
 
GT 375 
 
37.61% 
 
411 
 
38.48% 0.98 (0.82, 1.18) 
 
TT 80 
 
8.02% 
 
83 
 
7.77% 1.04 (0.74, 1.45) 
 
GT and TT 455 
 
45.63% 
 
494 
 
46.25% 0.99 (0.83, 1.18) 
MSH2 (rs4583514) GG 394 
 
39.01% 
 
404 
 
37.69% 1.00 Reference 
 
AG 485 
 
48.02% 
 
521 
 
48.60% 0.96 (0.80, 1.16) 
 
AA 131 
 
12.97% 
 
147 
 
13.71% 0.93 (0.70, 1.23) 
  AG and AA 616   60.99%   668   62.31% 0.95 (0.80, 1.14) 
OR, odds ratio; 95% CI, 95% confidence interval 
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TABLE 4.2 Age Adjusted Odds Ratios and 95% Confidence 
Intervals for the Main Effects of DNA Repair Genes on 
Postmenopausal Breast Cancer Risk. The Long Island Breast 
Cancer Study Project (1996-1997).  
SNPs for Gene-Environment Interactions OR 95% CI 
Gene Effect (Dominant Models) 
  Gene (rs) major/minor alleles 
  ERCC1 (rs3212986) C/A1 1.16 (0.93, 1.44) 
MGMT (rs12917) C/T2 1.12 (0.88, 1.43) 
MGMT (rs2308321) A/G2 0.89 (0.69, 1.15) 
MGMT (rs2308327) A/G2 0.85 (0.65, 1.11) 
OGG1 (rs1052133) C/G3 0.95 (0.76, 1.18) 
XPA (rs1800975) G/A1 1.04 (0.84, 1.29) 
XPC (rs2228000) C/T4 1.07 (0.86, 1.33) 
XPC (rs2228001) A/C4 0.99 (0.79, 1.25) 
XPD (rs1799793) G/A1 1.15 (0.92, 1.43) 
XPD (rs13181) A/C5 1.16 (0.93, 1.44) 
XPF (rs1800067) G/A1 1.03 (0.77, 1.40) 
XPG (rs17655) G/C1 0.98 (0.78, 1.22) 
XRCC1 (rs1799782) C/T6 1.00 (0.72, 1.38) 
XRCC1 (rs25487) G/A6 0.99 (0.80, 1.24) 
MSH3 (rs1650663) T/C 1.07 (0.86, 1.33) 
MLH1 (rs1799977) A/G 1.00 (0.80, 1.24) 
MLH1 (rs2286940) C/T 0.83 (0.66, 1.05) 
MSH2 (rs2303428) T/C 1.00 (0.73, 1.36) 
MSH2 (rs3732182) G/T 1.11 (0.89, 1.38) 
MSH2 (rs4583514) A/G 1.00 (0.80, 1.24) 
OR, odds ratio; 95% CI, 95% confidence interval  
1
 Crew et al. Cancer Epidemiol Biomarkers Prev. (2007)  
  
2
 Shen et al. Carcinogenesis. (2005) 
  3
 Rossner et al. Cancer Epidemiol Biomarkers Prev. (2006) 
 4
 Shen et al. Eur J. Cancer. (2008)   
  5
 Terry et al. Cancer Epidemiol Biomarkers Prev. (2004)  
  6
 Shen et al. Cancer Epidemiol Biomarkers Prev. (2005)  
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TABLE 4.3 Age Adjusted Odds Ratios and 95% Confidence Intervals for Multiplicative Effects of 
DNA Repair SNPs and Recreational Physical Activity on Postmenopausal Breast Cancer Risk. The 
Long Island Breast Cancer Study Project (1996-1997). 
 
Homozygous for major allele At least one copy of minor allele 
Gene (SNP) major/minor 
alleles 
          Postmenopausal RPA 
Ca/Co OR  (95% CI) Ca/Co OR  (95% CI) 
ERCC1 (rs3212986) C/A 
<0.01 hrs/wk 93/84 1.00 reference  82/71 1.00 (0.64, 1.55) 
0.01-9.23 hrs/wk  128/116 0.96 (0.65, 1.43) 104/82 1.14 (0.75, 1.73) 
>9.23 hrs/wk 93/114 0.70 (0.46, 1.05) 92/98 0.78 (0.52, 1.19) 
MGMT (rs12917) C/T 
<0.01 hrs/wk 137/113 1.00 reference  40/40 0.83 (0.50, 1.38) 
0.01-9.23 hrs/wk  163/141 0.96 (0.68, 1.34) 70/59 0.99 (0.64, 1.53) 
>9.23 hrs/wk 128/162 0.64 (0.45, 0.90) 58/50 0.87 (0.55, 1.39) 
MGMT (rs2308321) A/G 
<0.01 hrs/wk 141/125 1.00 reference  36/28 1.16 (0.66, 2.03) 
0.01-9.23 hrs/wk  175/149 1.04 (0.75, 1.45) 58/50 1.05 (0.67, 1.66) 
>9.23 hrs/wk 143/159 0.77 (0.55, 1.07) 43/53 0.68 (0.42, 1.10) 
MGMT (rs2308327) A/G 
<0.01 hrs/wk 149/130 1.00 reference  29/25 1.04 (0.57, 1.88) 
0.01-9.23 hrs/wk  186/156 1.04 (0.76, 1.44) 47/44 0.96 (0.59, 1.55) 
>9.23 hrs/wk 145/163 0.75 (0.54, 1.04) 42/50 0.70 (0.43, 1.13) 
OGG1 (rs1052133) C/G 
<0.01 hrs/wk 113/90 1.00 reference  64/61 0.82 (0.52, 1.28) 
0.01-9.23 hrs/wk  128/122 0.83 (0.57, 1.21) 94/73 1.02 (0.67, 1.55) 
>9.23 hrs/wk 106/118 0.69 (0.47, 1.02) 75/91 0.61 (0.40, 0.92) 
XPA (rs1800975) G/A 
<0.01 hrs/wk 84/73 1.00 reference  93/81 0.98 (0.63, 1.53) 
0.01-9.23 hrs/wk  110/83 1.15 (0.75, 1.77) 121/112 0.93 (0.62, 1.41) 
>9.23 hrs/wk 75/97 0.64 (0.41, 0.99) 112/115 0.80 (0.53, 1.22) 
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XPC (rs2228000) C/T 
<0.01 hrs/wk 93/81 1.00 reference  71/67 0.83 (0.53, 1.30) 
0.01-9.23 hrs/wk  121/112 0.83 (0.56, 1.22) 109/82 1.11 (0.74, 1.68) 
>9.23 hrs/wk 112/115 0.57 (0.38, 0.84) 91/86 0.82 (0.54, 1.25) 
XPC (rs2228001) A/C 
<0.01 hrs/wk 67/44 1.00 reference  110/108 0.68 (0.42, 1.09) 
0.01-9.23 hrs/wk  75/65 0.79 (0.47, 1.32) 156/131 0.79 (0.50, 1.23) 
>9.23 hrs/wk 55/71 0.50 (0.29, 0.84) 131/142 0.58 (0.37, 0.91) 
XPD (rs1799793) G/A 
<0.01 hrs/wk 72/64 1.00 reference  105/90 1.03 (0.66, 1.62) 
0.01-9.23 hrs/wk  92/95 0.87 (0.56, 1.37) 138/101 1.21 (0.79, 1.86) 
>9.23 hrs/wk 85/88 0.82 (0.52, 1.29) 101/125 0.68 (0.44, 1.06) 
XPD (rs13181) A/C 
<0.01 hrs/wk 66/68 1.00 reference  112/85 1.36 (0.87, 2.13) 
0.01-9.23 hrs/wk  87/88 1.05 (0.67, 1.66) 141/108 1.33 (0.87, 2.05) 
>9.23 hrs/wk 75/82 0.90 (0.56, 1.43) 107/130 0.82 (0.53, 1.27) 
XPF (rs1800067) G/A 
<0.01 hrs/wk 150/119 1.00 reference  21/27 0.57 (0.30, 1.07) 
0.01-9.23 hrs/wk  179/168 0.83 (0.60, 1.15) 43/25 1.38 (0.79, 2.40) 
>9.23 hrs/wk 150/175 0.64 (0.46, 0.89) 30/30 0.74 (0.42, 1.31) 
XPG (rs17655) G/C 
<0.01 hrs/wk 88/89 1.00 reference  80/57 1.42 (0.90, 2.25) 
0.01-9.23 hrs/wk  126/111 1.14 (0.77, 1.70) 92/81 1.15 (0.75, 1.76) 
>9.23 hrs/wk 113/107 0.98 (0.65, 1.47) 65/96 0.68 (0.44, 1.06) 
XRCC1 (rs1799782) C/T 
<0.01 hrs/wk 166/135 1.00 reference  12/19 0.56 (0.26, 1.21) 
0.01-9.23 hrs/wk  205/177 0.95 (0.70, 1.29) 28/22 1.10 (0.60, 2.03) 
>9.23 hrs/wk 160/186 0.69 (0.50, 0.94) 26/27 0.69 (0.38, 1.25) 
XRCC1 (rs25487) G/A 
<0.01 hrs/wk 64/65 1.00 reference  114/90 1.26 (0.81, 1.98) 
0.01-9.23 hrs/wk  86/80 1.05 (0.66, 1.68) 147/120 1.26 (0.82, 1.94) 
>9.23 hrs/wk 69/78 0.86 (0.53, 1.40) 118/135 0.83 (0.54, 1.28) 
MSH3 (rs1650663) T/C 
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<0.01 hrs/wk 97/79 1.00 reference  74/70 0.87 (0.55, 1.36) 
0.01-9.23 hrs/wk  103/109 0.80 (0.53, 1.20) 114/83 1.09 (0.72, 1.65) 
>9.23 hrs/wk 83/97 0.67 (0.44, 1.03) 94/113 0.65 (0.43, 0.98) 
MLH1 (rs1799977) A/G 
<0.01 hrs/wk 72/81 1.00 reference  101/70 1.63 (1.04, 2.56) 
0.01-9.23 hrs/wk  107/93 1.29 (0.84, 1.99) 110/99 1.27 (0.83, 1.94) 
>9.23 hrs/wk 93/96 1.09 (0.70, 1.68) 85/114 0.78 (0.51, 1.20) 
MLH1 (rs2286940) C/T 
<0.01 hrs/wk 50/47 1.00 reference  123/104 1.16 (0.72, 1.89) 
0.01-9.23 hrs/wk  76/55 1.37 (0.80, 2.34) 138/139 0.96 (0.60, 1.54) 
>9.23 hrs/wk 62/59 1.00 (0.58, 1.73) 114/150 0.70 (0.43, 1.12) 
MSH2 (rs2303428) T/C 
<0.01 hrs/wk 140/125 1.00 reference  25/20 1.07 (0.56, 2.05) 
0.01-9.23 hrs/wk  174/160 0.97 (0.70, 1.35) 36/31 1.04 (0.60, 1.79) 
>9.23 hrs/wk 152/176 0.73 (0.53, 1.02) 23/31 0.64 (0.35, 1.16) 
MSH2 (rs3732182) G/T 
<0.01 hrs/wk 98/82 1.00 reference  75/69 0.92 (0.59, 1.43) 
0.01-9.23 hrs/wk  108/102 0.89 (0.60, 1.34) 102/90 0.95 (0.63, 1.44) 
>9.23 hrs/wk 95/121 0.61 (0.41, 0.92) 80/88 0.76 (0.49, 1.17) 
MSH2 (rs4583514) A/G 
<0.01 hrs/wk 73/61 1.00 reference  100/90 0.96 (0.61, 1.51) 
0.01-9.23 hrs/wk  81/70 0.96 (0.60, 1.55) 135/124 0.94 (0.62, 1.44) 
>9.23 hrs/wk 71/80 0.71 (0.44, 1.15) 107/129 0.68 (0.44, 1.05) 
Ca, case; Co, control; OR, odds ratio; CI, confidence interval  
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TABLE 4.4 Age Adjusted Odds Ratios and 95% Confidence Intervals for Multiplicative Effects of 
DNA Repair SNPs and Lifetime Recreational Physical Activity on Breast Cancer Risk. The Long 
Island Breast Cancer Study Project (1996-1997). 
 
Homozygous for major allele At least one copy of minor 
allele 
Gene (SNP) major/minor 
alleles 
               Lifetime RPA  
Ca/Co OR 95% CI Ca/Co OR 95% CI 
ERCC1 (rs3212986) C/A 
      
<0.01 hrs/wk 119/122 1.00 reference  110/101 1.09 (0.75, 1.58) 
0.01-6.35 hrs/wk 227/243 1.02 (0.74, 1.39) 178/161 1.20 (0.86, 1.68) 
>6.35 hrs/wk 181/218 0.87 (0.63, 1.20) 193/204 0.99 (0.72, 1.37) 
MGMT (rs12917) C/T 
      
<0.01 hrs/wk 173/155 1.00 reference  58/67 0.78 (0.51, 1.18) 
0.01-6.35 hrs/wk 300/296 0.98 (0.75, 1.29) 107/111 0.92 (0.65, 1.31) 
>6.35 hrs/wk 276/329 0.75 (0.57, 0.99) 109/95 1.06 (0.74, 1.51) 
MGMT (rs2308321) A/G 
      
<0.01 hrs/wk 180/175 1.00 reference  51/46 1.09 (0.69, 1.71) 
0.01-6.35 hrs/wk 321/309 1.10 (0.84, 1.43) 86/96 0.92 (0.64, 1.33) 
>6.35 hrs/wk 286/322 0.90 (0.69, 1.17) 90/101 0.90 (0.63, 1.28) 
MGMT (rs2308327) A/G 
      
<0.01 hrs/wk 189/180 1.00 reference  44/43 1.00 (0.63, 1.61) 
0.01-6.35 hrs/wk 333/320 1.08 (0.83, 1.40) 74/88 0.86 (0.59, 1.24) 
>6.35 hrs/wk 294/336 0.87 (0.67, 1.13) 83/89 0.92 (0.63, 1.32) 
OGG1 (rs1052133) C/G 
      
<0.01 hrs/wk 148/132 1.00 reference  84/89 0.84 (0.57, 1.23) 
0.01-6.35 hrs/wk 214/262 0.78 (0.58, 1.05) 182/138 1.28 (0.92, 1.77) 
>6.35 hrs/wk 226/231 0.91 (0.68, 1.24) 141/187 0.68 (0.49, 0.95) 
XPA (rs1800975) G/A 
      
<0.01 hrs/wk 118/104 1.00 reference  114/118 0.83 (0.57, 1.21) 
0.01-6.35 hrs/wk 185/174 1.00 (0.71, 1.40) 218/228 0.90 (0.65, 1.25) 
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>6.35 hrs/wk 164/186 0.80 (0.57, 1.13) 211/238 0.79 (0.57, 1.09) 
XPC (rs2228000) C/T 
      
<0.01 hrs/wk 129/123 1.00 reference  102/99 0.95 (0.65, 1.38) 
0.01-6.35 hrs/wk 251/225 1.12 (0.82, 1.53) 153/179 0.88 (0.63, 1.22) 
>6.35 hrs/wk 208/252 0.80 (0.59, 1.10) 168/173 0.94 (0.68, 1.30) 
XPC (rs2228001) A/C 
      
<0.01 hrs/wk 88/71 1.00 reference  143/150 0.77 (0.52, 1.14) 
0.01-6.35 hrs/wk 124/140 0.77 (0.52, 1.15) 280/263 0.93 (0.65, 1.33) 
>6.35 hrs/wk 117/136 0.72 (0.48, 1.08) 258/289 0.74 (0.52, 1.06) 
XPD (rs1799793) G/A 
      
<0.01 hrs/wk 90/97 1.00 reference  140/125 1.21 (0.83, 1.76) 
0.01-6.35 hrs/wk 166/199 0.98 (0.68, 1.40) 237/204 1.35 (0.95, 1.91) 
>6.35 hrs/wk 144/173 0.93 (0.65, 1.35) 230/252 1.02 (0.72, 1.43) 
XPD (rs13181) A/C 
      
<0.01 hrs/wk 84/97 1.00 reference  149/124 1.41 (0.97, 2.07) 
0.01-6.35 hrs/wk 148/177 1.07 (0.74, 1.54) 250/226 1.39 (0.98, 1.97) 
>6.35 hrs/wk 131/155 1.02 (0.70, 1.49) 241/269 1.09 (0.77, 1.54) 
XPF (rs1800067) G/A 
      
<0.01 hrs/wk 191/170 1.00 reference  31/41 0.64 (0.38, 1.07) 
0.01-6.35 hrs/wk 322/315 0.98 (0.75, 1.27) 65/75 0.83 (0.56, 1.24) 
>6.35 hrs/wk 304/358 0.78 (0.60, 1.00) 56/54 0.96 (0.62, 1.48) 
XPG (rs17655) G/C 
      
<0.01 hrs/wk 117/117 1.00 reference  102/94 1.14 (0.77, 1.67) 
0.01-6.35 hrs/wk 205/211 1.06 (0.77, 1.47) 175/171 1.14 (0.81, 1.59) 
>6.35 hrs/wk 214/214 1.04 (0.76, 1.44) 140/191 0.78 (0.55, 1.09) 
XRCC1 (rs1799782) C/T 
      
<0.01 hrs/wk 212/196 1.00 reference  21/26 0.76 (0.41, 1.40) 
0.01-6.35 hrs/wk 347/349 0.99 (0.77, 1.27) 60/58 1.04 (0.69, 1.58) 
>6.35 hrs/wk 334/374 0.86 (0.67, 1.11) 42/51 0.74 (0.47, 1.17) 
XRCC1 (rs25487) G/A 
      
<0.01 hrs/wk 95/91 1.00 reference  138/132 0.99 (0.68, 1.45) 
0.01-6.35 hrs/wk 162/163 1.02 (0.70, 1.47) 245/245 1.03 (0.73, 1.46) 
>6.35 hrs/wk 134/166 0.80 (0.55, 1.16) 243/259 0.93 (0.66, 1.30) 
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MSH3 (rs1650663) T/C 
      
<0.01 hrs/wk 119/115 1.00 reference  103/104 0.97 (0.66, 1.41) 
0.01-6.35 hrs/wk 179/199 0.94 (0.68, 1.32) 201/187 1.11 (0.80, 1.55) 
>6.35 hrs/wk 175/190 0.92 (0.66, 1.28) 181/222 0.82 (0.59, 1.14) 
MLH1 (rs1799977) A/G 
      
<0.01 hrs/wk 106/123 1.00 reference  117/97 1.37 (0.94, 2.00) 
0.01-6.35 hrs/wk 204/193 1.31 (0.94, 1.82) 179/195 1.13 (0.81, 1.58) 
>6.35 hrs/wk 175/198 1.05 (0.75, 1.47) 181/214 1.00 (0.72, 1.39) 
MLH1 (rs2286940) C/T 
      
<0.01 hrs/wk 73/78 1.00 reference  150/142 1.12 (0.76, 1.67) 
0.01-6.35 hrs/wk 142/117 1.40 (0.93, 2.10) 239/274 1.00 (0.69, 1.44) 
>6.35 hrs/wk 112/127 0.99 (0.65, 1.49) 240/284 0.92 (0.64, 1.33) 
MSH2 (rs2303428) T/C 
      
<0.01 hrs/wk 180/186 1.00 reference  35/29 1.24 (0.73, 2.13) 
0.01-6.35 hrs/wk 315/322 1.08 (0.83, 1.40) 58/62 1.05 (0.69, 1.59) 
>6.35 hrs/wk 293/338 0.92 (0.71, 1.19) 56/65 0.92 (0.61, 1.40) 
MSH2 (rs3732182) G/T 
      
<0.01 hrs/wk 122/113 1.00 reference  101/106 0.90 (0.62, 1.31) 
0.01-6.35 hrs/wk 209/205 1.02 (0.73, 1.41) 166/181 0.93 (0.66, 1.30) 
>6.35 hrs/wk 185/228 0.78 (0.56, 1.07) 166/183 0.88 (0.63, 1.24) 
MSH2 (rs4583514) A/G 
      
<0.01 hrs/wk 86/84 1.00 reference  138/136 1.02 (0.70, 1.51) 
0.01-6.35 hrs/wk 148/143 1.10 (0.75, 1.62) 233/248 1.01 (0.71, 1.44) 
>6.35 hrs/wk 141/157 0.92 (0.63, 1.34) 215/252 0.88 (0.62, 1.26) 
                                    Ca, case; Co, control; OR, odds ratio; CI, confidence interval  
 
 
 
 
 113    
 
113
 
 
 
 
Chapter V: Discussion 
The purpose of this dissertation was to explore whether the association between 
recreational physical activity (RPA) and breast cancer risk was modified by individual 
variability in genetic polymorphisms from two closely linked pathways: oxidative stress 
(Chapter 3) and DNA repair (Chapter 4). To address these novel aims, this dissertation 
employed a candidate gene approach, focusing on potentially functional polymorphisms in 
pathways shown to be biologically relevant for both physical activity and breast cancer 
based on previous work in animal and clinical studies. These analyses were accomplished 
using data from a large, population-based, study of women with comprehensive exposure 
assessment and genetic data.  
Chapter five provides a detailed discussion of the study strengths, limitations and 
impact in light of the findings presented in chapters 3 and 4. Specifically, this chapter 
summarizes the study results (5.1), considers the impact of several sources of bias on the 
study findings (5.2-5.6) and concludes with directions for future research (5.7) and public 
health impact (5.8).  
5.1 Summary of Results 
This investigation began by estimating odds ratios for the association between 
individual genes in the oxidative stress pathway (CAT), the MMR pathway (MLH1, MSH2, 
and MSH3) and breast cancer risk. The majority of single SNP associations were non-
significant and close to the null, although some displayed moderate associations by 
menopausal or hormone receptor status. Notably, one SNP in CAT (rs4656146) was 
associated with a 23% reduced risk of postmenopausal breast cancer. Several variants in 
the MMR pathway (MLH1 rs1799977, MLH1 rs2286940, and MSH2 rs2303428) were 
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associated with 20-30% risk reduction among HR negative cases (ER and PR negative), but 
showed weak positive or approximately null associations among HR positive cases. None of 
the associations were statistically significant. When I considered effects of multiple genetic 
variants (either GxG or pathway effects) on breast cancer risk I found a significant 
multiplicative interaction between MLH1 (rs1799977) and MSH2 (rs2303428) as well as a 
positive association between the number of putative high risk alleles in CAT and risk of 
breast cancer. Women who carried 7-8 high-risk alleles had a 69% increased risk of breast 
cancer compared with women who had ≤ 2 high-risk alleles. Given lack of association 
among most single variants, these results support the hypothesis that it is important to 
consider multiple gene/SNP analyses in uncovering breast cancer etiology. 
Statistical interactions between RPA and breast cancer-associated SNPs in oxidative 
stress and DNA repair pathways were evaluated using both multiplicative and additive 
models. There was evidence to suggest multiplicative interaction between postmenopausal 
RPA and SNPs in CAT, GSTP1, XPC, XPG, XPF, and MLH1, supporting previous work in 
clinical and rodent studies. These investigations showed that physical activity, especially 
activity that is strenuous or exhaustive, may result in the generation of ROS [119, 163, 164]. 
However, regular exercise training results in adaptation of antioxidant capacity [170, 171] 
and improved damage repair systems [267, 268]. The results of this dissertation show that 
breast cancer risk reductions are greatest among active women with genotypes related to 
improved endogenous neutralization of ROS or DNA repair. Women without these 
genotypes experienced little benefit from physical activity, even if they were highly active. 
Collectively, these findings suggest that exercise induced ROS are best removed in 
environments where there are sufficient antioxidant and DNA repair capacity, although other 
mechanisms of interaction may also be present [74] and should be considered in future 
studies. 
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5.2 Generalizability of the Study Sample 
Despite the population-based sample selection approach utilized for the Long Island 
Breast Cancer Study Project (LIBCSP), a limitation of the study was its relatively 
homogenous population. Because of the racial and economic homogeneity of the source 
population in the geographic location of the parent study, the current study sample consists 
primarily of postmenopausal white women with high socioeconomic status. The experiences 
of the study participants, specifically with regard to RPA involvement or genetic profiles, may 
therefore not be representative of all US women. While this limits external validity, the 
internal validity of the study is enhanced and data obtained from these analyses will apply to 
individuals with the highest risk of developing breast cancer – namely white, 
postmenopausal women. Moreover, this study may provide some clues about the underlying 
biology of the physical activity-breast cancer association which is unlikely to vary by race, 
allele frequency or exposure prevalence.  
The racial homogeneity of the study population also restricted the ability to evaluate 
modification by breast cancer subtypes (e.g. Luminal A, Luminal B, Human epidermal 
growth factor receptor 2, and Basal-like) which are known to vary by both menopausal 
status and race [307]. The overwhelming majority of the women included in the parent 
LIBCSP study were classified as ER/PR positive, which is indicative of the luminal subtype 
and comprises approximately 60% of breast cancer cases [302]. These findings are 
therefore applicable to the largest proportion of women diagnosed with breast cancer in the 
U.S.  
5.3 Study Power  
Small sample size is an inherent limitation of many molecular epidemiology studies. 
Given the subtle risk often associated with low penetrant polymorphisms [292], large 
samples (e.g. 500-2000 case-control pairs) are most likely needed to estimate effects of 
genes [305, 333], when using a pathway-based approach. This study benefited from the 
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relatively-large sample size, which increased power to detect main effects of both oxidative 
stress and DNA repair variants, perform subgroup analyses, and examine joint effects of 
polymorphisms on breast cancer risk. However, even very large studies assessing main 
effects of genetic variants can quickly become underpowered when examining gene-
environment interactions. These analyses generally require 1500-5000 case control pairs 
[305, 333], depending on several factors including exposure prevalence, allele frequency, 
the magnitude of effects and the scale assessed for interaction (i.e. additive or 
multiplicative). Although the LIBCSP had a sample size of 2000+ women, I was restricted in 
my ability to detect modest gene-environment associations. This was primarily due to the 
infrequency of the homozygous recessive genotype, causing the cell sizes of some 
comparisons to be less than optimal.  
5.4 Selection Bias  
Another limitation of this dissertation was the potential for selection bias related to 
study participation. Similar to other population-based case control studies, the parent 
LIBCSP experienced lower participation rates among controls compared to cases (62.7% 
vs. 82.1%, respectively). Differences in participation among cases and controls are primarily 
attributed to poor response among elderly control women ≥ 65 years, where a 43.3% 
response rate was achieved in comparison to the 71.2% response rate among case women. 
These differences are less evident among women under 65 years of age with an 88.9% and 
76.1% response rate among cases and controls, respectively [18]. For these analyses, the 
underlying assumption is that genotypes among case study participants are most likely 
representative of genotypes among all cases sampled in the source population, and control 
participant genotypes are representative of genotypes among all sampled controls despite 
the differences in participation by age. When tested empirically, genotype frequencies 
among women <65 years and ≥ 65 years were approximately equal for both age groups, 
reducing likelihood of potential biases due to age-related non-participation.  
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In the LIBCSP blood donation not only varied by age, but also by race [18]. While 
genotype is likely unrelated to age in the LIBCSP, genotype frequencies have been 
observed to vary by race [334], and thus differences in the availability of blood by race could 
result in selection bias. Given the very small number of non-white women (6% of cases and 
8% of controls) included in the study [18], however, any racial variations in blood donation 
are likely negligible. In fact, effect estimates obtained in the restricted analyses among 
Caucasian women did not vary materially from those obtained among analyses based on 
data among all women.  
5.5 Information Bias  
Information bias refers to a systematic distortion or error that arises from the 
procedures used for classification or measurement of the disease, the exposure, or other 
relevant variables. In most molecular epidemiology studies, information bias may be 
introduced from genetic or self-reported exposure data. For this dissertation the major 
sources of bias include those associated with genotyping, including laboratory error and 
SNP selection, and those associated with RPA assessment, including problems associated 
with participant recall. 
5.5.1 Genotyping 
A number of steps were taken to minimize genotyping error in LIBCSP. Samples 
from matched sets were assayed together in the same batch to ensure that effect estimates 
did not vary because of inter-assay variability. For quality control purposes 10% duplicates 
of the samples were distributed throughout DNA samples and laboratory personnel were 
blinded to case control status. Thus, any laboratory or genotyping error that may have 
resulted in exposure misclassification is likely non-differential.  
The approach used to select for and assess genetic polymorphisms may introduce 
bias and warrant additional discussion. SNPs were selected using a combination of methods 
to increase the likelihood of identifying polymorphisms associated with breast cancer. Using 
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a candidate-gene approach I pre-selected regions of the genome that were most likely to be 
associated with both physical activity and breast cancer based on a priori knowledge of 
exercise pathophysiology and breast cancer etiology. This approach to uncovering the 
genetic architecture of complex traits capitalizes on both the biological understanding of the 
phenotype, as well as the increased statistical efficiency of association analysis [279]. While 
useful, this method lacks the flexibility of GWAS which has facilitated the identification of 
previously undiscovered regions of DNA shown to be associated with cancer outcomes. 
However, because genome-wide scanning methods are based primarily on statistical 
associations, ignoring prior knowledge about disease pathobiology [277, 278], and have 
limited facility in GxE studies, the candidate gene approach was most appropriate for this 
dissertation.  
The selection of tag SNPs (CAT and MMR pathway genes) in addition to potentially 
functional SNPs (MMR pathway genes) maximized the ability to capture genetic variation 
across a genomic region and allowed for the identification of previously unreported breast 
cancer associations. Tag SNPs are unlikely to have a direct effect on gene function, but they 
may be in linkage disequilibrium with one or more un-typed variants which are functional. 
Although the tagging procedure used in this analysis was designed to capture most of the 
variation for the population of interest (CEU), I could not evaluate all potential SNPs for each 
gene of interest or systematically capture the effects of non-SNP variation (e.g. copy 
number variants, insertion-deletion polymorphisms, and repeat polymorphisms) which may 
result in some residual unmeasured genetic variation.  
5.5.2 RPA Assessment  
Most epidemiologic studies are susceptible to differential recall bias, particularly in 
case-control studies where participants are asked to self-report environmental exposures 
from the distant past. Questions related to physical activity could be perceived as sensitive 
inducing social desirability bias. However, considering RPA levels within genotype during 
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the statistical analysis reduces the impact of potential recall bias, given that women were 
unaware of their genotype status at the time of the interview. While the exposure information 
on physical activity may be differentially recalled among diseased women, this 
misclassification is unlikely to vary by genotype [308]. Thus, any association between RPA 
and breast cancer observed within genotype cannot be simply a product of potential recall 
bias.    
In addition to biases in recall it is often a concern that physical activity questionnaires 
lack content validity and reliability, specifically when employed in case-control studies [335], 
and could result in non-differential recall error. Efforts to reduce this error were undertaken 
during the design and conduct of the parent study, and included use of visual aids and life 
course calendars to assist women in recalling specific activities and dates of participation. 
Similarly, LIBCSP investigators used a comprehensive RPA assessment, developed by Dr. 
Leslie Bernstein, designed specifically for case control studies of physical activity and breast 
cancer [274]. This instrument has revealed important relationships between exercise and 
breast cancer risk in several epidemiologic models [274, 309].  The semi open-ended format 
of the questions in the RPA assessment strengthens this study, by being sufficiently detailed 
making it difficult for cases, or controls, to gloss over what they are recalling and by 
providing a comprehensive assessment of activity type, duration and frequency over broad 
periods of time. The results obtained in the LIBCSP [63] for the main effect of physical 
activity among postmenopausal women (28% reduction in risk) is consistent with the 25% 
risk reduction reported in other studies [44, 46] suggesting that the RPA assessment 
methods employed in the parent LIBCSP were valid. Although short-term prospective 
evaluations of physical activity may be better for assessing current activity levels, the use of 
alternative assessments including activity diaries, accelerometers and pedometers are not 
feasible in large observational population-based studies, and would fail to capture the 
etiologically relevant time period for breast cancer incidence.  
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5.6 Multiple Comparisons  
Molecular epidemiology studies with a large number of comparisons are likely to find 
some statistically significant associations by chance alone. A number of formal approaches 
have been proposed to account for multiple comparisons [303]; however, there is continuing 
debate on whether and how to correct for these potential errors [336]. The first approach 
would be to make no correction for multiple testing. This approach would obligate that the 
SNPs assessed are not highly correlated. Other approaches, such as Bonferonni correction 
[311] and false discovery rate [337] adjust the alpha level based on the number of statistical 
comparisons. These methods are often criticized for being overly conservative [303, 338]. 
They additionally fail to account for study size and power and inadequately address the 
issue of false positive associations [339]. Post hoc calculations of the false positive report 
probability are easy to implement and require fewer assumptions than more complex 
empirical methods. However, it oversimplifies the assumption for the prior distribution, relies 
on the study p-value and may not useful for assessing GxE interactions [339, 340]. 
Bayesian adjustment, works by shrinking the estimates of various SNPs across genes 
toward the geometric mean of the estimates (empirical Bayes) or some pre-specified value 
(semi-Bayes). Although these methods can provide more accurate and precise estimates 
than single level models, they are computationally intensive [287, 310] and may provide no 
added benefit over more direct approaches. Second stage models (e.g. hierarchical models) 
similarly shrink the estimates towards their respective group means [341], and have been 
useful in addressing issues of multiple comparisons and GxE interactions in molecular 
epidemiology studies [310, 341]. Given the strong biologic rationale of this study and low 
correlation between SNPs (R2 range between 0.1-0.6), these dissertation analyses did not 
warrant the added complexity of Bayesian or hierarchal models. Moreover, other methods to 
correct for multiple comparisons (e.g. Bonferonni) may be unduly conservative and could 
increase the type II error rate reducing sensitivity [342]. By not correcting for multiple 
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comparisons it is possible that I have made incorrect determinations regarding the null 
hypothesis. However, by not adjusting for multiple comparisons I was able to fully explore 
my biologically driven hypothesis without penalty and was able to identify potentially 
important findings which can be verified (or refuted) in future studies.  
5.7 Future Directions 
The results of this dissertation support two main conclusions: 1) there is evidence 
that some oxidative stress or DNA repair genotypes, alone or in combination, are associated 
with breast cancer; and 2) allelic variability in genes related to oxidative stress or DNA repair 
may modify associations between RPA and breast cancer. While the strengths of this study 
are plentiful (including pathway-specific selection of potential genotypes, comprehensive 
assessment of lifecourse RPA, homogenous study sample to maximize the limited study 
power, and population-based selection of the study sample to increase generalizability of 
the study findings), there are limitations that warrant consideration in planning for future 
work in this area.  
Replication of SNP associations and gene*gene interactions are needed to make 
strong conclusions about the validity and strength of the association with respect to breast 
cancer. Data indicate that the first investigation often suggests a stronger genetic effect than 
is found by subsequent investigations [343]. This overestimation may be due to systematic 
biases, including publication bias, or population diversity. Although I identified few biases 
that would substantially impact the observed associations, it would be useful to consider the 
effect estimates obtained in LIBCSP in the context of associations estimated in other 
populations. Replication will provide the most comprehensive, un-biased, assessment of the 
relationship between these variants and breast cancer occurrence.  
In a similar manner, the gene*physical activity study results will need to be confirmed 
in replication studies. The genotype and physical activity variables were 2-level and 3-level 
variables, respectively, which may have led to imprecise stratified ORs and/or masked trend 
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effects. To improve on the precision of this investigation future studies should have: (1) 
expanded genetic data; and (2) equally detailed RPA assessment as the LIBCSP. Ideally, a 
prospective cohort would be used to address these questions, although such a design may 
limit detailed assessment of RPA. 
Many of the genetic associations observed in this investigation were among tag 
SNPs with no known function, suggesting that these polymorphisms are in linkage 
disequilibrium (LD) with the true causal variant. Alternatively, the typed SNPs may be 
associated with breast cancer through downstream genetic regulation (e.g. splicing, 
transcriptional regulation, translational regulation, or regulatory miRNA target sites). Future 
studies would benefit from comprehensive assessments of genomic elements in regions 
where the breast cancer-associated SNPs are located. This would aid in identifying causal 
variants and uncovering biological mechanism through which these variants act.  
Future studies may also consider simultaneously assessing genetic variation of all 
polymorphisms in the same or related biologic pathway. For example, studies assessing 
three-way interactions between DNA repair, oxidative stress and physical activity on breast 
incidence my facilitate a more comprehensive understanding of the physical activity-breast 
cancer association. Second stage models (i.e. hierarchical regression models) may be 
useful in these efforts. Moreover, these methods may increase precision and reduce the 
likelihood of false positives among relatively small samples [310]. Despite these 
advantages, however, an increased sample size of the study population would facilitate 
implementation of this approach.  
5.8 Significance 
Breast cancer remains an important public health concern in both the United States 
and abroad. Although risk factor epidemiology has aided in our understanding of breast 
cancer etiology, many of the underlying mechanisms that tie these factors to disease risk 
are not fully understood [5]. It is well established that a large number of risk factors, 
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specifically those related to hormones, play an important role in breast cancer development 
[5]. But many of these (e.g., menstrual and reproductive history) are not easily modifiable on 
an individual-level basis. However, a proportion of breast cancer risk can be attributed to 
those factors which are amendable to intervention. Physical activity has emerged as an 
important, potentially modifiable, target for breast cancer risk reduction and may account for 
a large proportion of breast cancer cases. Identifying pathways through which exercise 
operates could play an important role in advancing the knowledge of breast cancer etiology, 
and improving risk reduction strategies for breast cancer. Given the widespread accessibility 
to physical activity in the US [56], a better understanding of the genetic influences 
underlying the association with breast cancer has become increasingly important.  
The proposed study has widespread implications for breast cancer. First, this study 
was among the first to systematically evaluate associations between common variation in 
MLH1, MSH2, MSH3 and CAT using a large population-based sample. Uncovering the role 
of functional and non-functional SNPs in these pathways is important to understanding the 
etiology of breast cancer. Additional research may aid in identifying causal variants near 
these SNPs and could be used to define subgroups of susceptible women who may benefit 
from increased surveillance.  
Second, the novel approach of considering interactions between genotypes and 
recreational physical activity is an important aspect of investigation and may help define 
subgroups with elevated or decreased breast cancer risk as well as explain dose response 
associations. For example, the antagonism detected for CAT (rs1001179) and RPA 
suggests that women who carry the TT genotype and also engage in high levels of RPA 
would experience greater cases of breast cancer than would be expected by the 
independent effect of RPA on breast cancer. These observations could indicate that 
interventions to increase physical activity may not provide the expected breast cancer risk 
reduction if the TT genotype is highly prevalent in the population. Data from this 
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investigation show significant multiplicative interaction between RPA and several other 
polymorphisms including variants in GSTP1, XPC, XPF, XPG and MLH1. Collectively, these 
findings suggest that exercise induced ROS are best neutralized in environments where 
there is sufficient antioxidant and DNA repair capacity via endogenous or exogenous 
mechanisms.  
Studies such as this may help to identify women who are particularly susceptible to 
the beneficial effects of physical activity based on genetic characteristics. Increasing 
knowledge of the patterns of biological interaction in the population could aid in the 
identification of new targets for intervention and inform public health recommendations for 
lowering breast cancer risk.  
5.9 Conclusions 
The goal of this dissertation was to examine inter individual variation of genes 
involved in oxidative stress, DNA repair pathways and RPA to improve our understanding of 
breast cancer etiology, to explain heterogeneity between studies of physical activity and 
breast cancer and to identify subgroups of women who may be targeted for tailored public 
health interventions. Findings from this population-based case-control study of women 
indicate that most individual polymorphisms in CAT and the MMR pathway are not 
associated with breast cancer risk. However, this investigation is the first to show that when 
variants in catalase or MMR are considered in combination (gene*gene or pathway 
approaches) there may be some association with breast cancer occurrence. Further, this 
was the first epidemiologic study to explore interactions between genetic variants, physical 
activity and cancer risk. Data from this dissertation suggest that active women with 
genotypes related to enhanced endogenous neutralization of ROS or DNA repair capacity 
may receive the greatest benefits from exercise.  
Future studies should improve on the precision of this investigation by including 
larger numbers of study participants in addition to assessing genetic variation across 
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multiple pathways implicated in pathobiology of physical activity. Although genotype is non-
modifiable, it is encouraging to note that women who were moderately physically active had 
enhanced risk reduction when they were carriers of alleles related to higher enzymatic 
activity or DNA repair capacity. While highly active women with risk alleles did not 
experience the same benefit from exercise as their non-risk alleles carrying counterparts, 
these women were no more increased risk of breast cancer than non-active women with 
non-risk alleles. 
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Appendix I: Tables 
 
TABLE A.1 Risk Factors for Breast Cancer 
(Adapted from Hankinson et al., 2004) 
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TABLE A.2 Summary of DNA Repair Mechanisms (Adapted from Goode et al., 2002) 
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TABLE A.3 Response Rates by Study Interview Component and Age at Reference among Respondents.  
Long Island Breast Cancer Study Project, 1996-1997 (Adapted from Gammon et al., 2002) 
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TABLE A.4 Candidate Genes and SNPs for Gene-Environment Models  
Pathway Gene RS Functional Change 
Oxidative Stress CAT rs1001179 TFBS 
  
COMT rs4680 nsSNP 
  
  rs737865 TFBS 
  
GPX1 rs1050450 nsSNP 
  
GSTA1 rs3957356 TFBS 
  
GSTM1 -- Gene Deletion 
  
GSTP1 rs1695 nsSNP 
  
GSTT1 -- Gene Deletion 
  
MnSOD rs4880/s1799725 nsSNP 
  
MPO rs2333227 TFBS 
DNA Repair ERCC1/CD3EAP rs3212986 nsSNP 
  
MGMT rs12917 nsSNP 
  
  rs2308321 nsSNP 
  
  rs2308327 nsSNP 
  
MLH1 rs1799977 nsSNP 
  
OGG1 rs1052133 nsSNP 
  
XPA/XRCC4 rs1800975 TFBS 
  
XPC rs222800 nsSNP 
  
  rs2228001 nsSNP 
  
XPD rs1799793 nsSNP 
  
  rs 13181 nsSNP 
  
XPF/ERCC4 rs1800067 nsSNP 
  
XPG/ERCC5 rs17655 nsSNP 
  
XRCC1 rs1799782 nsSNP 
  
  rs25487 nsSNP 
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TABLE A.5 SNP Selection for Main Effects Models
 
 
   *TAG in CEU population  
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TABLE A.6 Pairwise LD for all Newly Genotyped CAT and Mismatch Repair 
SNPs. The Long Island Breast Cancer Study Project (1996-1997). 
Gene SNP1 SNP2 R2 
MSH2 rs3732182 rs4583514 0.634 
rs3732182 rs2303428 0.234 
rs4583514 rs3732182 0.634 
rs4583514 rs4583514 0.148 
rs2303428 rs2303428 0.234 
rs2303428 rs3732182 0.148 
MLH1 rs2286940 rs1799977 0.522 
rs1799977 rs2286940 0.522 
CAT rs1001179 rs480575 0.121 
rs4756146 rs2284365 0.527 
rs4756146 rs480575 0.243 
rs2284365 rs4756146 0.527 
rs2284365 rs480575 0.462 
rs480575 rs2284365 0.462 
rs480575 rs4756146 0.243 
  rs480575 rs1001179 0.121 
A priori criteria for haplotype analysis R2>0.70 
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TABLE A.7 Hardy Weinberg Equilibrium for Newly Genotyped Catalase SNPs. The Long 
Island Breast Cancer Study Project (1996-1997). 
Gene (rs) Genotype Frequency Chi Squared 
P-
Value Decision 
CAT (rs480575) AA 467 1.6225 0.2027 Fail to reject Null 
AG 393 
 GG 100 
CAT (rs2284365) CC 78 6.1010 0.0135 Reject Null 
CT 344 
 TT 565 
CAT (rs4756146) CC 27 5.7089 0.0169 Reject Null 
CT 214 
 
  TT 746       
A priori criteria for rejection of null is p<0.05 
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TABLE A.8 Hardy Weinberg Equilibrium for Newly Genotyped Mismatch Repair SNPs. The 
Long Island Breast Cancer Study Project (1996-1997). 
Gene (rs) Genotype Frequency Chi Squared 
P-
Value Decision 
MSH3 (rs1650663) CC 110 2.7663 0.0963 Fail to reject Null 
CT 429 
 TT 530 
 MLH1 (rs1799977) AA 542 0.0704 0.7908 Fail to reject Null 
AG 443 
 GG 87 
MLH1 (rs2286940) CC 342 0.8279 0.3629 Fail to reject Null 
CT 541 
 TT 191 
 MSH2 (rs2303428) CC 12 3.0300 0.0817 Fail to reject Null 
CT 155 
 TT 886 
 MSH2 (rs3732182) GG 574 0.6185 0.4316 Fail to reject Null 
GT 411 
 TT 83 
 MSH2 (rs4583514) AA 147 1.0494 0.3056 Fail to reject Null 
AG 521 
 
  GG 404       
A priori criteria for rejection of null is p<0.05 
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TABLE A.9 Distribution of Outcome, Main Exposure, and Key Covariates for 
CAT Analysis. The Long Island Breast Cancer Study Project (1996-1997). 
Study Variable Cases  (N=1508)  
Controls  
(N=1556) 
  
N 
 
% 
 
N 
 
% 
CAT (rs4756146) 
       
 
TT 774 
 
77.87% 
 
809 
 
75.82% 
 
CT 201 
 
20.22% 
 
229 
 
21.46% 
 
CC 19 
 
1.91% 
 
29 
 
2.72% 
 
CT and CC 220 
 
22.13% 
 
258 
 
24.18% 
 
missing 514 
 
-- 
 
489 
 
-- 
CAT (rs2284365) 
       
 
TT 589 
 
59.43% 
 
610 
 
57.22% 
 
CT 344 
 
34.71% 
 
371 
 
34.80% 
 
CC 58 
 
5.85% 
 
85 
 
7.97% 
 
CT and CC 402 
 
40.56% 
 
456 
 
42.77% 
 
missing 517 
 
-- 
 
490 
 
-- 
CAT (rs480575) 
       
 
AA 517 
 
52.54% 
 
504 
 
48.60% 
 
AG 378 
 
38.41% 
 
422 
 
40.69% 
 
GG 89 
 
9.04% 
 
111 
 
10.70% 
 
AG and 
GG 467  47.45%  533  51.39% 
 
missing 524 
 
-- 
 
519 
 
-- 
Race  
 
White 1411 
 
93.75% 
 
1429 
 
91.84% 
 
Black 69 
 
4.58% 
 
85 
 
5.46% 
 
Other  25 
 
1.66% 
 
42 
 
2.70% 
 
missing 3 
 
-- 
 
0 
 
-- 
Family History 
       
 
No  1166 
 
79.81% 
 
1321 
 
87.02% 
 
Yes 295 
 
20.19% 
 
197 
 
12.98% 
 
missing 47 
 
-- 
 
38 
 
-- 
Religion 
 
      
 
None 14 
 
0.93% 
 
12 
 
0.77% 
 
Protestant 360 
 
23.92% 
 
373 
 
24.02% 
 
Catholic 859 
 
57.08% 
 
916 
 
58.98% 
 
Jewish 259 
 
17.21% 
 
239 
 
15.39% 
 
Other  13 
 
0.86% 
 
13 
 
0.84% 
  
missing 3   --   3   -- 
 
 
  
 
 135    
 
135
 
TABLE A.10 Distribution of Outcome, Main Exposure, and Key Covariates for 
Mismatch Repair Analysis. The Long Island Breast Cancer Study Project 
(1996-1997). 
Study Variable Cases  (N=1508)  
Controls  
(N=1556) 
  
N 
 
% 
 
N 
 
% 
MSH3 
(rs1650663)        
 
TT 497 
 
49.35% 
 
530 
 
49.58% 
 
CT 412 
 
40.91% 
 
429 
 
40.13% 
 
CC 98 
 
9.73% 
 
110 
 
10.29% 
 
CT and CC 510 
 
50.64% 
 
539 
 
50.42% 
 
missing 501 
 
-- 
 
487 
 
-- 
MLH1 
(rs1799977)        
 
AA 503 
 
49.75% 
 
542 
 
50.56% 
 
AG 410 
 
40.55% 
 
443 
 
41.32% 
 
GG 98 
 
9.69% 
 
87 
 
8.12% 
 
AG and GG 508 
 
50.24% 
 
530 
 
49.44% 
 
missing 497 
 
-- 
 
484 
 
-- 
MLH1 
(rs2286940)        
 
CC 340 
 
33.83% 
 
342 
 
31.84% 
 CT 467 
 
46.47% 
 
541 
 
50.37% 
 
TT 198 
 
19.70% 
 
191 
 
17.87% 
 
CT and TT 665 
 
66.17% 
 
732 
 
68.24% 
 
missing 503 
 
-- 
 
482 
 
-- 
MSH2 
(rs2303428)        
 
TT 828 
 
83.98% 
 
886 
 
84.14% 
 
CT 150 
 
15.21% 
 
155 
 
14.72% 
 
CC 8 
 
0.81% 
 
12 
 
1.14% 
 
CT and CC 158 
 
16.02% 
 
167 
 
15.86% 
 
missing 522 
 
-- 
 
503 
 
-- 
MSH2 
(rs3732182)        
 
GG 542 
 
54.36% 
 
574 
 
53.75% 
 
GT 375 
 
37.61% 
 
411 
 
38.48% 
 
TT 80 
 
8.02% 
 
83 
 
7.77% 
 
GT and TT 455 
 
45.63% 
 
494 
 
46.25% 
 
missing 511 
 
-- 
 
488 
 
-- 
MSH2 
(rs4583514)        
 
GG 394 
 
39.01% 
 
404 
 
37.69% 
 
AG 485 
 
48.02% 
 
521 
 
48.60% 
 
AA 131 
 
12.97% 
 
147 
 
13.71% 
 
AG and AA 616 
 
60.99% 
 
668 
 
62.31% 
 
missing 498 
 
-- 
 
484 
 
-- 
Race  
 
White 1411 
 
93.75% 
 
1429 
 
91.84% 
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Black 69 
 
4.58% 
 
85 
 
5.46% 
 
Other  25 
 
1.66% 
 
42 
 
2.70% 
 
missing 3 
 
-- 
 
0 
 
-- 
Family History 
       
 
No  1166 
 
79.81% 
 
1321 
 
87.02% 
 
Yes 295 
 
20.19% 
 
197 
 
12.98% 
 
missing 47 
 
-- 
 
38 
 
-- 
Religion 
 
      
 
None 14 
 
0.93% 
 
12 
 
0.77% 
 
Protestant 360 
 
23.92% 
 
373 
 
24.02% 
 
Catholic 859 
 
57.08% 
 
916 
 
58.98% 
 
Jewish 259 
 
17.21% 
 
239 
 
15.39% 
 
Other  13 
 
0.86% 
 
13 
 
0.84% 
  
missing 3   --   3   -- 
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TABLE A.11 Distribution of Outcome and Main Exposure for CAT Analysis 
Among Whites. The Long Island Breast Cancer Study Project (1996-1997). 
Study Variable Cases  (N=1411)  
Controls  
(N=1429) 
  
N 
 
% 
 
N 
 
% 
CAT (rs4756146) 
       
 
TT 729 
 
77.72% 
 
746 
 
75.58% 
 
CT 191 
 
20.36% 
 
214 
 
21.68% 
 
CC 18 
 
1.92% 
 
27 
 
2.74% 
 
CT and CC 209 
 
22.28% 
 
241 
 
24.42% 
 
missing 473 
 
-- 
 
442 
 
-- 
CAT (rs2284365) 
       
 
TT 555 
 
59.36% 
 
565 
 
57.24% 
 
CT 328 
 
35.08% 
 
344 
 
34.85% 
 
CC 52 
 
5.56% 
 
78 
 
7.90% 
 
CT and CC 380 
 
40.64% 
 
422 
 
42.75% 
 
missing 476 
 
-- 
 
442 
 
-- 
CAT (rs480575) 
       
 
AA 496 
 
53.51% 
 
467 
 
48.65% 
 
AG 352 
 
37.97% 
 
393 
 
40.94% 
 
GG 79 
 
8.52% 
 
100 
 
10.42% 
 
AG and GG 431 
 
46.49% 
 
493 
 
51.36% 
 missing 484 
 
-- 
 
469 
 
-- 
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TABLE A.12 Distribution of Outcome and Main Exposure for Mismatch Repair 
Analysis among Whites. The Long Island Breast Cancer Study Project (1996-
1997).  
Study Variable Cases  (N=1411)  
Controls  
(N=1429) 
  
N 
 
% 
 
N 
 
% 
MSH3 (rs1650663) 
       
 
TT 473 
 
49.89% 
 
488 
 
49.29% 
 
CT 385 
 
40.61% 
 
403 
 
40.71% 
 
CC 90 
 
 9.49% 
 
99 
 
10.00% 
 
CT and CC 475 
 
50.10% 
 
502 
 
50.71% 
 
missing 463 
 
-- 
 
439 
 
-- 
MLH1 (rs1799977) 
       
 
AA 459 
 
48.21% 
 
481 
 
48.54% 
 
AG 397 
 
41.70% 
 
424 
 
42.79% 
 
GG 96 
 
10.08% 
 
86 
 
8.68% 
 
AG and 
GG 493  51.78%  510  51.47% 
 
missing 459 
 
-- 
 
438 
 
-- 
MLH1 (rs2286940) 
       
 
CC 302 
 
31.89% 
 
298 
 
30.01% 
 
CT 453 
 
47.84% 
 
513 
 
 51.66% 
 TT 192 
 
20.27% 
 
182 
 
18.33% 
 
CT and TT 645 
 
68.11% 
 
695 
 
69.99% 
 
missing 464 
 
-- 
 
436 
 
-- 
MSH2 (rs2303428) 
       
 
TT 778 
 
83.66% 
 
817 
 
83.79% 
 
CT 144 
 
 
15.48%  147  15.08% 
 
CC 8 
 
 0.86% 
 
11 
 
1.13% 
 
CT and CC 152 
 
16.34% 
 
158 
 
16.21% 
 
missing 481 
 
-- 
 
454 
 
-- 
MSH2 (rs3732182) 
       
 
GG 527 
 
56.12% 
 
554 
 
56.07% 
 
GT 351 
 
37.38% 
 
370 
 
37.45% 
 
TT 61 
 
6.50% 
 
64 
 
6.48% 
 
GT and TT 412 
 
43.88% 
 
434 
 
43.93% 
 
missing 472 
 
-- 
 
441 
 
-- 
MSH2 (rs4583514) 
       
 
GG 386 
 
40.55% 
 
390 
 
39.35% 
 
AG 459 
 
48.21% 
 
483 
 
48.74% 
 
AA 107 
 
11.24% 
 
118 
 
11.91% 
 
AG and AA 566 
 
59.45% 
 
601 
 
60.65% 
  
missing 459   --   438   -- 
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TABLE A.13 Age Adjusted Odds Ratios and 95% Confidence Intervals for the 
Association between CAT Genes and Breast Cancer Risk. The Long Island Breast 
Cancer Study Project (1996-1997).  
Gene (rs) Cases Controls Pre- and Postmenopausal women  
   
OR 95% CI CLR 
CAT (rs4756146) 
    
 
TT 774 809 1.00 Reference -- 
 
CT 201 229 0.93 (0.75, 1.16) 1.55 
 
CC 19 29 0.68 (0.37, 1.22) 3.30 
 
CT and CC 220 258 0.90 (0.74, 1.11) 1.50 
CAT (rs2284365) 
     
 
TT 589 610 1.00 Reference -- 
 
CT 344 371 0.98 (0.81, 1.18) 1.46 
 
CC 58 85 0.72 (0.50, 1.03) 2.06 
 
CT and CC 402 456 0.93 (0.78, 1.11) 1.42 
CAT (rs480575) 
   
 
AA 517 504 1.00 Reference -- 
 
AG 378 422 0.89 (0.74, 1.08) 1.46 
 
GG 89 111 0.78 (0.58, 1.06) 1.83 
  AG and GG 467 533 0.87 (0.73, 1.04) 1.42 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio 
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TABLE A.14 Age Adjusted Odds Ratios and 95% Confidence Intervals for the 
Association between Mismatch Repair Genes and Breast Cancer Risk. The Long 
Island Breast Cancer Study Project (1996-1997).  
Gene (rs) Cases Controls Pre- and Postmenopausal 
women  
   
OR 95% CI CLR 
MSH3 (rs1650663) 
    
 
TT 497 530 1.00 Reference 
-- 
 
CT 412 429 1.02 (0.85, 1.22) 1.44 
 
CC 98 110 0.98 (0.72, 1.32) 1.83 
 
CT and CC 510 539 1.01 (0.85, 1.20) 1.41 
MLH1 (rs1799977) 
     
 
AA 503 542 1.00 Reference 
-- 
 
AG 410 443 0.98 (0.81, 1.17) 1.44 
 
GG 98 87 1.17 (0.85, 1.60) 1.88 
 
AG and GG 508 530 1.01 (0.85, 1.20) 1.41 
MLH1 (rs2286940) 
     
 
CC 340 342 1.00 Reference 
-- 
 
CT 467 541 0.85 (0.70, 1.04) 1.49 
 
TT 198 191 1.01 (0.79, 1.30) 1.65 
 
CT and TT 665 732 0.89 (0.74, 1.08) 1.46 
MSH2 (rs2303428) 
     
 
TT 828 886 1.00 Reference 
-- 
 
CT 150 155 1.07 (0.83, 1.36) 1.64 
 
CC 8 12 0.66 (0.27, 1.66) 6.15 
 
CT and CC 158 167 1.04 (0.81, 1.32) 1.63 
MSH2 (rs3732182) 
     
 
GG 542 574 1.00 Reference 
-- 
 
GT 375 411 0.98 (0.82, 1.18) 1.44 
 
TT 80 83 1.04 (0.74, 1.45) 1.96 
 
GT and TT 455 494 0.99 (0.83, 1.18) 1.42 
MSH2 (rs4583514) 
     
 
GG 394 404 1.00 Reference 
-- 
 
AG 485 521 0.96 (0.80, 1.16) 1.45 
 
AA 131 147 0.93 (0.70, 1.23) 1.76 
  AG and AA 616 668 0.95 (0.80, 1.14) 1.43 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio 
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TABLE A.15 Age Adjusted Odds Ratios and 95% Confidence Intervals for the 
Association between CAT Genes and Breast Cancer Risk Among Whites. The Long 
Island Breast Cancer Study Project (1996-1997).  
Gene (rs) Cases Controls Pre- and Postmenopausal women  
   
OR 95% CI CLR 
CAT (rs4756146) 
    
 
TT 774 809 1.00 Reference -- 
 
CT 201 229 0.93 (0.75, 1.17) 1.56 
 
CC 12 29 0.69 (0.37, 1.27) 3.43 
 
CT and CC 213 258 0.90 (0.73, 1.12) 1.53 
CAT (rs2284365) 
     
 
TT 589 610 1.00 Reference -- 
 
CT 344 371 0.99 (0.81, 1.20) 1.48 
 
CC 58 85 0.69 (0.48, 1.01) 2.10 
 
CT and CC 402 456 0.93 (0.78, 1.12) 1.44 
CAT (rs480575) 
   
 
AA 517 504 1.00 Reference -- 
 
AG 378 411 0.86 (0.71, 1.05) 1.48 
 
GG 89 111 0.75 (0.54, 1.04) 1.93 
  AG and GG 467 533 0.84 (0.70, 1.01) 1.44 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio 
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TABLE A.16 Age Adjusted Odds Ratios and 95% Confidence Intervals for the 
Association between Mismatch Repair Genes and Breast Cancer Risk among Whites. 
The Long Island Breast Cancer Study Project (1996-1997).  
Gene (rs) Cases Controls Pre- and Postmenopausal 
women  
   
OR 95% CI CLR 
MSH3 (rs1650663) 
    
 
TT 497 530 1.00 Reference 
-- 
 
CT 412 429 0.98 (0.81, 1.18) 1.46 
 
CC 98 110 0.96 (0.70, 1.32) 1.89 
 
CT and CC 510 539 1.01 (0.85, 1.20) 1.41 
MLH1 (rs1799977) 
     
 
AA 503 542 1.00 Reference 
-- 
 
AG 410 443 0.97 (0.80, 1.18) 1.48 
 
GG 98 87 1.14 (0.83, 1.57) 1.89 
 
AG and GG 508 530 1.01 (0.85, 1.20) 1.41 
MLH1 (rs2286940) 
     
 
CC 340 342 1.00 Reference 
-- 
 
CT 467 541 0.87 (0.71, 1.07) 1.51 
 
TT 198 191 1.03 (0.79, 1.34) 1.70 
 CT and TT 665 732 0.89 (0.74, 1.08) 1.46 
MSH2 (rs2303428) 
     
 
TT 828 886 1.00 Reference 
-- 
 
CT 150 155 1.07 (0.83, 1.37) 1.65 
 
CC 8 12 0.72 (0.28, 1.84) 6.57 
 
CT and CC 158 167 1.04 (0.81, 1.32) 1.63 
MSH2 (rs3732182) 
     
 
GG 542 574 1.00 Reference 
-- 
 
GT 375 411 1.01 (0.84, 1.22) 1.45 
 
TT 80 83 1.02 (0.67, 1.48) 2.21 
 
GT and TT 455 494 0.99 (0.83, 1.18) 1.42 
MSH2 (rs4583514) 
     
 
GG 394 404 1.00 Reference 
-- 
 
AG 485 521 0.96 (0.79, 1.16) 0.08 
 
AA 131 147 0.94 (0.69, 1.26) 1.83 
  AG and AA 616 668 0.95 (0.80, 1.14) 1.43 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio 
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TABLE A.17 Comparison of CAT Crude and Adjusted Odds Ratios by each Covariate. The Long Island Breast Cancer Study Project 
(1996-1997). 
  
 
 Covariate 
Gene (rs)                
 
 
Race Family History 
 
Religion 
 
Crude 
Estimate 
 
Covariate 
Adjusted OR In[coOR]  
Covariate 
Adjusted 
OR 
In[coOR] 
 
Covariate 
Adjusted 
OR 
In[coOR] 
CAT (rs4756146) 
 
 
         
 
TT 1.00 
 
 
CT and CC 0.90 
 
0.91 0.0110 
 
0.87 0.0110 
 
0.92 0.0220 
CAT (rs2284365) 
 
 
      
 
TT 1.00 
 
 
CT and CC 0.93 
 
0.93 0.0000 
 
0.90 0.0000 
 
0.93 0.0000 
CAT (rs480575) 
 
 
      
 
AA 1.00 
 
  AG and GG 0.87   0.88 0.0114   0.83 0.0114   0.87 0.0000 
OR, odds ratio; ln [coOR] = ln [crude estimate/adjusted estimate] 
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TABLE A.18 Comparison of Mismatch Repair Crude and Adjusted Odds Ratios by each Covariate. The Long 
Island Breast Cancer Study Project (1996-1997). 
  
 
 Covariate 
Gene (rs)                
 
 
Race Family History 
 
Religion 
ln (Crude/Adjusted)  
Crude 
Estimate 
 
Covariate 
Adjusted 
OR 
In[coOR] 
 
Covariate 
Adjusted 
OR 
In[coOR] 
 
Covariate 
Adjusted 
OR 
In[coOR] 
MSH3 (rs1650663) 
 
 
         
 
TT 1.00 
 
1.00 
 
1.00 
 
1.00 
 
CT and CC 1.01 
 
1.00 0.0109 
 
1.00 0.0159 
 
1.02 0.0030 
MLH1 (rs1799977) 
 
 
      
 
AA 1.00 
 
1.00 
 
1.00 
 
1.00 
 
AG and GG 1.01 
 
0.99 0.0209 
 
1.02 0.0079 
 
1.01 0.0010 
MLH1 (rs2286940) 
 
 
      
 
CC 1.00 
 
1.00 
 
1.00 
 
1.00 
 
CT and TT 0.89 
 
0.87 0.0182 
 
0.92 0.0332 
 
0.90 0.0090 
MSH2 (rs2303428) 
 
 
      
 
TT 1.00 
 
1.00 
 
1.00 
 
1.00 
 
CT and CC 1.04 
 
1.04 0.0019 
 
1.06 0.0190 
 
1.04 0.0019 
MSH2 (rs3732182) 
 
 
      
 
GG 1.00 
 
1.00 
 
1.00 
 
1.00 
 
GT and TT 0.99 
 
1.01 0.0170 
 
0.99 0.0010 
 
1.00 0.0070 
MSH2 (rs4583514) 
 
 
      
 
GG 1.00 
 
1.00 
 
1.00 
 
1.00 
  AG and AA 0.95   0.96 0.0115   0.95 0.0063   0.96 0.0063 
OR, odds ratio; ln [coOR] = ln [crude estimate/adjusted estimate] 
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TABLE A.19 Assessment of Effect Measure Modification in Strata of Covariates for 
CAT. The Long Island Breast Cancer Study Project (1996-1997). 
Covariate Stratum Specific 
Breslow-
Day  
p-value 
Mantel Hanzel  
 
OR 95% CI 
 
OR 95% CI 
CAT (rs4756146) 
Menopausal Status 
 Pre 1.20 (0.84, 1.73) 0.0419 0.88 (0.72, 1.09) 
Post 0.76 (0.59, 0.98) 
 
  
Race  
 
  
White 0.89 (0.72, 1.10) 0.9120 0.89 (0.73, 1.10) 
Black 0.87 (0.23, 3.33) 
 
  
Other  1.16 (0.35, 3.84) 
 Family History 
   
  
No  0.88 (0.70, 1.10) 0.5913 0.86 (0.70, 1.06) 
Yes 0.75 (0.45, 1.27) 
 Religion 
  
 None 1.00 (0.10, 9.61) 0.8265 0.90 (0.74, 1.11) 
Protestant 1.04 (0.67, 1.63) 
 Catholic 0.83 (0.64, 1.08) 
 Jewish 1.09 (0.64, 1.85) 
 Other  0.60 (0.09, 3.99) 
 
 
 CAT (rs2284365) 
Menopausal Status 
 Pre 1.04 (0.77, 1.42) 0.3031 0.91 (0.77, 1.09) 
Post 0.86 (0.69, 1.07) 
 
  
Race  
 
  
White 0.92 (0.76, 1.10) 0.1699 0.91 (0.77, 1.09) 
Black 0.52 (0.21, 1.31) 
 
  
Other  2.23 (0.66, 7.54) 
 
  
Family History 
   
  
No  0.90 (0.74, 1.10) 0.6068 0.88 (0.74, 1.06) 
Yes 0.79 (0.51, 1.24) 
 Religion 
  
 None 1.67 (0.23, 12.22) 0.8723 0.91 (0.76, 1.09) 
Protestant 0.90 (0.63, 1.30) 
 Catholic 0.90 (0.71, 1.13) 
 Jewish 0.91 (0.58, 1.41) 
 Other  2.40 (0.30, 19.04) 
 
 
 CAT (rs480575) 
    Menopausal Status 
 Pre 0.91 (0.67, 1.24) 0.5237 0.84 (0.70, 1.01) 
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Post 0.81 (0.65, 1.00) 
 
  
Race  
 
  
White 0.82 (0.69, 0.99) 0.0962* 0.86 (0.72, 1.03) 
Black 1.99 (0.83, 4.74) 
 
  
Other  1.70 (0.38, 7.50) 
 
  
Family History 
   
  
No  0.86 (0.71, 1.05) 0.1791 0.82 (0.68, 0.97) 
Yes 0.62 (0.40, 0.96) 
 Religion 
  
 None 1.00 (0.14, 7.10) 0.9681 0.85 (0.72, 1.02) 
Protestant 0.93 (0.65, 1.33) 
 Catholic 0.82 (0.66, 1.04) 
 Jewish 0.82 (0.53, 1.29) 
 Other  1.50 (0.11, 20.68)       
A priori, criteria for rejecting the null hypothesis of homogeneity across strata of a covariate is α<0.10  
* CLR too wide (few 'black' and 'other' study participants) 
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TABLE A.20 Assessment of Effect Measure Modification in Strata of Covariates for 
Mismatch Repair. The Long Island Breast Cancer Study Project (1996-1997). 
Covariate Stratum Specific  
Breslow-
Day  
p-value 
Mantel Hanzel 
 
OR 95% CI 
 
OR 95% CI 
MSH3 (rs1650663) 
Menopausal Status 
 Pre 0.91 (0.67, 1.23) 0.3519 1.02 (0.86, 1.21) 
Post 1.08 (0.87, 1.34) 
 
  Race  
 
  White 0.98 (0.82, 1.17) 0.3879 1.00 (0.84, 1.19) 
Black 1.36 (0.56, 3.29) 
 
  Other  2.04 (0.61, 6.84) 
 Family History 
   
  No  0.98 (0.81, 1.19) 0.6465 1.00 (0.84, 1.19) 
Yes 1.10 (0.71, 1.70) 
 Religion 
  
 None 1.67 (0.23, 12.22) 0.7708 1.02  (0.85, 1.21) 
Protestant 1.02 (0.72, 1.44) 
 Catholic 0.97 (0.78, 1.22) 
 Jewish 1.21 (0.78, 1.89) 
 Other  0.33 (0.03, 4.04) 
 
 
 MLH1 (rs1799977) 
Menopausal Status 
 Pre 1.05 (0.77, 1.41) 0.8887 1.03 (0.86, 1.22) 
Post 1.02 (0.82, 1.26) 
 
  Race  
 
  White 1.01 (0.85, 1.21) 0.9653 1.01 (0.85, 1.20) 
Black 0.93 (0.34, 2.49) 
 
  Other  1.15 (0.31, 4.26) 
 
  Family History 
   
  No  1.02 (0.84, 1.23) 0.5113 1.04 (0.88, 1.24) 
Yes 1.19 (0.77, 1.84) 
 Religion 
  
 None 2.33 (0.17, 32.58) 0.5872 1.04 (0.87, 1.23) 
Protestant 0.94 (0.66, 1.34) 
 Catholic 1.15 (0.92, 1.44) 
 Jewish 0.80 (0.52, 1.24) 
 Other  0.90 (0.13, 6.08) 
 
 
 MLH1 (rs2286940) 
Menopausal Status 
 Pre 1.11 (0.81, 1.52) 0.1719 0.93 (0.77, 1.12) 
Post 0.84 (0.67, 1.07) 
 
  
Race  
 
  White 0.92 (0.76, 1.11) 0.2987 0.89 (0.74, 1.07) 
Black 0.44 (0.18, 1.10) 
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Other  0.91 (0.28, 2.89) 
 
  Family History 
   
  No  0.91 (0.74, 1.12) 0.5685 0.94 (0.78, 1.13) 
Yes 1.05 (0.67, 1.66) 
 Religion 
  
 None 2.33 (0.17, 32.58) 0.2613 0.92 (0.76, 1.10) 
Protestant 0.80 (0.55, 1.15) 
 Catholic 1.04 (0.82, 1.33) 
 Jewish 0.65 (0.41, 1.04) 
 Other  2.50 (0.37, 16.89) 
 
 
 MSH2 (rs2303428) 
Menopausal Status 
 Pre 1.07 (0.71, 1.59) 0.7255 1.01 (0.79, 1.28) 
Post 0.97 (0.72, 1.32) 
 
  Race  
 
  White 1.01 (0.79, 1.29) 0.5960 1.01 (0.80, 1.29) 
Black 0.42 (0.04, 4.21) 
 
  Other  1.60 (0.41, 6.26) 
 
  Family History 
   
  No  1.02 (0.78, 1.32) 0.6049 1.04 (0.82, 1.33) 
Yes 1.22 (0.64, 2.36) 
 Religion 
  
 None -- 
 Protestant 0.83 (0.50, 1.38) 0.6849 1.02 (0.80, 1.29) 
Catholic 1.13 (0.84, 1.54) 
 Jewish 0.93 (0.52, 1.69) 
 Other  1.17 (0.12, 10.99) 
 
 
 MSH2 (rs3732182) 
Menopausal Status 
 Pre 0.85 (0.63, 1.16) 0.2393 0.99 (0.83, 1.18) 
Post 1.07 (0.86, 1.33) 
 
  
Race  
 
  White 1.00 (0.83, 1.19) 0.6467 0.99 (0.83, 1.18) 
Black 0.64 (0.21, 1.96) 
 
  Other  1.37 (0.41, 4.58) 
 
  Family History 
   
  No  0.99 (0.82, 1.20) 0.7032 0.98 (0.82, 1.16) 
Yes 0.90 (0.58, 1.40) 
 Religion 
  
 None 0.40 (0.05, 3.42) 0.3763 0.98 (0.82, 1.16) 
Protestant 0.86 (0.60, 1.22) 
 Catholic 1.01 (0.81, 1.27) 
 Jewish 1.02 (0.65, 1.60) 
 Other  7.00 (0.61, 79.87) 
 
 
 MSH2 (rs4583514) 
Menopausal Status 
 Pre 0.88 (0.65, 1.21) 0.6385 0.94 (0.79, 1.13) 
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Post 0.97 (0.78, 1.21) 
 
  Race  
 
  White 0.95 (0.79, 1.14) 0.7173 0.96 (0.80, 1.14) 
Black 0.76 (0.18, 3.24) 
 
  Other  1.59 (0.42, 6.07) 
 
  Family History 
   
  No  0.95 (0.78, 1.16) 0.6465 0.94 (0.78, 1.12) 
Yes 0.85 (0.55, 1.33) 
 Religion 
  
 None 2.33 (0.17, 32.58) 0.3257 0.95 (0.79, 1.13) 
Protestant 0.95 (0.66, 1.37) 
 Catholic 0.87 (0.69, 1.10) 
 Jewish 1.14 (0.74, 1.77) 
 Other  7.00 (0.61, 79.87)       
A priori, criteria for rejecting the null hypothesis of homogeneity across strata of a covariate is α<0.10  
 
 
 150    
 
150
 
 
 
TABLE A.21 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Association between CAT 
SNPs and Hormone Receptor Status. The Long Island Breast Cancer Study Project (1996-1997).  
Gene (rs) HR Negative 
 
HR Positive 
 
Case/Control OR 95% CI 
 
Case/Control OR 95% CI 
CAT (rs4756146) 
        TT 100/809 1.00 Reference 
 
398/809 1.00 Reference 
 
CT and CC 21/258 0.66 (0.40, 1.08) 
 
112/258 0.89 (0.69, 1.15) 
CAT (rs2284365) 
        TT 76/610 1.00 Reference 
 
303/610 1.00 Reference 
 
CT and CC 45/456 0.81 (0.54, 1.20) 
 
206/456 0.94 (0.75, 1.17) 
CAT (rs480575) 
        AA 61/504 1.00 Reference 
 
272/504 1.00 Reference 
  AG and GG 61/533 0.99 (0.67, 1.44)   237/533 0.84 (0.68, 1.04) 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio; HR Positive, ER+/PR+ ER+/PR- ER-/PR+; HR Negative, ER-/PR- 
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TABLE A.22 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Association between Mismatch 
Repair Genes and Hormone Receptor Status. The Long Island Breast Cancer Study Project (1996-1997).  
Gene (rs) HR Negative 
 
HR Positive 
 
Case/Control OR 95% CI 
 
Case/Control OR 95% CI 
MSH3 (rs1650663) 
       
 
TT 62/530 1.00 Reference 
 
272/530 1.00 Reference 
 
CT and CC 61/539 0.99 (0.68, 1.44) 
 
247/539 0.89 (0.72, 1.10) 
MLH1 (rs1799977) 
        
 
AA 70/542 1.00 Reference 
 
248/542 1.00 Reference 
 
AG and GG 53/530 0.77 (0.52, 1.12) 
 
273/530 1.11 (0.89, 1.37) 
MLH1 (rs2286940) 
        
 
CC 49/342 1.00 Reference 
 
162/342 1.00 Reference 
 
CT and TT 73/732 0.69 (0.46, 1.01) 
 
356/732 0.99 (0.78, 1.24) 
MSH2 (rs2303428) 
        
 
TT 106/886 1.00 Reference 
 
422/886 1.00 Reference 
 
CT and CC 14/167 0.71 (0.39, 1.27) 
 
87/167 1.15 (0.86, 1.54) 
MSH2 (rs3732182) 
        
 
GG 69/574 1.00 Reference 
 
278/574 1.00 Reference 
 
GT and TT 51/494 0.85 (0.58, 1.25) 
 
235/494 1.00 (0.80, 1.24) 
MSH2 (rs4583514) 
        
 
GG 44/404 1.00 Reference 
 
210/404 1.00 Reference 
  AG and AA 78/668 1.05 (0.71, 1.57)   311/668 0.91 (0.73, 1.13) 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio; HR Positive, ER+/PR+ ER+/PR- ER-/PR+; HR Negative, ER-
/PR- 
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TABLE A.23 Likelihood Ratio Test for SNP*SNP Interactions in the CAT Gene. The Long Island 
Breast Cancer Study Project (1996-1997). 
No Interaction 
Term  
Interaction Term 
Included 
Difference  
(B-C) p-value 
SNP*SNP Interactions 
 CAT (rs4756146*rs2284365) 2760.515 2759.047 1.468 0.226 
CAT (rs4756146*rs480575) 2718.150 2716.790 1.360 0.244 
CAT (rs2284365*rs480575) 2717.824 2714.903 2.921 0.087 
CAT (rs1001179*rs4756146) 2739.668 2739.606 0.062 0.803 
CAT (rs1001179*rs2284365) 2732.163 2732.146 0.017 0.896 
CAT (rs1001179*rs480575) 2688.248 2687.495 0.753 0.386 
A priori p value for interaction on the multiplicative scale is 0.10 
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TABLE A.24 Likelihood Ratio Test for Gene*Gene and SNP*SNP Interactions in the Mismatch Repair 
Pathway. The Long Island Breast Cancer Study Project (1996-1997). 
No 
Interaction 
Term  
Interaction 
Term Included Difference  p-value 
Gene*Gene Interactions 
 MSH3 (rs1650663) * MLH1 (rs1799977) 2825.194 2823.410 1.784 0.182 
MSH3 (rs1650663) * MLH1 (rs2286940) 2815.901 2812.445 3.456 0.063 
MSH3 (rs1650663) * MSH2 (rs2303428) 2770.021 2769.270 0.751 0.386 
MSH3 (rs1650663) * MSH2 (rs3732182) 2798.508 2798.507 0.001 0.975 
MSH3 (rs1650663) * MSH2 (rs4583514) 2819.465 2819.329 0.136 0.712 
MLH1 (rs1799977) * MSH2 (rs2303428) 2774.930 2770.922 4.008 0.045 
MLH1 (rs1799977) * MSH2 (rs3732182) 2810.043 2808.329 1.714 0.190 
MLH1 (rs1799977) * MSH2 (rs4583514) 2830.626 2829.295 1.331 0.249 
MLH1 (rs2286940) * MSH2 (rs2303428) 2770.263 2770.139 0.124 0.725 
MLH1 (rs2286940) * MSH2 (rs3732182) 2803.660 2802.143 1.517 0.218 
MLH1 (rs2286940) * MSH2 (rs4583514) 2824.145 2822.577 1.568 0.210 
SNP*SNP Interactions 
 MLH1 (rs1799977 * rs2286940) 2825.258 2823.759 1.499 0.221 
MSH2 (rs2303428 * rs3732182) 2752.403 2751.024 1.379 0.240 
MSH2 (rs2303428 * rs4583514) 2773.357 2771.924 1.433 0.231 
MSH2 (rs3732182 * rs4583514) 2809.689 2808.243 1.446 0.229 
A priori p value for interaction on the multiplicative scale is 0.10 
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TABLE A.25 Decision for Inclusion - Combined Effects of Polymorphisms in the CAT Gene on 
Breast Cancer Risk. The Long Island Breast Cancer Study Project (1996-1997). 
Gene (rs) Cases Controls 
Pre- and 
Postmenopausal 
women  
Decision using # 
at-risk alleles 
   
OR 95% CI 
 
CAT (rs4756146) 
    
 
 
TT 774 809 1.00 Reference Include CAT-
rs4756146 (wild-
type T allele is 
risk allele)  
 
CT 201 229 0.92 (0.74, 1.14) 
 
CC 12 29 0.65 (0.36, 1.18) 
 
CT and CC 213 258 0.89 (0.73, 1.10) 
CAT (rs2284365) 
     
 
 
TT 589 610 1.00 Reference Include CAT-
rs2284365 (wild-
type T allele is 
risk allele)  
 
CT 344 371 0.97 (0.80, 1.16) 
 
CC 58 85 0.70 (0.49, 1.00) 
 
CT and CC 402 456 0.92 (0.77, 1.09) 
CAT (rs480575) 
   
 
 
AA 517 504 1.00 Reference Include CAT-
rs480575 (wild-
type A allele is 
risk allele)  
 
AG 378 411 0.88 (0.73, 1.06) 
 
GG 89 111 0.77 (0.57, 1.05) 
 
AG and GG 467 533 0.86 (0.72, 1.02) 
CAT (rs1001179) 
   
 
 
CC 634 696 1.00 Reference Include CAT-
rs1001179 
(variant T allele is 
risk allele)  
 
CT 356 348 1.12 (0.93, 1.35) 
 
TT 46 42 1.20 (0.78, 1.85) 
  CT and TT 402 390 1.13 (0.95, 1.35) 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio 
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TABLE A.26 Decision for Inclusion - The Analysis of Combined Effects of Polymorphisms in the 
MMR Pathway on Breast Cancer Risk. The Long Island Breast Cancer Study Project (1996-
1997). 
Gene (rs) Cases Controls 
Pre- and 
Postmenopausal 
women  
Decision using  
# variant alleles 
   
OR 95% CI 
 
MSH3 (rs1650663) 
    
 
 
TT 497 530 1.00 Reference 
Include MSH3-
rs1650663 (TT=0; 
CT=1; CC=2)  
 
CT 412 429 1.03 (0.86, 1.23) 
 
CC 98 110 0.97 (0.72, 1.30) 
 
CT and CC 510 539 1.01 (0.85, 1.21) 
MLH1 (rs1799977) 
     
 
 
AA 503 542 1.00 Reference 
Include MLH1-
rs1799977 (AA=0; 
AG=1; GG=2)  
 
AG 410 443 0.98 (0.82, 1.18) 
 
GG 98 87 1.18 (0.86, 1.62) 
 
AG and 
GG 508 530 1.01 (0.85, 1.21) 
MLH1 (rs2286940) 
     
 
 
CC 340 342 1.00 Reference 
Include MLH1-
rs2286940 (CC=0; 
CT=1; TT=2)  
 CT 467 541 0.85 (0.70, 1.03) 
 
TT 198 191 1.02 (0.79, 1.31) 
 
CT and TT 665 732 0.89 (0.74, 1.07) 
MSH2 (rs2303428) 
     
 
 
TT 828 886 1.00 Reference 
Include MSH2-
rs2303428 (TT=0; 
CT=1; CC=2)  
 
CT 150 155 1.04 (0.81, 1.33) 
 
CC 8 12 0.72 (0.29, 1.77) 
 
CT and CC 158 167 1.02 (0.80, 1.29) 
MSH2 (rs3732182) 
     
 
 
GG 542 574 1.00 Reference Include MSH2-
rs3732182 
(GG=0; GT=1; 
TT=2) 
 
GT 375 411 0.97 (0.81, 1.17) 
 
TT 80 83 1.02 (0.73, 1.41) 
 
GT and TT 455 494 0.98 (0.82, 1.17) 
MSH2 (rs4583514) 
     
 
 
GG 394 404 1.00 Reference Include MSH2-
rs4583514 
(GG=0; AG=1; 
AA=2)  
 
AG 485 521 0.96 (0.80, 1.16) 
 
AA 131 147 0.91 (0.70, 1.20) 
  AG and AA 616 668 0.95 (0.80, 1.14) 
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio 
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TABLE A.27 Association between Number of High-Risk Alleles in the CAT gene and Breast Cancer 
Risk. The Long Island Breast Cancer Study Project (1996-1997). 
number 
of at risk 
alleles* 
Cases Controls Pre- and Postmenopausal 
women  
Pathway Category 
  
   
OR 95% CI CLR 
 
OR 95% CI 
0 14 23 1.00 Reference -- 0-2 high-risk alleles 1.00 Reference 
1 28 35 1.35 (0.58, 3.12) 5.38 
 
  2 23 40 0.94 (0.40, 2.19) 5.48 
 
  3 115 125 1.54 (0.75, 3.16) 4.21 3-6 high-risk alleles 1.36 (0.97, 1.90) 
4 148 164 1.52 (0.75, 3.07) 4.09 
 
  
5 93 115 1.34 (0.65, 2.77) 4.26 
 
  6 253 274 1.53 (0.76, 3.05) 4.01 
 
  
7 209 186 1.85 (0.92, 3.72) 4.04 ≥7 high-risk alleles 1.69 (1.18, 2.44) 
8 45 39 1.90 (0.86, 4.21) 4.90       
OR, odds ratio (age adjusted); 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio  
  
*Includes rs4756146 (wild-type T allele); rs2284365 (wild-type T allele); rs480575 (wild-type A allele); rs1001179 (variant T allele) 
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TABLE A.28 Association between Number of Variant Alleles in the Mismatch Repair Pathway and Breast 
Cancer Risk. The Long Island Breast Cancer Study Project (1996-1997). 
# variant 
alleles Cases Controls 
Pre- and Postmenopausal 
women  
Pathway Category 
  
   
OR 95% CI CLR 
 
OR 95% CI 
0 55 51 1.00 Reference -- 0-3 variant alleles 1.00 Reference 
1 106 110 0.89 (0.56, 1.43) 2.55 
 
  2 161 184 0.83 (0.54, 1.29) 2.39 
 
  3 183 205 0.83 (0.54, 1.28) 2.37 
 
  
4 169 181 0.88 (0.57, 1.36) 2.39 4-7 variant alleles 1.01 (0.85, 1.22) 
5 132 143 0.88 (0.56, 1.39) 2.48 
 
  6 81 85 0.86 (0.53, 1.41) 2.66 
 
  
7 40 47 0.81 (0.45, 1.44) 3.20 
 
  8 24 17 1.28 (0.61, 2.67) 4.38 8-11 variant alleles 1.28 (0.76, 2.16) 
9 4 7 0.50 (0.14, 1.83) 13.07 
 
  10 4 3 1.24 (0.26, 5.90) 22.69 
 
  
11 2 1 1.93 (0.17, 22.12) 130.12       
OR, odds ratio; 95% CI, 95% confidence interval; CLR, Confidence Limit Ratio 
  
 
 
 158    
 
158
 
 
 
TABLE A.29 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Multiplicative Effect of Oxidative 
Stress SNPs and Lifetime Recreational Physical Activity on Breast Cancer Risk in the Long Island Breast Cancer 
Study Project (1996-1997). 
 
Homozygous for major 
allele  
At least one copy of minor 
allele   
Gene (SNP) major/minor alleles 
Lifetime RPA  Ca/Co OR 95% CI   Ca/Co OR 95% CI   
p for 
interaction 
CAT (rs4756146) T/C 
     
<0.01 hrs/wk 169/161 1.00 reference  
 
48/57 0.75 (0.47, 1.18) 
 
0.247 
0.01-6.35 hrs/wk 296/290 1.00 reference  
 
82/94 0.86 (0.61, 1.21) 
  
>6.35 hrs/wk 270/318 1.00 reference  
 
82/95 1.05 (0.74, 1.48) 
 
 
CAT (rs2284365) T/C 
     
<0.01 hrs/wk 131/117 1.00 reference  
 
88/101 0.77 (0.52, 1.14) 
 
0.311 
0.01-6.35 hrs/wk 229/227 1.00 reference  
 
151/163 0.95 (0.71, 1.27) 
  
>6.35 hrs/wk 198/223 1.00 reference  
 
145/174 1.01 (0.75, 1.36) 
 
 
CAT (rs480575) A/G 
     
<0.01 hrs/wk 115/100 1.00 reference  
 
102/114 0.77 (0.52, 1.14) 
 
0.479 
0.01-6.35 hrs/wk 197/190 1.00 reference  
 
176/184 0.93 (0.70, 1.25) 
  
>6.35 hrs/wk 179/191 1.00 reference  
 
167/206 0.90 (0.67, 1.20) 
 
 
CAT (rs1001179) C/T 
     
<0.01 hrs/wk 133/134 1.00 reference  
 
94/81 1.12 (0.75, 1.66) 
 
0.141 
0.01-6.35 hrs/wk 254/254 1.00 reference  
 
138/144 0.98 (0.73, 1.31) 
  
>6.35 hrs/wk 216/275 1.00 reference  
 
152/144 1.30 (0.97, 1.75) 
 
 
COMT (rs4680) G/A 
     
<0.01 hrs/wk 61/58 1.00 reference  
 
167/162 0.95 (0.61, 1.46) 
 
0.490 
0.01-6.35 hrs/wk 114/109 1.00 reference  
 
284/291 0.96 (0.70, 1.32) 
  
>6.35 hrs/wk 100/99 1.00 reference  
 
271/321 0.83 (0.60, 1.16) 
 
 
COMT (rs737865) T/C 
     
<0.01 hrs/wk 113/105 1.00 reference  
 
111/116 0.85 (0.58, 1.26) 
 
0.536 
0.01-6.35 hrs/wk 190/190 1.00 reference  
 
204/207 0.96 (0.73, 1.28) 
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>6.35 hrs/wk 168/202 1.00 reference  
 
193/218 1.04 (0.78, 1.39) 
 
 
GPX (rs1050450) C/T 
     
<0.01 hrs/wk 110/106 1.00 reference  
 
116/113 0.99 (0.67, 1.46) 
 
0.736 
0.01-6.35 hrs/wk 178/184 1.00 reference  
 
219/214 1.04 (0.79, 1.39) 
  
>6.35 hrs/wk 169/205 1.00 reference  
 
198/213 1.07 (0.80, 1.42) 
 
 
GSTA1 (rs3957356) G/A 
     
<0.01 hrs/wk 70/74 1.00 reference  
 
157/145 1.03 (0.68, 1.55) 
 
0.779 
0.01-6.35 hrs/wk 136/143 1.00 reference  
 
260/255 1.05 (0.78, 1.41) 
  
>6.35 hrs/wk 120/149 1.00 reference  
 
247/270 1.14 (0.85, 1.55) 
 
 
GSTP1 (rs1695) A/G 
     
<0.01 hrs/wk 116/107 1.00 reference  
 
111/106 0.86 (0.58, 1.27) 
 
0.269 
0.01-6.35 hrs/wk 206/184 1.00 reference  
 
183/203 0.80 (0.60, 1.06) 
  
>6.35 hrs/wk 167/195 1.00 reference  
 
193/221 1.03 (0.77, 1.38) 
 
 
GSTM1 (gene deletion) 
     
<0.01 hrs/wk 109/111 1.00 reference  
 
102/87 1.17 (0.78, 1.76) 
 
0.381 
0.01-6.35 hrs/wk 182/197 1.00 reference  
 
190/170 1.22 (0.91, 1.64) 
  
>6.35 hrs/wk 188/215 1.00 reference  
 
158/171 1.05 (0.78, 1.42) 
 
 
GSTT1 (gene deletion) 
     
<0.01 hrs/wk 163/155 1.00 reference  
 
49/46 1.00 (0.62, 1.63) 
 
0.664 
0.01-6.35 hrs/wk 292/288 1.00 reference  
 
83/85 0.92 (0.65, 1.30) 
  
>6.35 hrs/wk 287/311 1.00 reference  
 
64/81 0.91 (0.63, 1.32) 
 
 
MnSOD (rs4880) T/C 
     
<0.01 hrs/wk 48/55 1.00 reference  
 
178/160 1.20 (0.76, 1.91) 
 
0.383 
0.01-6.35 hrs/wk 105/96 1.00 reference  
 
288/302 0.86 (0.62, 1.19) 
  
>6.35 hrs/wk 100/108 1.00 reference  
 
264/309 0.97 (0.70, 1.34) 
 
 
MPO (rs2333227) G/A 
     
<0.01 hrs/wk 142/127 1.00 reference  
 
86/93 0.84 (0.57, 1.25) 
 
0.353 
0.01-6.35 hrs/wk 247/232 1.00 reference  
 
151/167 0.87 (0.65, 1.16) 
  
>6.35 hrs/wk 226/257 1.00 reference    140/161 1.00 (0.74, 1.34)     
OR, odds ratio; 95% CI, 95% confidence interval 
        
A priori, criteria for interaction on the multiplicative scale is α<0.10  
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TABLE A.30 Age Adjusted Odds Ratios and 95% Confidence Intervals for Multiplicative Effects of Oxidative Stress 
SNPs and Postmenopausal Recreational Physical Activity on Postmenopausal Breast Cancer Risk. The Long Island 
Breast Cancer Study Project (1996-1997). 
Homozygous for major 
allele 
At least one copy of minor 
allele 
Gene (SNP) major/minor alleles 
Postmenopausal RPA  
Ca/Co OR 95% CI   Ca/Co OR 95% CI   
p for 
interaction 
CAT (rs4756146) T/C 
     
<0.01 hrs/wk 133/104 1.00 reference  
 
33/44 0.57 (0.33, 0.98) 
 
0.126 
0.01-9.23 hrs/wk 169/140 1.00 reference  
 
48/51 0.78 (0.49, 1.24) 
  
>9.23 hrs/wk 137/163 1.00 reference  
 
36/45 1.05 (0.63, 1.76) 
 
 
CAT (rs2284365) T/C 
     
<0.01 hrs/wk 104/80 1.00 reference  
 
64/69 0.70 (0.44, 1.13) 
 
0.331 
0.01-9.23 hrs/wk 126/109 1.00 reference  
 
92/81 0.97 (0.65, 1.44) 
  
>9.23 hrs/wk 104/117 1.00 reference  
 
64/89 0.87 (0.57, 1.35) 
 
 
CAT (rs480575) A/G 
     
<0.01 hrs/wk 90/71 1.00 reference  
 
77/76 0.76 (0.48, 1.22) 
 
0.692 
0.01-9.23 hrs/wk 107/85 1.00 reference  
 
104/98 0.83 (0.55, 1.24) 
  
>9.23 hrs/wk 93/99 1.00 reference  
 
79/100 0.91 (0.60, 1.39) 
 
 
CAT (rs1001179) C/T 
   <0.01 hrs/wk 103/95 1.00 reference  70/53 1.36 (0.83, 2.21) 0.043 
0.01-9.23 hrs/wk 149/126 1.00 reference  75/71 0.89 (0.59, 1.34) 
 >9.23 hrs/wk 100/143 1.00 reference  82/69 1.61 (1.06, 2.45) 
 COMT (rs4680) G/A 
   <0.01 hrs/wk 46/37 1.00 reference  128/116 0.81 (0.47, 1.40)  0.446 
0.01-9.23 hrs/wk 64/54 1.00 reference  162/142 0.99 (0.64, 1.53) 
 >9.23 hrs/wk 56/52 1.00 reference  130/160 0.78 (0.49, 1.23) 
 COMT (rs737865) T/C 
   <0.01 hrs/wk 89/77 1.00 reference  80/76 0.97 (0.60, 1.56) 0.439 
0.01-9.23 hrs/wk 109/87 1.00 reference  118/107 0.88 (0.59, 1.30) 
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>9.23 hrs/wk 77/98 1.00 reference  102/114 1.11 (0.74, 1.68) 
 GPX (rs1050450) C/T 
   <0.01 hrs/wk 97/82 1.00 reference  93/70 1.46 (0.92, 2.34) 0.349 
0.01-9.23 hrs/wk 107/97 1.00 reference  120/96 1.08 (0.73, 1.61) 
 >9.23 hrs/wk 79/103 1.00 reference  103/109 1.18 (0.78, 1.79) 
 GSTA1 (rs3957356) G/A 
   <0.01 hrs/wk 49/48 1.00 reference  124/104 1.11 (0.67, 1.84) 0.295 
0.01-9.23 hrs/wk 76/68 1.00 reference  151/126 1.07 (0.71, 1.63) 
 >9.23 hrs/wk 59/61 1.00 reference  124/152 0.84 (0.54, 1.30) 
 GSTP1 (rs1695) A/G 
   <0.01 hrs/wk 84/80 1.00 reference  90/68 1.22 (0.77, 1.95) 0.006 
0.01-9.23 hrs/wk 123/80 1.00 reference  97/109 0.56 (0.38, 0.84) 
 >9.23 hrs/wk 76/92 1.00 reference  103/120 1.08 (0.71, 1.64) 
 GSTM1 (gene deletion) 
   <0.01 hrs/wk 72/73 1.00 reference  86/65 1.40 (0.86, 2.28) 0.387 
0.01-9.23 hrs/wk 105/99 1.00 reference  111/78 1.38 (0.92, 2.08) 
 >9.23 hrs/wk 93/108 1.00 reference  82/88 1.12 (0.73, 1.71) 
 GSTT1 (gene deletion) 
   <0.01 hrs/wk 124/109 1.00 reference  34/31 0.92 (0.51, 1.64) 0.526 
0.01-9.23 hrs/wk 175/136 1.00 reference  42/42 0.78 (0.48, 1.28) 
 >9.23 hrs/wk 139/153 1.00 reference  36/47 0.96 (0.58, 1.60) 
 MnSOD (rs4880) T/C 
   <0.01 hrs/wk 46/39 1.00 reference  128/110 0.87 (0.51, 1.48) 0.219 
0.01-9.23 hrs/wk 59/57 1.00 reference  164/138 1.17 (0.76, 1.81) 
 >9.23 hrs/wk 57/51 1.00 reference  125/161 0.74 (0.47, 1.16) 
 MPO (rs2333227) G/A 
   <0.01 hrs/wk 105/95 1.00 reference  69/57 1.16 (0.72, 1.87) 0.119 
0.01-9.23 hrs/wk 144/112 1.00 reference  82/84 0.76 (0.51, 1.14) 
 >9.23 hrs/wk 109/136 1.00 reference    74/76 1.16 (0.76, 1.76)     
OR, odds ratio; 95% CI, 95% confidence interval 
 A priori, criteria for interaction on the multiplicative scale is α<0.10  
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TABLE A.31 Age Adjusted Odds Ratios and 95% Confidence Intervals for Multiplicative Effects of DNA Repair 
SNPs and Lifetime Recreational Physical Activity on Breast Cancer Risk. The Long Island Breast Cancer Study 
Project (1996-1997). 
 
Homozygous for major 
allele  
At least one copy of minor 
allele   
Gene (SNP) major/minor alleles 
Postmenopausal RPA  Ca/Co OR 95% CI   Ca/Co OR 95% CI   
p for 
interaction 
ERCC1 (rs3212986) C/A 
     
<0.01 hrs/wk 119/122 1.00 reference  
 
110/101 1.06 (0.72, 1.55) 
 
0.665 
0.01-6.35 hrs/wk 227/243 1.00 reference  
 
178/161 1.16 (0.87, 1.54) 
 
 
>6.35 hrs/wk 181/218 1.00 reference  
 
193/204 1.16 (0.87, 1.54) 
 
 
MGMT (rs12917) C/T 
     
<0.01 hrs/wk 173/155 1.00 reference  
 
58/67 0.81 (0.53, 1.23) 
 
0.022 
0.01-6.35 hrs/wk 300/296 1.00 reference  
 
107/111 0.92 (0.67, 1.26) 
 
 
>6.35 hrs/wk 276/329 1.00 reference  
 
109/95 1.40 (1.01, 1.94) 
 
 
MGMT (rs2308321) A/G 
     
<0.01 hrs/wk 180/175 1.00 reference  
 
51/46 1.05 (0.66, 1.68) 
 
0.324 
0.01-6.35 hrs/wk 321/309 1.00 reference  
 
86/96 0.81 (0.58, 1.13) 
 
 
>6.35 hrs/wk 286/322 1.00 reference  
 
90/101 0.98 (0.70, 1.37) 
 
 
MGMT (rs2308327) A/G 
     
<0.01 hrs/wk 189/180 1.00 reference  
 
44/43 0.99 (0.61, 1.60) 
 
0.217 
0.01-6.35 hrs/wk 333/320 1.00 reference  
 
74/88 0.76 (0.54, 1.08) 
 
 
>6.35 hrs/wk 294/336 1.00 reference  
 
83/89 1.05 (0.74, 1.48) 
 
 
MLH1 (rs1799977) A/G 
       
<0.01 hrs/wk 106/123 1.00 reference  
 
117/97 1.37 (0.92, 2.03) 
 
0.051 
0.01-6.35 hrs/wk 204/193 1.00 reference  
 
179/195 0.84 (0.63, 1.12) 
  
>6.35 hrs/wk 175/198 1.00 reference  
 
181/214 0.95 (0.71, 1.26) 
  
MLH1 (rs2286940) C/T 
       
<0.01 hrs/wk 73/78 1.00 reference  
 
150/142 1.13 (0.75, 1.70) 
 
0.058 
0.01-6.35 hrs/wk 142/117 1.00 reference  
 
239/274 0.69 (0.51, 0.94) 
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>6.35 hrs/wk 112/127 1.00 reference  
 
240/284 0.92 (0.67, 1.26) 
  
MSH2 (rs2303428) T/C 
       
<0.01 hrs/wk 180/186 1.00 reference  
 
35/29 1.33 (0.76, 2.33) 
 
0.392 
0.01-6.35 hrs/wk 315/322 1.00 reference  
 
58/62 0.97 (0.65, 1.45) 
  
>6.35 hrs/wk 293/338 1.00 reference  
 
56/65 1.01 (0.68, 1.50) 
  
MSH2 (rs3732182) G/T 
       
<0.01 hrs/wk 122/113 1.00 reference  
 
101/106 0.87 (0.59, 1.29) 
 
0.212 
0.01-6.35 hrs/wk 209/205 1.00 reference  
 
166/181 0.92 (0.69, 1.24) 
 
 
>6.35 hrs/wk 185/228 1.00 reference  
 
166/183 1.15 (0.86, 1.54) 
  
MSH2 (rs4583514) A/G 
       
<0.01 hrs/wk 86/84 1.00 reference  
 
138/136 1.01 (0.68, 1.51) 
 
0.713 
0.01-6.35 hrs/wk 148/143 1.00 reference  
 
233/248 0.92 (0.68, 1.24) 
 
 
>6.35 hrs/wk 141/157 1.00 reference  
 
215/252 0.96 (0.71, 1.29) 
  
MSH3 (rs1650663) T/C 
       
<0.01 hrs/wk 119/115 1.00 reference  
 
103/104 0.98 (0.67, 1.44) 
 
0.150 
0.01-6.35 hrs/wk 179/199 1.00 reference  
 
201/187 1.20 (0.89, 1.60) 
  
>6.35 hrs/wk 175/190 1.00 reference  
 
181/222 0.89 (0.67, 1.19) 
  
OGG1 (rs1052133) C/G 
     
<0.01 hrs/wk 148/132 1.00 reference  
 
84/89 0.88 (0.59, 1.30) 
 
<0.001 
0.01-6.35 hrs/wk 214/262 1.00 reference  
 
182/138 1.68 (1.26, 2.24) 
 
 
>6.35 hrs/wk 226/231 1.00 reference  
 
141/187 0.73 (0.54, 0.97) 
 
 
XPA (rs1800975) G/A 
     
<0.01 hrs/wk 118/104 1.00 reference  
 
114/118 0.81 (0.55, 1.19) 
 
0.458 
0.01-6.35 hrs/wk 185/174 1.00 reference  
 
218/228 0.91 (0.69, 1.21) 
 
 
>6.35 hrs/wk 164/186 1.00 reference  
 
211/238 0.99 (0.74, 1.32) 
 
 
XPC (rs2228000) C/T 
     
<0.01 hrs/wk 129/123 1.00 reference  
 
102/99 0.98 (0.66, 1.43) 
 
0.038 
0.01-6.35 hrs/wk 251/225 1.00 reference  
 
153/179 0.76 (0.57, 1.00) 
 
 
>6.35 hrs/wk 208/252 1.00 reference  
 
168/173 1.19 (0.90, 1.59) 
 
 
XPC (rs2228001) A/C 
     
<0.01 hrs/wk 88/71 1.00 reference  
 
143/150 0.76 (0.51, 1.14) 
 
0.060 
 
 164    
 
164
 
0.01-6.35 hrs/wk 124/140 1.00 reference  
 
280/263 1.25 (0.93, 1.68) 
 
 
>6.35 hrs/wk 117/136 1.00 reference  
 
258/289 1.01 (0.75, 1.37) 
 
 
XPD (rs1799793) G/A 
     
<0.01 hrs/wk 90/97 1.00 reference  
 
140/125 1.24 (0.84, 1.82) 
 
0.242 
0.01-6.35 hrs/wk 166/199 1.00 reference  
 
237/204 1.38 (1.04, 1.83) 
  
>6.35 hrs/wk 144/173 1.00 reference  
 
230/252 1.09 (0.82, 1.46) 
 
 
XPD (rs13181) A/C 
     
<0.01 hrs/wk 84/97 1.00 reference  
 
149/124 1.42 (0.96, 2.09) 
 
0.231 
0.01-6.35 hrs/wk 148/177 1.00 reference  
 
250/226 1.30 (0.98, 1.73) 
  
>6.35 hrs/wk 131/155 1.00 reference  
 
241/269 1.07 (0.80, 1.45) 
  
XPF (rs1800067) G/A 
     
<0.01 hrs/wk 191/170 1.00 reference  
 
31/41 0.59 (0.34, 1.01) 
 
0.046 
0.01-6.35 hrs/wk 322/315 1.00 reference  
 
65/75 0.85 (0.59, 1.23) 
  
>6.35 hrs/wk 304/358 1.00 reference  
 
56/54 1.26 (0.83, 1.90) 
  
XPG (rs17655) G/C 
     
<0.01 hrs/wk 117/117 1.00 reference  
 
102/94 1.14 (0.77, 1.70) 
 
0.043 
0.01-6.35 hrs/wk 205/211 1.00 reference  
 
175/171 1.08 (0.81, 1.45) 
  
>6.35 hrs/wk 214/214 1.00 reference  
 
140/191 0.76 (0.56, 1.02) 
  
XRCC1 (rs1799782) C/T 
     
<0.01 hrs/wk 212/196 1.00 reference  
 
21/26 0.81 (0.43, 1.52) 
 
0.340 
0.01-6.35 hrs/wk 347/349 1.00 reference  
 
60/58 1.06 (0.72, 1.58) 
  
>6.35 hrs/wk 334/374 1.00 reference  
 
42/51 0.85 (0.54, 1.33) 
 
 
XRCC1 (rs25487) G/A 
     
<0.01 hrs/wk 95/91 1.00 reference  
 
138/132 1.01 (0.68, 1.49) 
 
0.446 
0.01-6.35 hrs/wk 162/163 1.00 reference  
 
245/245 1.00 (0.75, 1.33) 
  
>6.35 hrs/wk 134/166 1.00 reference    243/259 1.16 (0.87, 1.56)     
OR, odds ratio; 95% CI, 95% confidence interval 
        
A priori, criteria for interaction on the multiplicative scale is α<0.10  
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TABLE A.32 Age Adjusted Odds Ratios and 95% Confidence Intervals for Multiplicative Effects of DNA Repair 
SNPs and Postmenopausal Recreational Physical Activity on Breast Cancer Risk. The Long Island Breast Cancer 
Study Project (1996-1997). 
 
Homozygous for major 
allele  
At least one copy of minor 
allele   
Gene (SNP) major/minor alleles 
Postmenopausal RPA  Ca/Co OR 95% CI   Ca/Co OR 95% CI   
p for 
interaction 
ERCC1 (rs3212986) C/A 
     
<0.01 hrs/wk 93/84 1.00 reference  
 
82/71 0.98 (0.62, 1.56) 
 
0.466 
0.01-9.23 hrs/wk 128/116 1.00 reference  
 
104/82 1.13 (0.76, 1.68) 
 
 
>9.23 hrs/wk 93/114 1.00 reference  
 
92/98 1.14 (0.76, 1.71) 
 
 
MGMT (rs12917) C/T 
     
<0.01 hrs/wk 137/113 1.00 reference  
 
40/40 0.83 (0.48, 1.41) 
 
0.129 
0.01-9.23 hrs/wk 163/141 1.00 reference  
 
70/59 1.02 (0.67, 1.55) 
 
 
>9.23 hrs/wk 128/162 1.00 reference  
 
58/50 1.41 (0.89, 2.23) 
 
 
MGMT (rs2308321) A/G 
     
<0.01 hrs/wk 141/125 1.00 reference  
 
36/28 1.06 (0.60, 1.88) 
 
0.554 
0.01-9.23 hrs/wk 175/149 1.00 reference  
 
58/50 0.99 (0.63, 1.54) 
 
 
>9.23 hrs/wk 143/159 1.00 reference  
 
43/53 0.93 (0.58, 1.51) 
 
 
MGMT (rs2308327) A/G 
     
<0.01 hrs/wk 149/130 1.00 reference  
 
29/25 0.94 (0.51, 1.73) 
 
0.752 
0.01-9.23 hrs/wk 186/156 1.00 reference  
 
47/44 0.88 (0.55, 1.42) 
 
 
>9.23 hrs/wk 145/163 1.00 reference  
 
42/50 0.99 (0.61, 1.61) 
 
 
MLH1 (rs1799977) A/G 
   <0.01 hrs/wk 72/81 1.00 reference  
 
101/70 1.65 (1.04, 2.64) 
 
0.010 
0.01-9.23 hrs/wk 107/93 1.00 reference  
 
110/99 0.91 (0.61, 1.36) 
 
 
>9.23 hrs/wk 93/96 1.00 reference  
 
85/114 0.68 (0.45, 1.03) 
 
 
MLH1 (rs2286940) C/T 
   <0.01 hrs/wk 50/47 1.00 reference  123/104 1.19 (0.72, 1.98) 0.085 
0.01-9.23 hrs/wk 76/55 1.00 reference  138/139 0.69 (0.45, 1.05) 
>9.23 hrs/wk 62/59 1.00 reference  114/150 0.65 (0.42, 1.02) 
 MSH2 (rs2303428) T/C 
   <0.01 hrs/wk 140/125 1.00 reference  25/20 1.37 (0.66, 2.82) 0.476 
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0.01-9.23 hrs/wk 174/160 1.00 reference  36/31 1.03 (0.61, 1.76) 
>9.23 hrs/wk 152/176 1.00 reference  23/31 0.89 (0.49, 1.63) 
 MSH2 (rs3732182) G/T 
   <0.01 hrs/wk 98/82 1.00 reference  75/69 0.95 (0.59, 1.51) 0.329 
0.01-9.23 hrs/wk 108/102 1.00 reference  102/90 1.04 (0.70, 1.55) 
>9.23 hrs/wk 95/121 1.00 reference  80/88 1.26 (0.83, 1.93) 
 MSH2 (rs4583514) A/G 
   <0.01 hrs/wk 73/61 1.00 reference  100/90 0.98 (0.61, 1.56) 0.964 
0.01-9.23 hrs/wk 81/70 1.00 reference  135/124 0.94 (0.63, 1.41) 
>9.23 hrs/wk 71/80 1.00 reference  107/129 0.98 (0.64, 1.50) 
 MSH3 (rs1650663) T/C 
  <0.01 hrs/wk 97/79 1.00 reference  74/70 0.89 (0.56, 1.42) 0.127 
0.01-9.23 hrs/wk 103/109 1.00 reference  114/83 1.38 (0.93, 2.06) 
>9.23 hrs/wk 83/97 1.00 reference  94/113 0.95 (0.63, 1.44) 
OGG1 (rs1052133) C/G 
     
<0.01 hrs/wk 113/90 1.00 reference  
 
64/61 0.86 (0.53, 1.38) 
 
0.177 
0.01-9.23 hrs/wk 128/122 1.00 reference  
 
94/73 1.27 (0.85, 1.89) 
  
>9.23 hrs/wk 106/118 1.00 reference  
 
75/91 0.80 (0.52, 1.22) 
 
 
XPA (rs1800975) G/A 
     
<0.01 hrs/wk 84/73 1.00 reference  
 
93/81 0.89 (0.56, 1.43) 
 
0.131 
0.01-9.23 hrs/wk 110/83 1.00 reference  
 
121/112 0.83 (0.56, 1.22) 
 
 
>9.23 hrs/wk 75/97 1.00 reference  
 
112/115 1.27 (0.84, 1.91) 
 
 
XPC (rs2228000) C/T 
     
<0.01 hrs/wk 93/81 1.00 reference  
 
71/67 0.84 (0.53, 1.34) 
 
0.048 
0.01-9.23 hrs/wk 121/112 1.00 reference  
 
109/82 1.29 (0.87, 1.91) 
 
 
>9.23 hrs/wk 112/115 1.00 reference  
 
91/86 1.53 (1.01, 2.30) 
 
 
XPC (rs2228001) A/C 
     
<0.01 hrs/wk 67/44 1.00 reference  
 
110/108 0.63 (0.39, 1.04) 
 
0.077 
0.01-9.23 hrs/wk 75/65 1.00 reference  
 
156/131 1.06 (0.69, 1.60) 
 
 
>9.23 hrs/wk 55/71 1.00 reference  
 
131/142 1.20 (0.77, 1.86) 
 
 
XPD (rs1799793) G/A 
     
<0.01 hrs/wk 72/64 1.00 reference  
 
105/90 0.99 (0.62, 1.59) 
 
0.066 
0.01-9.23 hrs/wk 92/95 1.00 reference  
 
138/101 1.35 (0.92, 2.00) 
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>9.23 hrs/wk 85/88 1.00 reference  
 
101/125 0.83 (0.55, 1.24) 
 
 
XPD (rs13181) A/C 
     
<0.01 hrs/wk 66/68 1.00 reference  
 
112/85 1.35 (0.85, 2.15) 
 
0.173 
0.01-9.23 hrs/wk 87/88 1.00 reference  
 
141/108 1.25 (0.84, 1.85) 
 
 
>9.23 hrs/wk 75/82 1.00 reference  
 
107/130 0.92 (0.61, 1.40) 
 
 
XPF (rs1800067) G/A 
     
<0.01 hrs/wk 150/119 1.00 reference  
 
21/27 0.54 (0.28, 1.06) 
 
0.012 
0.01-9.23 hrs/wk 179/168 1.00 reference  
 
43/25 1.64 (0.95, 2.82) 
 
 
>9.23 hrs/wk 150/175 1.00 reference  
 
30/30 1.17 (0.66, 2.06) 
 
 
XPG (rs17655) G/C 
     
<0.01 hrs/wk 88/89 1.00 reference  
 
80/57 1.45 (0.90, 2.34) 
 
0.022 
0.01-9.23 hrs/wk 126/111 1.00 reference  
 
92/81 0.99 (0.67, 1.48) 
 
 
>9.23 hrs/wk 113/107 1.00 reference  
 
65/96 0.71 (0.46, 1.08) 
 
 
XRCC1 (rs1799782) C/T 
     
<0.01 hrs/wk 166/135 1.00 reference  
 
12/19 0.66 (0.29, 1.48) 
 
0.188 
0.01-9.23 hrs/wk 205/177 1.00 reference  
 
28/22 1.20 (0.65, 2.19) 
 
 
>9.23 hrs/wk 160/186 1.00 reference  
 
26/27 0.96 (0.53, 1.77) 
 
 
XRCC1 (rs25487) G/A 
     
<0.01 hrs/wk 64/65 1.00 reference  
 
114/90 1.27 (0.79, 2.04) 
 
0.343 
0.01-9.23 hrs/wk 86/80 1.00 reference  
 
147/120 1.19 (0.80, 1.76) 
 
 
>9.23 hrs/wk 69/78 1.00 reference    118/135 0.96 (0.63, 1.46)     
OR, odds ratio; 95% CI, 95% confidence interval 
       
 
A priori, criteria for interaction on the multiplicative scale is α<0.10  
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TABLE A.33 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Additive Effect of Oxidative Stress SNPs 
and Lifetime Recreational Physical Activity on Breast Cancer Risk in the Long Island Breast Cancer Study Project (1996-
1997). 
 
Homozygous for major allele 
 
At least one copy of minor 
allele   
Gene (SNP) major/minor alleles 
Lifetime RPA  Ca/Co OR 95% CI   Ca/Co OR 95% CI   ICR (95% CI) 
    
 
    
 CAT (rs4756146) T/C 
     
<0.01 hrs/wk 169/161 1.00 reference  
 
48/57 0.80 (0.51, 1.25) 
 
 
0.01-6.35 hrs/wk 296/290 1.05 (0.80, 1.38) 
 
82/94 0.90 (0.62, 1.30) 
 
0.05 (-0.86, 0.96) 
>6.35 hrs/wk 270/318 0.83 (0.63, 1.09) 
 
82/95 0.88 (0.61, 1.27) 
 
0.25 (-0.61, 1.10) 
CAT (rs2284365) T/C 
     
<0.01 hrs/wk 131/117 1.00 reference  
 
88/101 0.78 (0.53, 1.14) 
 
 
0.01-6.35 hrs/wk 229/227 0.96 (0.70, 1.31) 
 
151/163 0.90 (0.65, 1.27) 
 
0.17 (-0.70, 1.23) 
>6.35 hrs/wk 198/223 0.78 (0.56, 1.06) 
 
145/174 0.78 (0.56, 1.09) 
 
0.22 (-0.55, 0.99) 
CAT (rs480575) A/G 
     
<0.01 hrs/wk 115/100 1.00 reference  
 
102/114 0.77 (0.52, 1.13) 
 
 
0.01-6.35 hrs/wk 197/190 0.96 (0.68, 1.34) 
 
176/184 0.90 (0.64, 1.26) 
 
0.17 (-0.71, 1.06) 
>6.35 hrs/wk 179/191 0.83 (0.59, 1.17) 
 
167/206 0.73 (0.52, 1.03) 
 
0.13 (-0.66, 0.92) 
CAT (rs1001179) C/T 
     
<0.01 hrs/wk 133/134 1.00 reference  
 
94/81 1.19 (0.81, 1.74) 
 
 0.01-6.35 hrs/wk 254/254 1.09 (0.80, 1.47) 
 
138/144 1.05 (0.75, 1.48) 
 
-0.22 (-1.30, 0.86) 
>6.35 hrs/wk 216/275 0.83 (0.61, 1.12) 
 
152/144 1.09 (0.78, 1.52) 
 
0.08 (-0.96, 1.11) 
COMT (rs4680) G/A 
     
<0.01 hrs/wk 61/58 1.00 reference  
 
167/162 1.00 (0.65, 1.52) 
 
 0.01-6.35 hrs/wk 114/109 1.06 (0.68, 1.67) 
 
284/291 1.02 (0.68, 1.52) 
 
-0.04 (-1.33, 1.25) 
>6.35 hrs/wk 100/99 1.00 (0.63, 1.59) 
 
271/321 0.84 (0.56, 1.25) 
 
-0.16 (-1.35, 1.03) 
COMT (rs737865) T/C 
     
<0.01 hrs/wk 113/105 1.00 reference  
 
111/116 0.88 (0.61, 1.29) 
 
 0.01-6.35 hrs/wk 190/190 1.01 (0.72, 1.42) 
 
204/207 0.98 (0.70, 1.36) 
 
0.08 (-0.88, 1.05) 
>6.35 hrs/wk 168/202 0.81 (0.57, 1.13) 
 
193/218 0.84 (0.60, 1.17) 
 
0.15 (-0.71, 1.00) 
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GPX (rs1050450) C/T 
     
<0.01 hrs/wk 110/106 1.00 reference  
 
116/113 1.01 (0.70, 1.48) 
 
 0.01-6.35 hrs/wk 178/184 1.02 (0.72, 1.43) 
 
219/214 1.07 (0.77, 1.49) 
 
0.04 (-1.01, 1.09) 
>6.35 hrs/wk 169/205 0.85 (0.60, 1.19) 
 
198/213 0.92 (0.66, 1.28) 
 
0.05 (-0.89, 1.00) 
GSTA1 (rs3957356) G/A 
     
<0.01 hrs/wk 70/74 1.00 reference  
 
157/145 1.13 (0.76, 1.68) 
 
 0.01-6.35 hrs/wk 136/143 1.08 (0.72, 1.62) 
 
260/255 1.15 (0.79, 1.67) 
 
-0.06 (-1.35, 1.23) 
>6.35 hrs/wk 120/149 0.87 (0.58, 1.30) 
 
247/270 0.99 (0.68, 1.43) 
 
0.00 (-1.15, 1.14) 
GSTP1 (rs1695) A/G 
     
<0.01 hrs/wk 116/107 1.00 reference  
 
111/106 0.95 (0.65, 1.39) 
 
 0.01-6.35 hrs/wk 206/184 1.10 (0.79, 1.53) 
 
183/203 0.89 (0.64, 1.25) 
 
-0.16 (-1.14, 0.82) 
>6.35 hrs/wk 167/195 0.80 (0.57, 1.12) 
 
193/221 0.83 (0.59, 1.15) 
 
0.07 (-0.80, 0.94) 
GSTM1 (gene deletion) 
     
<0.01 hrs/wk 109/111 1.00 reference  
 
102/87 1.16 (0.78, 1.72) 
 
 0.01-6.35 hrs/wk 182/197 0.99 (0.71, 1.39) 
 
190/170 1.24 (0.88, 1.75) 
 
0.09 (-1.09, 1.27) 
>6.35 hrs/wk 188/215 0.91 (0.65, 1.27) 
 
158/171 0.96 (0.68, 1.36) 
 
-0.11 (-1.16, 0.94) 
GSTT1 (gene deletion) 
     
<0.01 hrs/wk 163/155 1.00 reference  
 
49/46 1.02 (0.64, 1.62) 
 
 0.01-6.35 hrs/wk 292/288 1.05 (0.80, 1.39) 
 
83/85 0.98 (0.67, 1.43) 
 
-0.09 (-1.15, 0.98) 
>6.35 hrs/wk 287/311 0.90 (0.69, 1.19) 
 
64/81 0.80 (0.54, 1.19) 
 
-0.12 (-1.08, 0.85) 
MnSOD (rs4880) T/C 
     
<0.01 hrs/wk 48/55 1.00 reference  
 
178/160 1.26 (0.81, 1.97) 
 
 
0.01-6.35 hrs/wk 105/96 1.36 (0.84, 2.20) 
 
288/302 1.16 (0.76, 1.78) 
 
-0.46 (-2.14, 1.22) 
>6.35 hrs/wk 100/108 1.06 (0.66, 1.71) 
 
264/309 1.01 (0.66, 1.55) 
 
-0.31 (-1.78, 1.17) 
MPO (rs2333227) G/A 
     
<0.01 hrs/wk 142/127 1.00 reference  
 
86/93 0.84 (0.58, 1.23) 
 
 0.01-6.35 hrs/wk 247/232 1.03 (0.76, 1.39) 
 
151/167 0.88 (0.63, 1.23) 
 
0.01 (-0.87, 0.89) 
>6.35 hrs/wk 226/257 0.81 (0.60, 1.10)   140/161 0.82 (0.58, 1.14)   0.16 (-0.64, 0.96) 
OR, odds ratio; 95% CI, 95% confidence interval; ICR, interaction contrast ratio 
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TABLE A.34 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Additive Effect of Oxidative Stress SNPs 
and Postmenopausal Recreational Physical Activity on Postmenopausal Breast Cancer Risk in the Long Island Breast 
Cancer Study Project (1996-1997). 
Homozygous for major allele 
At least one copy of minor 
allele 
Gene (SNP) major/minor 
alleles 
Postmenopausal RPA  Ca/Co OR 95% CI   Ca/Co OR 95% CI   ICR (95% CI) 
CAT (rs4756146) T/C 
     
<0.01 hrs/wk 133/104 1.00 reference  
 
33/44 0.59 (0.35, 1.00) 
 
 
0.01-9.23 hrs/wk 169/140 0.95 (0.67, 1.34) 
 
48/51 0.74 (0.46, 1.20) 
 
0.21 (-0.70, 1.11) 
>9.23 hrs/wk 137/163 0.62 (0.44, 0.88) 
 
36/45 0.63 (0.38, 1.06) 
 
0.42 (-0.36, 1.20) 
CAT (rs2284365) T/C 
    
 <0.01 hrs/wk 104/80 1.00 reference  
 
64/69 0.71 (0.45, 1.11) 
 
 0.01-9.23 hrs/wk 126/109 0.88 (0.59, 1.30) 
 
92/81 0.88 (0.58, 1.35) 
 
0.30 (-0.69, 1.28) 
>9.23 hrs/wk 104/117 0.63 (0.42, 0.94) 
 
64/89 0.54 (0.35, 0.84) 
 
0.20 (-0.55, 0.96) 
CAT (rs480575) A/G 
    
 <0.01 hrs/wk 90/71 1.00 reference  
 
77/76 0.77 (0.49, 1.22) 
 
 0.01-9.23 hrs/wk 107/85 0.97 (0.63, 1.50) 
 
104/98 0.84 (0.55, 1.28) 
 
0.09 (-0.98, 1.16) 
>9.23 hrs/wk 93/99 0.67 (0.44, 1.04) 
 
79/100 0.60 (0.39, 0.93) 
 
0.15 (-0.70, 1.00) 
CAT (rs1001179) C/T 
   <0.01 hrs/wk 103/95 1.00 reference  70/53 1.30 (0.82, 2.06) 
 0.01-9.23 hrs/wk 149/126 1.13 (0.78, 1.63) 75/71 0.99 (0.64, 1.53) -0.43 (-1.78, 0.92) 
>9.23 hrs/wk 100/143 0.64 (0.43, 0.94) 82/69 1.04 (0.68, 1.60) 0.11 (-1.28, 1.35) 
COMT (rs4680) G/A 
   <0.01 hrs/wk 46/37 1.00 reference  128/116 0.89 (0.54, 1.49) 
 0.01-9.23 hrs/wk 64/54 0.95 (0.54, 1.70) 162/142 0.93 (0.56, 1.53) 0.08 (-1.36, 1.52) 
>9.23 hrs/wk 56/52 0.82 (0.48, 1.48) 130/160 0.63 (0.38, 1.03) -0.08 (-1.30, 1.12) 
COMT (rs737865) T/C 
   <0.01 hrs/wk 89/77 1.00 reference  80/76 0.89 (0.57, 1.39) 
 0.01-9.23 hrs/wk 109/87 1.08 (0.71, 1.65) 118/107 0.94 (0.62, 1.42) -0.03 (-1.24,1.15) 
>9.23 hrs/wk 77/98 0.65 (0.42, 1.01) 102/114 0.72 (0.47, 1.08) 0.18 (-0.75, 1.11) 
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GPX (rs1050450) C/T 
   <0.01 hrs/wk 97/82 1.00 reference  93/70 1.44 (0.92, 2.25) 
 0.01-9.23 hrs/wk 107/97 1.21 (0.80, 1.85) 120/96 1.28 (0.85, 1.95) -0.37 (-1.98, 1.24) 
>9.23 hrs/wk 79/103 0.80 (0.52, 1.24) 103/109 0.92 (0.61, 1.40) 0.32 (-1.63, 0.99) 
GSTA1 (rs3957356) G/A 
   <0.01 hrs/wk 49/48 1.00 reference  124/104 1.19 (0.73, 1.93) 
 0.01-9.23 hrs/wk 76/68 1.09 (0.65, 1.85) 151/126 1.20 (0.75, 1.92) -0.08 (-1.75, 3.16) 
>9.23 hrs/wk 59/61 0.90 (0.52, 1.56) 124/152 0.77 (0.48, 1.23) -0.33 (-1.70, 1.05) 
GSTP1 (rs1695) A/G 
   <0.01 hrs/wk 84/80 1.00 reference  90/68 1.24 (0.79, 1.95) 
 0.01-9.23 hrs/wk 123/80 1.45 (0.95, 2.22) 97/109 0.84 (0.55, 1.28) -0.85 (-2.28, 0.57) 
>9.23 hrs/wk 76/92 0.72 (0.46, 1.12) 103/120 0.78 (0.51, 1.18) -0.19(-1.33, 0.95) 
GSTM1 (gene deletion) 
   <0.01 hrs/wk 72/73 1.00 reference  86/65 1.34 (0.84, 2.14) 
 0.01-9.23 hrs/wk 105/99 1.06 (0.69, 1.63) 111/78 1.48 (0.95, 2.30) 0.07 (-1.60, 1.75) 
>9.23 hrs/wk 93/108 0.82 (0.53, 1.27) 82/88 0.91 (0.58, 1.44) -0.25 (-1.58, 1.08) 
GSTT1 (gene deletion) 
   <0.01 hrs/wk 124/109 1.00 reference  34/31 0.94 (0.54, 1.64) 
 0.01-9.23 hrs/wk 175/136 1.13 (0.80, 1.60) 42/42 0.86 (0.52, 1.42) -0.21 (-1.43, 1,01) 
>9.23 hrs/wk 139/153 0.74 (0.52, 1.06) 36/47 0.68 (0.41, 1.13) -0.00 (-1.04, 1.04) 
MnSOD (rs4880) T/C 
   <0.01 hrs/wk 46/39 1.00 reference  128/110 0.91 (0.55, 1.51) 
 0.01-9.23 hrs/wk 59/57 0.84 (0.47, 1.48) 164/138 0.95 (0.58, 1.56) 0.20 (-1.18, 1.58) 
>9.23 hrs/wk 57/51 0.82 (0.46, 1.46) 125/161 0.60 (0.37, 0.99) -0.13 (-1.32, 1.07) 
MPO (rs2333227) G/A 
   <0.01 hrs/wk 105/95 1.00 reference  69/57 1.15 (0.73, 1.82) 
 0.01-9.23 hrs/wk 144/112 1.17 (0.80, 1.72) 82/84 0.92 (0.61, 1.40) -0.41 (-1.67, 0.86) 
>9.23 hrs/wk 109/136 0.71 (0.48, 1.04)   74/76 0.85 (0.55, 1.30)   -0.02 (-1.11, 1.08) 
OR, odds ratio; 95% CI, 95% confidence interval; ICR, interaction contrast ratio 
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TABLE A.35 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Additive Effect of DNA Repair SNPs and 
Lifetime Recreational Physical Activity on Breast Cancer Risk in the Long Island Breast Cancer Study Project (1996-1997). 
 
Homozygous for major allele 
 
At least one copy of minor 
allele   
Gene (SNP) major/minor alleles 
Lifetime RPA  Ca/Co OR 95% CI   Ca/Co OR 95% CI   ICR (95% CI) 
ERCC1 (rs3212986) C/A 
     
<0.01 hrs/wk 119/122 1.00 reference  
 
110/101 1.09 (0.75, 1.58) 
 
 
0.01-6.35 hrs/wk 227/243 1.02 (0.74, 1.39) 
 
178/161 1.20 (0.86, 1.68) 
 
0.10 (-0.99, 1.18) 
>6.35 hrs/wk 181/218 0.87 (0.63, 1.20) 
 
193/204 0.99 (0.72, 1.37) 
 
0.03 (-0.94, 1.01) 
MGMT (rs12917) C/T 
     
<0.01 hrs/wk 173/155 1.00 reference  
 
58/67 0.78 (0.51, 1.18) 
 
 
0.01-6.35 hrs/wk 300/296 0.98 (0.75, 1.29) 
 
107/111 0.92 (0.65, 1.31) 
 
0.17 (-0.69, 1.03) 
>6.35 hrs/wk 276/329 0.75 (0.57, 0.99) 
 
109/95 1.06 (0.74, 1.51) 
 
0.53 (-0.34, 1.39) 
MGMT (rs2308321) A/G 
     
<0.01 hrs/wk 180/175 1.00 reference  
 
51/46 1.09 (0.69, 1.71) 
 
 
0.01-6.35 hrs/wk 321/309 1.10 (0.84, 1.43) 
 
86/96 0.92 (0.64, 1.33) 
 
-0.26 (-1.31, 0.79) 
>6.35 hrs/wk 286/322 0.90 (0.69, 1.17) 
 
90/101 0.90 (0.63, 1.28) 
 
-0.09 (-1.09, 0.91) 
MGMT (rs2308327) A/G 
     
<0.01 hrs/wk 189/180 1.00 reference  
 
44/43 1.00 (0.63, 1.61) 
 
 
0.01-6.35 hrs/wk 333/320 1.08 (0.83, 1.40) 
 
74/88 0.86 (0.59, 1.24) 
 
-0.23 (-1.23, 0.77) 
>6.35 hrs/wk 294/336 0.87 (0.67, 1.13) 
 
83/89 0.92 (0.63, 1.32) 
 
0.04 (-0.95, 1.03) 
MLH1 (rs1799977) A/G 
     
<0.01 hrs/wk 106/123 1.00 reference  
 
117/97 1.37 (0.94, 2.00) 
 
 
0.01-6.35 hrs/wk 204/193 1.31 (0.94, 1.82) 
 
179/195 1.13 (0.81, 1.58) 
 
-0.55 (-1.82, 0.72) 
>6.35 hrs/wk 175/198 1.05 (0.75, 1.47) 
 
181/214 1.00 (0.72, 1.39) 
 
-0.42 (-1.57, 0.73) 
MLH1 (rs2286940) C/T 
     
<0.01 hrs/wk 73/78 1.00 reference  
 
150/142 1.12 (0.76, 1.67) 
 
 
0.01-6.35 hrs/wk 142/117 1.40 (0.93, 2.10) 
 
239/274 1.00 (0.69, 1.44) 
 
-0.53 (-1.87, 0.82) 
>6.35 hrs/wk 112/127 0.99 (0.65, 1.49) 
 
240/284 0.92 (0.64, 1.33) 
 
-0.19 (-1.36, 0.97) 
 
 173    
 
173
 
MSH2 (rs2303428) T/C 
     
<0.01 hrs/wk 180/186 1.00 reference  
 
35/29 1.24 (0.73, 2.13) 
  
0.01-6.35 hrs/wk 315/322 1.08 (0.83, 1.40) 
 
58/62 1.05 (0.69, 1.59) 
 
-0.28 (-1.60, 1.05) 
>6.35 hrs/wk 293/338 0.92 (0.71, 1.19) 
 
56/65 0.92 (0.61, 1.40) 
 
-0.24 (-1.48, 1.00) 
MSH2 (rs3732182) G/T 
     
<0.01 hrs/wk 122/113 1.00 reference  
 
101/106 0.90 (0.62, 1.31) 
 
 
0.01-6.35 hrs/wk 209/205 1.02 (0.73, 1.41) 
 
166/181 0.93 (0.66, 1.30) 
 
0.01 (-0.93, 0.95) 
>6.35 hrs/wk 185/228 0.78 (0.56, 1.07) 
 
166/183 0.88 (0.63, 1.24) 
 
0.21 (-0.64, 1.07) 
MSH2 (rs4583514) A/G 
     
<0.01 hrs/wk 86/84 1.00 reference  
 
138/136 1.02 (0.70, 1.51) 
 
 
0.01-6.35 hrs/wk 148/143 1.10 (0.75, 1.62) 
 
233/248 1.01 (0.71, 1.44) 
 
-0.11 (-1.26, 1.03) 
>6.35 hrs/wk 141/157 0.92 (0.63, 1.34) 
 
215/252 0.88 (0.62, 1.26) 
 
-0.06 (-1.09, 0.97) 
MSH3 (rs1650663) T/C 
     
<0.01 hrs/wk 119/115 1.00 reference  
 
103/104 0.97 (0.66, 1.41) 
 
 
0.01-6.35 hrs/wk 179/199 0.94 (0.68, 1.32) 
 
201/187 1.11 (0.80, 1.55) 
 
0.20 (-0.81, 1.21) 
>6.35 hrs/wk 175/190 0.92 (0.66, 1.28) 
 
181/222 0.82 (0.59, 1.14) 
 
-0.07 (-0.96, 0.83) 
OGG1 (rs1052133) C/G 
     
<0.01 hrs/wk 148/132 1.00 reference  
 
84/89 0.84 (0.57, 1.23) 
 
 
0.01-6.35 hrs/wk 214/262 0.78 (0.58, 1.05) 
 
182/138 1.28 (0.92, 1.77) 
 
0.66 (-0.29, 1.61) 
>6.35 hrs/wk 226/231 0.91 (0.68, 1.24) 
 
141/187 0.68 (0.49, 0.95) 
 
-0.07 (-0.84, 0.70) 
XPA (rs1800975) G/A 
     
<0.01 hrs/wk 118/104 1.00 reference  
 
114/118 0.83 (0.57, 1.21) 
 
 
0.01-6.35 hrs/wk 185/174 1.00 (0.71, 1.40) 
 
218/228 0.90 (0.65, 1.25) 
 
0.08 (-0.83, 0.99) 
>6.35 hrs/wk 164/186 0.80 (0.57, 1.13) 
 
211/238 0.79 (0.57, 1.09) 
 
0.16 (-0.66, 0.97) 
XPC (rs2228000) C/T 
     
<0.01 hrs/wk 129/123 1.00 reference  
 
102/99 0.95 (0.65, 1.38) 
 
 
0.01-6.35 hrs/wk 251/225 1.12 (0.82, 1.53) 
 
153/179 0.88 (0.63, 1.22) 
 
-0.19 (-1.13, 0.75) 
>6.35 hrs/wk 208/252 0.80 (0.59, 1.10) 
 
168/173 0.94 (0.68, 1.30) 
 
0.19 (-0.69, 1.07) 
XPC (rs2228001) A/C 
     
<0.01 hrs/wk 88/71 1.00 reference  
 
143/150 0.77 (0.52, 1.14) 
 
 
0.01-6.35 hrs/wk 124/140 0.77 (0.52, 1.15) 
 
280/263 0.93 (0.65, 1.33) 
 
0.39 (-0.54, 1.32) 
>6.35 hrs/wk 117/136 0.72 (0.48, 1.08) 
 
258/289 0.74 (0.52, 1.06) 
 
0.25 (-0.59, 1.09) 
XPD (rs1799793) G/A  
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<0.01 hrs/wk 90/97 1.00 reference  
 
140/125 1.21 (0.83, 1.76) 
 
 
0.01-6.35 hrs/wk 166/199 0.98 (0.68, 1.40) 
 
237/204 1.35 (0.95, 1.91) 
 
0.16 (-1.08, 1.41) 
>6.35 hrs/wk 144/173 0.93 (0.65, 1.35) 
 
230/252 1.02 (0.72, 1.43) 
 
-0.13 (-1.24, 0.99) 
XPD (rs13181) A/C 
     
<0.01 hrs/wk 84/97 1.00 reference  
 
149/124 1.41 (0.97, 2.07) 
  
0.01-6.35 hrs/wk 148/177 1.07 (0.74, 1.54) 
 
250/226 1.39 (0.98, 1.97) 
 
-0.09 (-1.47, 1.29) 
>6.35 hrs/wk 131/155 1.02 (0.70, 1.49) 
 
241/269 1.09 (0.77, 1.54) 
 
-0.34 (-1.60, 0.92) 
XPF (rs1800067) G/A 
     
<0.01 hrs/wk 191/170 1.00 reference  
 
31/41 0.64 (0.38, 1.07) 
  
0.01-6.35 hrs/wk 322/315 0.98 (0.75, 1.27) 
 
65/75 0.83 (0.56, 1.24) 
 
0.22 (-0.63, 1.08) 
>6.35 hrs/wk 304/358 0.78 (0.60, 1.00) 
 
56/54 0.96 (0.62, 1.48) 
 
0.55 (-0.34, 1.44) 
XPG (rs17655) G/C 
     
<0.01 hrs/wk 117/117 1.00 reference  
 
102/94 1.14 (0.77, 1.67) 
  
0.01-6.35 hrs/wk 205/211 1.06 (0.77, 1.47) 
 
175/171 1.14 (0.81, 1.59) 
 
-0.06 (-1.18, 1.06) 
>6.35 hrs/wk 214/214 1.04 (0.76, 1.44) 
 
140/191 0.78 (0.55, 1.09) 
 
-0.40 (-1.38, 0.58) 
XRCC1 (rs1799782) C/T 
     
<0.01 hrs/wk 212/196 1.00 reference  
 
21/26 0.76 (0.41, 1.40) 
 
 
0.01-6.35 hrs/wk 347/349 0.99 (0.77, 1.27) 
 
60/58 1.04 (0.69, 1.58) 
 
0.29 (-0.83, 1.40) 
>6.35 hrs/wk 334/374 0.86 (0.67, 1.11) 
 
42/51 0.74 (0.47, 1.17) 
 
0.12 (-0.85, 1.08) 
XRCC1 (rs25487) G/A 
     
<0.01 hrs/wk 95/91 1.00 reference  
 
138/132 0.99 (0.68, 1.45) 
 
 
0.01-6.35 hrs/wk 162/163 1.02 (0.70, 1.47) 
 
245/245 1.03 (0.73, 1.46) 
 
0.02 (-1.05, 1.10) 
>6.35 hrs/wk 134/166 0.80 (0.55, 1.16)   243/259 0.93 (0.66, 1.30)   0.13 (-0.83, 1.10) 
OR, odds ratio; 95% CI, 95% confidence interval; ICR, Interaction Contrast Ratio 
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TABLE A.36 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Additive Effect of DNA Repair SNPs and 
Postmenopausal Recreational Physical Activity on Breast Cancer Risk in the Long Island Breast Cancer Study Project (1996-
1997). 
Homozygous for major allele 
At least one copy of minor 
allele 
Gene (SNP) major/minor alleles 
Postmenopausal RPA  
Ca/Co OR 95% CI   Ca/Co OR 95% CI   ICR (95% CI) 
ERCC1 (rs3212986) C/A 
   <0.01 hrs/wk 93/84 1.00 reference  82/71 1.00 (0.64, 1.55) 
0.01-9.23 hrs/wk 128/116 0.96 (0.65, 1.43) 104/82 1.14 (0.75, 1.73) 0.18 (-1.06, 1.41) 
>9.23 hrs/wk 93/114 0.70 (0.46, 1.05) 92/98 0.78 (0.52, 1.19) 0.09 (-0.91, 1.09) 
MGMT (rs12917) C/T 
  <0.01 hrs/wk 137/113 1.00 reference  40/40 0.83 (0.50, 1.38) 
 0.01-9.23 hrs/wk 163/141 0.96 (0.68, 1.34) 70/59 0.99 (0.64, 1.53) 0.21 (-0.89, 1.32) 
>9.23 hrs/wk 128/162 0.64 (0.45, 0.90) 58/50 0.87 (0.55, 1.39) 0.41 (-0.57, 1.40) 
MGMT (rs2308321) A/G 
  <0.01 hrs/wk 141/125 1.00 reference  36/28 1.16 (0.66, 2.03) 
 0.01-9.23 hrs/wk 175/149 1.04 (0.75, 1.45) 58/50 1.05 (0.67, 1.66) -0.15 (-1.54, 1.23) 
>9.23 hrs/wk 143/159 0.77 (0.55, 1.07) 43/53 0.68 (0.42, 1.10) -0.25 (-1.39, 0.89) 
MGMT (rs2308327) A/G 
  <0.01 hrs/wk 149/130 1.00 reference  29/25 1.04 (0.57, 1.88) 
 0.01-9.23 hrs/wk 186/156 1.04 (0.76, 1.44) 47/44 0.96 (0.59, 1.55) -0.12 (-1.44, 1.20) 
>9.23 hrs/wk 145/163 0.75 (0.54, 1.04) 42/50 0.70 (0.43, 1.13) -0.09 (1.21, 1.04) 
MLH1 (rs1799977) A/G 
  
 
<0.01 hrs/wk 72/81 1.00 reference  101/70 1.63 (1.04, 2.56) 
 
0.01-9.23 hrs/wk 107/93 1.29 (0.84, 1.99) 110/99 1.27 (0.83, 1.94) -0.66 (-2.38, 1.05) 
>9.23 hrs/wk 93/96 1.09 (0.70, 1.68) 85/114 0.78 (0.51, 1.20) -0.94 (-2.38, 0.50) 
MLH1 (rs2286940) C/T 
  
 
<0.01 hrs/wk 50/47 1.00 reference  123/104 1.16 (0.72, 1.89) 
0.01-9.23 hrs/wk 76/55 1.37 (0.80, 2.34) 138/139 0.96 (0.60, 1.54) -0.57 (-2.26,1.12) 
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>9.23 hrs/wk 62/59 1.00 (0.58, 1. 73) 114/150 0.70 (0.43, 1.12) -0.47 (-1.85, 0.91) 
MSH2 (rs2303428) T/C 
  
 
<0.01 hrs/wk 140/125 1.00 reference  25/20 1.07 (0.56, 2.05) 
 
0.01-9.23 hrs/wk 174/160 0.97 (0.70, 1.35) 36/31 1.04 (0.60, 1.79) -0.01 (-1.49, 1.47) 
>9.23 hrs/wk 152/176 0.73 (0.53, 1.02) 23/31 0.64 (0.35, 1.16) -1.17 (-1.37, 1.03) 
MSH2 (rs3732182) G/T 
  
 
<0.01 hrs/wk 98/82 1.00 reference  75/69 0.92 (0.59, 1.43) 
0.01-9.23 hrs/wk 108/102 0.89 (0.60, 1.34) 102/90 0.95 (0.63, 1.44) 0.14 (-0.97, 1.25) 
>9.23 hrs/wk 95/121 0.61 (0.41, 0.92) 80/88 0.76 (0.49, 1.17) 0.23 (-0.70, 1.16) 
MSH2 (rs4583514) A/G 
  
 
<0.01 hrs/wk 73/61 1.00 reference  100/90 0.96 (0.61, 1.51) 
 
0.01-9.23 hrs/wk 81/70 0.96 (0.60, 1.55) 135/124 0.94 (0.62, 1.44) 0.02 (-1.23, 1.27) 
>9.23 hrs/wk 71/80 0.71 (0.44, 1.15) 107/129 0.68 (0.44, 1.05) 0.01 (-1.01, 1.03) 
MSH3 (rs1650663) T/C 
  
 
<0.01 hrs/wk 97/79 1.00 reference  74/70 0.87 (0.55, 1.36) 
 
0.01-9.23 hrs/wk 103/109 0.80 (0.53, 1.20) 114/83 1.09 (0.72, 1.65) 0.42 (-0.70, 1.54) 
>9.23 hrs/wk 83/97 0.67 (0.44, 1.03) 94/113 0.65 (0.43, 0.98) 0.11 (-0.78, 1.00) 
OGG1 (rs1052133) C/G 
  <0.01 hrs/wk 113/90 1.00 reference  64/61 0.82 (0.52, 1.28) 
0.01-9.23 hrs/wk 128/122 0.83 (0.57, 1.21) 94/73 1.02 (0.67, 1.55) 0.37 (-0.68, 1.42) 
>9.23 hrs/wk 106/118 0.69 (0.47, 1.02) 75/91 0.61 (0.40, 0.92) 0.10 (-0.74, 0.93) 
XPA (rs1800975) G/A 
  <0.01 hrs/wk 84/73 1.00 reference  93/81 0.98 (0.63, 1.53) 
 0.01-9.23 hrs/wk 110/83 1.15 (0.75, 1.77) 121/112 0.93 (0.62, 1.41) -0.20 (-1.45, 1.06) 
>9.23 hrs/wk 75/97 0.64 (0.41, 0.99) 112/115 0.80 (0.53, 1.22) 0.18 (-0.83, 1.19) 
XPC (rs2228000) C/T 
 <0.01 hrs/wk 93/81 1.00 reference  71/67 0.83 (0.53, 1.30) 
 0.01-9.23 hrs/wk 121/112 0.83 (0.56, 1.22) 109/82 1.11 (0.74, 1.68) 0.46 (-0.65, 1.56) 
>9.23 hrs/wk 112/115 0.57 (0.38, 0.84) 91/86 0.82 (0.54, 1.25) 0.43 (-0.47, 1.33) 
XPC (rs2228001) A/C 
  <0.01 hrs/wk 67/44 1.00 reference  110/108 0.68 (0.42, 1.09) 
 0.01-9.23 hrs/wk 75/65 0.79 (0.47, 1.32) 156/131 0.79 (0.50, 1.23) 0.32 (-0.74, 1.37) 
>9.23 hrs/wk 55/71 0.50 (0.29, 0.84) 131/142 0.58 (0.37, 0.91) 0.41 (-0.42, 1.23) 
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XPD (rs1799793) G/A 
  <0.01 hrs/wk 72/64 1.00 reference  105/90 1.03 (0.66, 1.62) 
 0.01-9.23 hrs/wk 92/95 0.87 (0.56, 1.37) 138/101 1.21 (0.79, 1.86) 0.30 (-1.03, 1.63) 
>9.23 hrs/wk 85/88 0.82 (0.52, 1.29) 101/125 0.68 (0.44, 1.06) -0.17 (-1.24, 0.91) 
XPD (rs13181) A/C 
  <0.01 hrs/wk 66/68 1.00 reference  112/85 1.36 (0.87, 2.13) 
 0.01-9.23 hrs/wk 87/88 1.05 (0.67, 1.66) 141/108 1.33 (0.87, 2.05) -0.08 (-1.69, 1.53) 
>9.23 hrs/wk 75/82 0.90 (0.56, 1.43) 107/130 0.82 (0.53, 1.27) -0.44 (-1.75, 0.88) 
XPF (rs1800067) G/A 
  <0.01 hrs/wk 150/119 1.00 reference  21/27 0.57 (0.30, 1.07) 
 0.01-9.23 hrs/wk 179/168 0.83 (0.60, 1.15) 43/25 1.38 (0.79, 2.40) 0.98 (-0.33, 2.29) 
>9.23 hrs/wk 150/175 0.64 (0.46, 0.89) 30/30 0.74 (0.42, 1.31) 0.53 (-0.39, 1.45) 
XPG (rs17655) G/C 
  <0.01 hrs/wk 88/89 1.00 reference  80/57 1.42 (0.90, 2.25) 
 0.01-9.23 hrs/wk 126/111 1.14 (0.77, 1.70) 92/81 1.15 (0.75, 1.76) -0.41 (-1.92, 1.09) 
>9.23 hrs/wk 113/107 0.98 (0.65, 1.47) 65/96 0.68 (0.44, 1.06) -0.72 (-1.96, 0.53) 
XRCC1 (rs1799782) C/T 
  <0.01 hrs/wk 166/135 1.00 reference  12/19 0.56 (0.26, 1.21) 
 0.01-9.23 hrs/wk 205/177 0.95 (0.70, 1.29) 28/22 1.10 (0.60, 2.03) 0.59 (-0.72, 1.90) 
>9.23 hrs/wk 160/186 0.69 (0.50, 0.94) 26/27 0.69 (0.38, 1.25) 0.45 (-0.56, 1.45) 
XRCC1 (rs25487) G/A 
  <0.01 hrs/wk 64/65 1.00 reference  114/90 1.26 (0.81, 1.98) 
 
0.01-9.23 hrs/wk 86/80 1.05 (0.66, 1.68) 147/120 1.26 (0.82, 1.94) -0.06 (-1.62, 1.50) 
>9.23 hrs/wk 69/78 0.86 (0.53, 1.40)   118/135 0.83 (0.54, 1.28)   -0.30 (-1.58, 0.99) 
OR, odds ratio (age adjusted); 95% CI, 95% confidence interval; ICR, interaction contrast ratio 
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TABLE A.37 Distribution and Main Effects of Oxidative Stress Genes for Gene-Environment Interactions among all 
Women and Postmenopausal Women. The Long Island Breast Cancer Study Project (1996-1997). 
 
All Women 
 
Postmenopausal Women 
Gene (rs) Genotype Ca/Co OR 95% CI 
 
Ca/Co OR 95% CI 
CAT (rs4756146) TT 774/809 1.00 Reference 
 
514/491 1.00 Reference 
 
CT 201/229 0.68 (0.37, 1.22) 
    
 
CC 19/29 0.93 (0.75, 1.16) 
    
 
CT and CC 220/258 0.90 (0.74, 1.11) 
 
139/175 0.77 (0.59, 0.99) 
 
 
       CAT (rs2284365) TT 589/610 1.00 Reference 
 
390/372 1.00 Reference 
 
CT 344/371 0.72 (0.50, 1.03) 
    
 
CC 58/85 0.98 (0.81, 1.18) 
    
 
CT and CC 402/456 0.93 (0.78, 1.11) 
 
261/291 0.87 (0.70, 1.09) 
 
 
       CAT (rs480575) AA 517/504 1.00 Reference 
 
341/306 1.00 Reference 
 
AG 378/422 0.89 (0.74, 1.08) 
    
 
GG 89/111 0.78 (0.58, 1.06) 
    
 
AG and GG 467/533 0.87 (0.73, 1.04) 
 
306/340 0.82 (0.65, 1.02) 
 
 
       CAT (rs1001179) 1 CC 634/696 1.00 Reference 
 
416/435 1.00 Reference 
 
CT 356/348 1.12 (0.93, 1.35) 
    
 
TT 46/42 1.20 (0.77, 1.85) 
    
 
CT and TT 402/390 1.13 (0.95, 1.35) 
 
265/241 1.15 (0.92, 1.43) 
 
 
       COMT (rs4680) 2 GG 287/277 1.00 Reference 
 
192/176 1.00 Reference 
 
AG 520/549 0.92 (0.75, 1.13) 
    
 
AA 240/266 0.88 (0.69, 1.13) 
    
 
AG and AA 760/815 0.91 (0.75, 1.10) 
 
496/502 0.90 (0.70, 1.14) 
 
 
       COMT (rs737865) 2 TT 498/523 1.00 Reference 
 
329/318 1.00 Reference 
 
CT 430/457 0.97 (0.81, 1.17) 
    
 
CC 101/111 0.93 (0.69, 1.26) 
    
 
CT and CC  531/568 0.97 (0.81, 1.15) 
 
348/359 0.91 (0.73, 1.13) 
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       GPX (rs1050450) 3 CC 475/524 1.00 Reference 
 
309/331 1.00 Reference 
 
CT 456/453 1.09 (0.91, 1.31) 
    
 
TT 109/112 1.04 (0.78, 1.40) 
    
 
CT and TT 565/565 1.08 (0.91, 1.28) 
 
374/345 1.13 (0.91, 1.41) 
 
 
       GSTA1 (rs3957356) 4 GG 343/386 1.00 Reference 
 
224/229 1.00 Reference 
 
AG 501/522 1.06 (0.88, 1.29) 
    
 
AA 196/182 1.18 (0.92, 1.51) 
    
 
AG and AA 697/704 1.09 (0.91, 1.31) 
 
461/449 1.04 (0.83, 1.31) 
 
 
       GSTP1 (rs1695) 5 AA 517/518 1.00 Reference 
 
338/317 1.00 Reference 
 
AG 413/461 0.89 (0.75, 1.07) 
    
 
GG 96/90 1.09 (0.80, 1.50) 
    
 
AG and GG 509/551 0.93 (0.78, 1.10) 
 
335/345 0.93 (0.74, 1.15) 
 
 
       GSTM1 (Null vs. Present) 5 0 505/547 1.00 Reference 
 
329/343 1.00 Reference 
 
1 470/454 1.13 (0.94, 1.35) 
 
315/273 1.21 (0.97, 1.52) 
 
 
       GSTT1 (Null vs. Present) 5 0 774/795 1.00 Reference 
 
515/487 1.00 Reference 
 
1 209/221 0.98 (0.79, 1.21) 
 
132/137 0.92 (0.70, 1.21) 
 
 
       MnSOD (rs4880) 6 TT 270/281 1.00 Reference 
 
184/179 1.00 Reference 
 
CT 510/539 0.99 (0.78, 1.27) 
    
 
CC 253/264 0.98 (0.80, 1.21) 
    
 
CT and CC 763/803 0.99 (0.81, 1.20) 
 
494/494 0.99 (0.81, 1.21) 
 
 
       MPO (rs2333227) 7 GG 649/648 1.00 Reference 
 
427/407 1.00 Reference 
 
AG 331/369 0.82 (0.57, 1.17) 
    
 
AA 62/74 0.91 (0.76, 1.10) 
    
  AG and AA 393/443 0.90 (0.75, 1.07)   257/272 0.91 (0.73, 1.14) 
Ca, cases; Co, controls; OR, odds ratio; 95% CI, 95% confidence interval 
     1
 Ahn et al. Am J Epidemiol. (2005) Note: Previous report used recessive model  
    2
 Gaudet et al. Breast Cancer Res Treat. (2006) 
       3
 Ahn et al. Cancer Epidemiol Biomarkers Prev. (2005) 
      4
 Ahn et al. Carcinogenesis. (2006)   
       5
 Steck et al. J Nutr. (2007)  
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6
 Gaudet et al. Cancer Causes Control. (2005)         
7
 Ahn et al. Cancer Res. (2004)  Note: Previous report adjusted for age, family history and parity 
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TABLE A.38 Age Adjusted Odds Ratios and 95% Confidence Intervals for the Multiplicative Effect of CAT SNPs 
on Breast Cancer Risk. The Long Island Breast Cancer Study Project (1996-1997). 
Gene (rs) Ca/Co OR 95% CI 
 
Ca/Co OR 95% CI 
 
p for interaction 
          
 
  
CAT (rs2284365) 
  
CAT (rs480575) 
 
TT 
 
CT and CC 
 
0.087 
AA 
 
505/487 1.00 reference  
 
9/14 1.00 reference  
 
 
AG and GG   71/100 0.68 (0.49, 0.95)   383/428 1.57 (0.64, 3.84)     
Ca, case; Co, control; OR, odds ratio; 95% CI, 95% confidence interval 
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TABLE A.39. Age Adjusted Odds Ratios and 95% Confidence Intervals for the Multiplicative Effect of 
MMR Genes on Breast Cancer Risk. The Long Island Breast Cancer Study Project (1996-1997). 
Gene (rs) Ca/Co OR 95% CI 
 
Ca/Co OR 95% CI 
 
p for 
interaction 
          
 
  
MSH3 (rs1650663) 
  MLH1 
(rs2286940)  TT  CT and CC  0.063 
CC 
 
157/176 1.00 reference  
 
181/163 1.00 reference  
 
 
CT and TT 
 
337/354 1.07 (0.82, 1.40) 
 
324/373 0.75 (0.57, 0.97) 
 
 
          
 
  
MLH1 (rs1799977) 
  MSH2 
(rs2303428)  AA  AG and GG  0.045 
TT 
 
417/434 1.00 reference  
 
410/448 1.00 reference  
 
 
CT and CC 
 
72/96 0.82 (0.58, 1.15) 
 
86/71 1.35 (0.96, 1.92) 
 
 
  
                  
  
Ca, case; Co, control; OR, odds ratio; 95% CI, 95% confidence interval 
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FIGURE A.1 Female Breast Cancer - Incidence and Mortality Rates by Age and Race, US, 2002-2006 
(American Cancer Society, Breast Cancer Facts and Figures 2009-2010) 
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FIGURE A.2 Commonly Cited Physical Activity Mechanisms 
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FIGURE A.3 Physical Activity Mechanisms and Carcinogenesis (Adapted from Rundle 2005) 
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FIGURE A.4 Interactions between complexes of MutS and MutL related proteins during mismatch repair  
(Adapted from Kolodner and Marsischky 1999) 
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FIGURE A.5 Contact, Cooperation, and Response Rates among case and controls, 
Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.6 Linkage Disequilibrium Plot CAT (CEU HapMap population) 
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FIGURE A.7 Linkage Disequilibrium Plot MLH1 (CEU HapMap population) 
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FIGURE A.8 Linkage Disequilibrium Plot MSH2 (CEU HapMap population) 
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FIGURE A.9 Linkage Disequilibrium Plot MSH3 (CEU HapMap population) 
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FIGURE A.10 Simple Continuous Plot of Postmenopausal Recreational Physical Activity and Risk of Breast Cancer,  
Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.11 Quadratic Plot of Postmenopausal Recreational Physical Activity and Risk of Breast Cancer, Long Island Breast 
Cancer Study Project. 1996-1997 
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FIGURE A.12 Postmenopausal Recreational Physical Activity and Risk of Breast Cancer Categorized by Deciles among 
Controls, Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.13 Postmenopausal Recreational Physical Activity and Risk of Breast Cancer Categorized by Quartiles among 
Controls, Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.14 Linear Spline of Postmenopausal Recreational Physical Activity and Risk of Breast Cancer, Long Island Breast 
Cancer Study Project. 1996-1997 
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FIGURE A.15 Quadratic Spline of Postmenopausal Recreational Physical Activity and Risk of Breast Cancer,  
Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.16 Directed Acyclic Graph for the Association Between  
Breast Cancer Risk and Genetic Variants. 
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Figure A.17 Power Curves for Main Effects of Genotype and Breast Cancer (All women Combined),  
Long Island Breast Cancer Study Project. 1996-1997 
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Figure A.18 Power Curves for Multiplicative Interactions and Breast Cancer (All women Combined),  
Long Island Breast Cancer Study Project. 1996-1997 
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Figure A.19 Power Curves for Additive Interactions and Breast Cancer (All women Combined),  
Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.20(a) Stratum Specific Effects of CAT CC genotype using Linear Spline for Postmenopausal  
Recreational Physical Activity, Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.20(b) Stratum Specific Effects of CAT CT or TT genotype using Linear Spline for  
Postmenopausal Recreational Physical Activity, Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.21(a) Stratum Specific Effects of GSTP1 AA genotype using Linear Spline for  
Postmenopausal Recreational Physical Activity, Long Island Breast Cancer Study Project. 1996-1997 
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FIGURE A.21(b) Stratum Specific Effects of GSTP1 AG or GG genotype using Linear Spline for  
Postmenopausal Recreational Physical Activity, Long Island Breast Cancer Study Project. 1996-1997 
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